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CHAPTER 1: BACKGROUND 
This dissertation focuses on the response of neurons to global brain ischemia/reperfusion 
(I/R) injury.  Brain I/R injury affects millions of individual and costs billions of dollars in 
healthcare and loss of productivity worldwide.  However, all treatments designed to prevent 
neuron death have failed in clinical trials, and therefore the underlying mechanisms are still not 
clear.  This work proposes to investigate novel mechanisms underlying the selective 
vulnerability of Cornu Ammonis 1 (CA1) neurons in I/R injury compared with resistant CA3 
neurons.  The proposed studies are ultimately intended to contribute to the development of 
effective therapies that could prevent the death of ischemic sensitive neurons during I/R injury. 
The main focus of this prospectus is on the posttranscriptional control of gene expression 
in neurons following I/R injury.  It has been known since 1971 that protein synthesis is inhibited 
in neurons after I/R1.  Several lines of investigation have shown that this translation arrest (TA) 
is linked to post-transcriptional regulation of neuronal stress responses.  In the Background 
section I discuss previous investigations of: (1) translation initiation factors, (2) selective 
translation of stress proteins, and (3) sequestration of ribosomes into cytoplasmic particles.  
From this evidence, it is now clear that a transient TA is linked to stress gene expression and 
survival of resistant post-ischemic neurons.  However, prolonged TA is pathological and 
correlates to death of selectively vulnerable neurons.  Previous work from our lab implicates 
post-transcriptional regulation of mRNA in the form of mRNA granules that are reversible in 
surviving neurons and irreversible in vulnerable neurons.  mRNA regulation is today understood 
in terms of the ribonomic network, which consists of subcellular structures that regulate mRNAs.  
My experimental plan aims to investigate ribonomic regulation after I/R injury in CA1 and CA3 
neurons.  Biochemical fractionation, proteomics and microarrays were used to detect whether 
different mRNA protein binding complexes correlate with vulnerability of neurons after I/R 
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injury by comparing hippocampal regions CA1 and CA3. 
Brain ischemia and reperfusion 
Ischemia is the decrease or cessation in blood supply to an organ or tissue, caused by 
constriction or obstruction of blood vessels.  Reperfusion is the restoration of blood flow to the 
previously ischemic organ or tissue.  There are two types of brain ischemia: focal and global 
ischemia. Focal brain ischemia affects a circumscribed area of the brain, whereas global brain 
ischemia results in decreased or cessation of blood flow to the entire brain.  In humans, focal 
brain I/R occurs as stroke, and global brain I/R manifests as cardiac arrest and resuscitation.  
Focal and global brain ischemia both results in severe mortality and morbidity from brain 
damage.  
Significant consequence of brain ischemia 
Focal brain ischemia from stroke is the fourth leading cause of death in U.S. according to 
the latest report2 and a leading cause of long-term disability3.  The estimated direct and indirect 
cost of stroke added up to around $34.3 billion annually in U.S.4. 
Global brain ischemia from cardiac arrest is also a major contributor to death: irreversible 
brain damage starts after only 5 min of cardiac arrest.  With the increase of the duration of 
cardiac arrest to 30 min and above, drastic CNS damage with necrosis would occur with very 
low long-term survival rate.  With approximate 200,000 hospitalized patients suffering cardiac 
arrest annually in U.S.5, only 35.0% of the children and 23.1% of the adults survive to 
discharge4. In the case of out-of-hospital cardiac arrest, survival rate is even lower, ranging from 
4.6% to 6.4%6,7.  Cardiac arrest causes cessation of blood flow to the whole brain resulting in 
dysfunction ranging from mild to severe to lethal.  In a U.K. study aiming to determine the major 
mode of death in intensive care unit (ICU) patients after cardiac arrest, neurological injury 
contributes two thirds of the death of patients who suffered out-of-hospital cardiac arrest and one 
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fourth of death of patients who suffered in-hospital cardiac arrest8.  In other studies of out-of- 
hospital cardiac arrest patients’ survival, only around 6% of the cardiac arrest patients survive to 
hospital discharge with satisfactory neural-function status measured as modified Rankin scale, 
with the rest of the patients ranging from severe disability to death9, 10. 
Current treatment: unsatisfactory 
Due to the short time frame from the onset of ischemia to neuronal damage, the 
application of revascularization therapy is limited.  Early restoration of blood flow within 3 hrs 
by tissue plasminogen activator (tPA) is the only FDA-approved treatment for restoring blood 
flow in stroke patients11.  However, due to the stringent application window and risk of 
hemorrhage, less than 10% of patients are candidates for tPA treatment.  Acute treatment with 
hypothermia after brain I/R injury has been reported to have beneficial effect, but long-term 
outcomes reports are still sparse, and the mechanism of this protection is still unclear12, 13.  
 Brain ischemia treatment is an area of intense research.  However, all large scale clinical 
trials of neuroprotectants have failed14.  Out of the 1026 drugs that prevented neuron death in 
preclinical animal models of brain ischemia by the year 2006, 114 drugs were tested in clinical 
trial, and all failed to improve outcome14. 
With few effective therapies, brain ischemia is still killing and mutilating millions of 
people.  Failure of those neuron-protection clinical trials suggests that the problem is more 
complex and the understanding is not clear yet.  To date, many injury mechanisms have been 
identified, and below I provide a brief description.  
Experimental models of I/R injury 
There are various biological models for both global and focal brain I/R injury: from cell 
culture system, in vitro brain slices to whole animal models.  Although cell culture system is 
simpler and better controlled, whole animal models are superior.  Culture systems cannot fully 
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model I/R injury in vivo because culture systems lack the diversity of cell types, CNS 
architecture, blood flow dynamics, immune system effects, inflammatory responses, and the 
physical environment of neurons15. 
Focal brain ischemia animal models are achieved by introducing an occluding filament 
into the middle cerebral artery, the most common site of occlusion during ischemic stroke15.  
Due to the significant gradation of ischemia level from the inner core to the ischemia boundary 
in focal ischemia, the global brain ischemia model is a much cleaner model with less variability 
and better consistency15.  Global brain ischemia is achieved via (1) four-vessel occlusion (4-VO), 
(2) two-vessel occlusion combined with hypotension (2-VO/HT) or (3) cardiac arrest models in 
rats15.  In Dr. DeGracia’s lab, 2-VO/HT global brain ischemia rat model is used.  Details about 
this model will be discussed later.  The model causes less damage to peripheral organs compared 
with the 4-VO and the cardiac arrest models, so that the rats are able to survive and be observed 
to a longer duration.  The model generates transient global brain ischemia, which reproducibly 
induces delayed neuronal death in ischemia vulnerable neurons such as the CA1 regions in the 
hippocampus while leaving ischemia resistant neurons such as the CA3 regions in the 
hippocampus alive. 
The fact that both CA1 and CA3 neurons are pyramidal neurons, in the same brain 
structure (hippocampus), and experience the same ischemia insult, but have drastically different 
outcomes after transient global ischemia suggests that this model is ideal for investigating the 
different intrinsic defense response of neurons towards I/R injury.  The research proposed below 
will focus on the hippocampal neuron populations.  
Mechanisms for ischemia reperfusion damage of neurons 
Introduction 
Brain I/R injury is a complex protracted process, which can cause necrosis during or soon 
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after the insult, or can progress over days, called delayed neuronal death (DND).  Many 
mechanisms have been established to contribute to the I/R injury, and they are collectively 
referred to as the “ischemic cascade” (Figure 1).   
Figure 1. Overview of ischemic cascade 








With the cessation of blood flow, glucose and oxygen delivery to the neurons in that area 
stops, leading to energy deprivation.  With the failing of energy dependent pump and the 
subsequent dissipation of ion gradients, neurons get depolarized, opening voltage-gated calcium 
channels, and excitatory amino acid neurotransmitters, such as glutamate, are released.  
Glutamate release causes further depolarization and increase of calcium ions.  Subsequent 
lipolysis, proteolysis, and free radical damage are all activated.  Inflammatory responses also 
play an important role in focal brain ischemia animal models.  But in transient global brain 
ischemia models, inflammatory responses are not as important15. 
Loss of energy and excitotoxicity 
In the rat global brain ischemia 2-VO/HT model, with the cessation of blood flow, ATP 
level drops to 50% control level in the first minute of ischemia, and then drops to 6% control 
level after 5 min ischemia15.  Lactate level goes up with cell pH level decreasing17.  Without 
energy supply, the sodium potassium ATP pump (Na+-K+ ATPase) fails to keep the ion gradient 
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across cell membranes, which is vital for normal neuron activity.  Sodium and potassium ion 
thus equilibrate across the neuron membrane during ischemia, leading to failure of the transport 
of glucose and amino acids and depolarization of the neurons18.  Depolarization induces calcium 
influx from open voltage-gated calcium channel and the endoplasmic reticulum, leading to 
further neurotransmitter release.  The influx of calcium is able to drop extracellular calcium level 
from a starting concentration of 1.2 mM to less than 100 nM after 1 min of global ischemia in 
rats18,19.  Calcium overload in ischemic neurons then activates many enzymes leading to 
downstream effects, which will be discussed in more detail below.  A large increase of 
extracellular glutamate was observed during transient global brain ischemia20.  Glutamate 
released from depolarized neurons will act on 2-amino-3- (5-methyl-3-oxo-1, 2- oxazol-4-yl) 
propionate (AMPA) and N-methyl-D-aspartic acid (NMDA) ionotropic glutamate receptors and 
causes further depolarization21.  Depolarization leads to further calcium influx and 
neurotransmitter release, thus perpetuating the cycle, known as excitotoxicity.  
Calcium overload 
Calcium ions play important roles in many processes, such as signal transduction, 
membrane potential, enzyme activity, etc.  Thus calcium ion is strictly regulated. Calcium ion 
overload during I/R activates many enzymes, which contributes to the deleterious effects of 
ischemia.  
Calpains, a family of cysteine proteases, get activated by increased intracellular calcium, 
either micromolar (-calpain) or millimolar (m-calpain)15,22.  Calpain activity is increased in both 
focal and global brain ischemia rat models.  Substrates of calpain include eukaryotic initiation 
factor eIF-4G and eIF-4E, two important factors in translation initiation15,23. 
Phospholipase A2 (PLA2) is activated by increased intracellular calcium ions, and PLA2 
releases free fatty acid from the second carbon of glycerol in the phospholipids24.  The 
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arachidonic acid liberated from triglycerides by PLA2 can be converted to pro-inflammatory 
prostaglandins and leukotrienes by the inducible cyclooxygenase-2 (COX-2) and downstream 
enzymes25.  COX-2 is induced globally in both neuronal and glial cells, in the infarct core, the 
periinfarct region, and the homologous region of the contralateral hemisphere after stroke in 
human post mortem samples25.  But in the acute phase, COX-2 is concentrated near the ischemic 
core, and this suggests that PLA2 and COX-2 may play a role in the deleterious reactions25.  
Inhibition of prostaglandin production by COX inhibitor is correlated with a reduction of early 
infarct size in rat focal I/R model26. 
Other enzymes activated by increased calcium ions during neurons I/R injury include 
protein kinase C (PKC) and calcium/calmodulin-dependent kinase II-alpha (CaMKII)27.  Both 
PKC and CaMKII are serine/threonine protein kinases, deregulation of which is likely to 
compromise the integrity of neuronal signaling system.  
Neuronal nitric oxide synthase (nNOS) is induced by increased calcium.  The activation 
of nNOS is associated with the generation of the highly active peroxynitrite free radicals28.  
Inhibition of either nNOS or inducible nitric oxide synthase (iNOS) is shown to mitigate 
ischemic cell death in animal models15.  Free radicals from many sources are produced during 
I/R. 
Free radicals and reperfusion 
Restoration of blood flow is called reperfusion.  Reperfusion not only brings glucose and 
oxygen, but also generates free radicals or reactive oxygen species (ROS).  At 4 hr of reperfusion 
after 30 min global brain ischemia in rats, nitric oxide, superoxide, and peroxynitrite are all 
elevated in both cerebral hemisphere during reperfusion29.  Free radicals come from many 
sources in I/R neurons.  Mitochondria are an important source of free radicals.  Calcium overload 
in mitochondria during ischemia permeabilize the inner membrane of mitochondria, which leaks 
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superoxide during reperfusion30.  Oxidative metabolism of arachidonic acid, which is released 
from phospholipid, also leads to superoxide production, via either the COX or the lipoxygenase 
pathway15.  Xanthine oxidase generates superoxide by acting on hypoxanthine from the 
breakdown of adenine nucleotide during reperfusion31.  Neutrophils accumulated after focal I/R 
injury are also a contributor to the superoxide production via oxidizing NADPH, and both nNOS 
and iNOS contribute to the production of NO15. 
Numerous consequences follow the over-production of free radicals.  They affect 
structures of lipids and proteins.  Lipid peroxidation changes membrane permeability and 
fluidity32.  Several important enzymes are inhibited after modification by ROS, including 
plasmalemma Na+ and Ca2+ pump, and creatine kinase15.  Free radicals also lead to dysfunctional 
mitochondria, protein synthesis inhibition, and DNA cleavage15. 
Protein synthesis malfunction during I/R injury 
Neuron subpopulations have different threshold towards I/R injury.  Some neurons are 
selectively vulnerable to I/R injury and die in the form of delayed neuronal death (DND) after 
transient ischemia attack.  Prolonged protein synthesis inhibition, or translation arrest (TA), is an 
early marker of the vulnerable neurons.  
Delayed neuronal death and selective vulnerability  
After brain I/R injury, neurons either survive or die.  There are two forms of death: 
necrotic cell death and DND.  Necrosis forms the core of focal ischemia, and also appears in 
global brain ischemia when the duration of ischemia is long. Necrosis appears during or shortly 
after ischemia15.  Necrotic neurons are not salvageable, and are not the attention of clinical 




Figure 2. Selective vulnerability of CA1 neurons compared with CA3 neurons after 10 min 
ischemia via 2VO/HT model, shown by Toluidine blue staining adopted from Jamison, 200833. 
Distinct neuron populations have different response to ischemia, and transient ischemia 
can cause selective neurons to die in the form of DND. DND was first documented in rats by 
Pulsinelli and Brierly34 and in gerbils by Kirino35.  DND depends on both the insult duration and 
the cell population.  In DND, the substantial delay between the transient ischemia insult until 
neuron death is generally between 12 hrs and several days.  But the longer the duration of the 
ischemia, the shorter the delay15.  Both in rats and gerbils, CA1 neurons in the hippocampus are 
selectively killed by DND after transient global brain I/R injury, and this pattern is also 
consistent with the findings in human postmortem after ischemic event36.  Hippocampus is vital 
in functional declarative memory36 and DND of CA1 in hippocampus after transient ischemia 
results in compromised memory.  In humans, enduring memory deficits were reported to be 
associated with destruction limited to bilateral CA1 neurons37.  Increasing the duration of 
ischemia leads to accelerated DND of vulnerable CA1, and other neuron populations will show 
DND as well, such as CA4 and CA3 regions in the hippocampus and cortex layer II and V15. 
Isolated DND restricted to CA1 neurons with surviving CA3 neurons has been 
successfully modeled after transient global brain ischemia in Dr. DeGracia’s lab using 2-VO/HT 
rat model (Figure 2).  The basis for the selective DND of CA1, or alternatively, the selective 
survival of CA3, is not understood.  We hope that research using this model will further our 
understanding of the intrinsic response of different neuron populations.  
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Translation Arrest and selective vulnerability 
Protein synthesis is a complex biological function, which is essential for life. In the 
context of cell injury, translation is required for the expression of stress response transcripts that 
protect neurons after I/R injury.  It was first discovered in 1971 that protein synthesis was 
inhibited (translation arrest, TA) during brain I/R injury1.  After 30 min complete cerebral 
ischemia followed by 30 min reperfusion, cat brain homogenates showed a significant decrease 
in radioactive amino acid incorporation.  Polysomes were found to be intact during ischemia, but 
dissociated during reperfusion1.  TA is concomitant with the disaggregation of polyribosomes 
into monosomes1.  It was inferred that there was inhibition predominantly affecting the protein 
synthesis initiation phase during reperfusion1.  Later in rhesus monkeys, rats, mice and other 
species, similar findings of TA were reported15,17,38. 
Protein synthesis recovers over time in most post-ischemic neurons1.  However, an 
important discovery in the brain I/R field was that in neurons destined to die after transient 
ischemia, TA is persistent and protein synthesis is not recovered (Figure 3).  The fact that protein 
synthesis remains halted in ischemic vulnerable neurons but recovered in ischemic resistant 
neurons39 differentiates CA1 from CA3 neurons at a much earlier stage than the appearance of 
classical morphological changes of ischemic cell death15.  It was thus proposed that persistent 
TA contributes to or even causes DND after transient ischemia in vulnerable neurons.  Below, 






Figure 3. Radioactive tyrosine incorporation after 5 min 
global brain. This shows prolonged translation arrest in 
selective vulnerable CA1 neurons in gerbil hippocampus 
at various reperfusion durations as listed in each panel 
adopted from Thilmann, 198640. 
 
Posttranscriptional control and TA in reperfused neurons 
Expression of protein-coding genes is controlled at multiple levels, which include 
transcriptional, posttranscriptional and translational levels of regulation.  Below I will discuss the 
background of these processes and the three stages of research evaluating prolonged TA in 
ischemic sensitive neurons: (1) translation initiation, (2) stress protein synthesis, and (3) 
ribosomal sequestration. 
Translation initiation and TA under normal and I/R condition 
To initiate translation, cells need to bring together four components: the 40S ribosomal 
subunit, the 60S ribosomal subunit, the mRNA chosen to be translated, and the methionyl-
containing initiator tRNA.  Initiation of protein synthesis can be divided into 3 stages: (1) 
binding of the initiator tRNA (Met-tRNAi), eIF2, GTP to form the ternary complex, followed by 
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binding of other initiation factors and 40S ribosomal subunit to form the 43S preinitiation 
complex (PIC); (2) 43S PIC binds to mRNA and other initiation factors, with mRNA migrating 
to the correct AUG start codon, forming 48S PIC; recognition of the start codon triggers the 
hydrolysis of the eIF2 bound GTP and subsequent release of the initiation factors and (3) the 
addition of 60S ribosomal subunit at the start codon to form the 80S initiation complex 
(monosome), with nascent polypeptide chain begin to be synthesized41.  The polypeptides 
elongates as the mRNA is read in the 5’ to 3’ direction until it reaches a stop codon, and 
termination occurs.  
There are two rate limiting steps in the translation initiation stage42.  The first step involves 
eukaryotic initiation factor 2 (eIF2), which delivers the initiator tRNA to the 40S ribosomal 
subunit.  The second step involves the eukaryotic initiation factor 4 (eIF4/eIF4F), which delivers 
mRNA to the 48S PIC.  The cells control global rate of protein synthesis via the activity of eIF2 
and fine tune how much mRNA and which mRNA will be translated via the activity of eIF4. The 
abbreviated steps are shown (Figure 4).  
 
Figure 4. Abbreviated steps in translation inhibition, showing eIF2 and eIF4 steps, adopted from 
DeGracia, 200243. 
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eIF2 is a GTP binding protein, a complex consisting of three polypeptide chains: two 
catalytic subunits, eIF2 beta, eIF2 gamma and one regulatory subunit, eIF2 alpha (eIF2α).  In the 
initiation stage of protein synthesis, eIF2 binds GTP and Met-tRNAi to form the ternary complex, 
which is then brought to the 40S ribosomal subunits with other initiation factors, and they 
together forms the 43S PIC.  The 43S PIC is brought to the 5’ untranslated region (5’UTR) of 
mRNA, promoted by eIF4, forming the 48S PIC.  The PIC scans the mRNA until it reaches the 
start codon, AUG.  Once the start codon is found, the scan stops, with a conformational change 
in eIF2 resulting in the hydrolysis of eIF2-asscociated GTP, followed with the release of eIF2-
GDP complex44. 
Prior to subsequent round of translation initiation, the GDP bound with eIF2 must be 
exchanged for GTP, a reaction catalyzed by eukaryotic initiation factor 2B (eIF2B), a guanine 
nucleotide exchange factor45.  Recycling of GDP to GTP is blocked by phosphorylation of eIF2α 
at serine 5146.  Upon this phosphorylation, there is a 150-fold increase in binding affinity 
between eIF2α and eIF2B compared with its unphosphorylated counterpart of eIF2α46.  Thus, 
eIF2 is converted from a substrate into a competitive inhibitor of eIF2B47 and the global protein 
translation initiation is decreased.  The stoichiometry of eIF2 to eIF2B is around 5:1 in most 
cells48,49.  Thus, it takes only 20% of eIF2α to be phosphorylated to shut down all translation 
initiation in cells41. 
In neuron I/R injury, eIF2 plays an important role in TA.  Almost 30% of eIF2α is 
phosphorylated at 90 min reperfusion following 10 min of global brain ischemia42 and eIF2α 
phosphorylated at serine 51 is increased 20-fold at 10 min and 90 min reperfusion50. 
However, evidence shows that eIF2α phosphorylation doesn’t correlate with prolonged 
TA.  After focal I/R injury, eIF2α(P) markedly increased after 1 hr reperfusion, but normalized 
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after 6 hr recirculation in spite of the depressed protein synthesis51.  After transient global brain 
I/R injury, at 4 to 6 hr reperfusion, the level of eIF2α(P) gradually declines in all brain regions, 
and, eIF2α(P) level returns back to control level despite of the ongoing TA52.  Similar results 
were observed in Dr. DeGracia’s lab in that eIF2α(P) returned to control level at 4 hr reperfusion 
after transient global brain ischemia while protein synthesis remained low53.  Together the data 
indicates that the phosphorylation of eIF2α only contributes to the early phase of translation 
arrest and cannot explain the prolonged TA54. 
eIF4F 
The other rate limiting step of translation initiation involves eIF4F, which is a 
heterotrimer consisting of eIF4E, eIF4G and eIF4A. eIF4F delivers the mRNA to the 43S PIC 
and loads the start codon onto the P site of the ribosome.  Specifically, eIF4E binds to the 7-
methylguanylate (m7G) cap at the 5’ end of mRNA, and eIF4G acts as a scaffolding protein 
linking eIF4E with other initiation factors, while eIF4A working as a helicase unwinding the 
secondary structure of mRNA41.  Regulation of eIF4 enables the cell to control how much and 
which mRNAs are translated.  In addition, eIF4G also binds with poly (A) binding protein 
(PABP), which has a high affinity to the 3’ end of the poly (A) tail of mRNA, and thus the 
interaction between eIF4G and PABP promotes the circularization of mRNA, which is 
associated with improved translation efficiency55.  There is a family of proteins that bind with 
eIF4E and exclude it from the eIF4F complex, called eIF4E binding proteins41.  Phosphorylation 
of eIF4E-BPs release the eIF-4E to be incorporated into initiation machinery thus promote 
protein synthesis56. 
eIF4G is partially degraded during global brain ischemia42 by -calpain, activated by 
increased cellular calcium level23.  eIF4E level decreases during reperfusion57 while eIF4E-BP is 
dephosphorylated during ischemia58.  Degradation of eIF4F components requires ischemia 
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longer than needed to induce DND, and other changes correlate with transient but not prolonged 
TA. 
Gene activation and TA  
In order to adapt to environmental stresses, eukaryotic cells have evolved genetically-
encoded stress responses.  Integral to stress responses is the shutting down of protein synthesis.  
This serves to conserve energy for the repair and provide time to change the pattern of gene 
expression via transcription.  TA is selective: translation of constitutive transcripts is turned off, 
but translation of stress-induced genes is maintained.  
Both heat-shock response and the unfolded protein response are activated in brain I/R 
injury59.  While there is global TA, specific proteins are selectively translated.  The expression 
pattern of these protein is not uniform in all neurons, leading to the inference: protein expressed 
in resistant neurons and not in vulnerable neurons is protective, and that the absence of the 
expression of that protein is important in the development of DND15. 
Heat shock protein (HSP) family is one of those translated during brain I/R injury. HSPs 
are induced in a variety of physiochemical insults.  Induced HSP helps prevent protein 
aggregation and the misfolding of polypeptides60.  Polysomes isolated from reperfused rat brain 
after global I/R and then subjected to in vitro protein synthesis generate heat shock proteins from 
the HSP70, HSP90, HSP110 families61.  Below the discussion will focus on HSP70, the most 
extensively studied HSP family member.  
HSP70 (also known as the HSP72) is the induced form of 70 kDa stress protein. HSP70 
is usually not detectable under normal conditions, but is induced at high level after a variety of 
CNS insults.  HSP70 functions as a chaperone, binding to denatured proteins to restore their 
structure and function60.  Overproduction of HSP70 in vitro in cell culture62 or by gene transfer 
into wild-type animals via direct cerebral injection yields protective effect on neuron survival60.  
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In focal cerebral I/R, HSP70 expression is only seen in neurons at the infarct penumbra, at the 
endothelial cells in the infarction, but not in the neurons in the infarction which are necrotic63. 
After transient global I/R, both vulnerable CA1 and resistant CA3 neurons show large 
increase of hsp70 mRNA  at  8 hr  reperfusion, 160- and  50- fold respectively59.  hsp70  mRNA 
Figure 5. hsp70 mRNA after 10min global brain 
ischemia and reperfusion time indicated in CA1 




peaks at 8 hr in CA3 neurons and returned to control by 30 hr reperfusion, but peak at 18 hr in 
CA1 neurons and remain high even at 42 hr reperfusion (Figure 5)59.  However, there is a  
disjunction between the transcription and the 
translation of HSP70 in CA1 neurons. HSP70 protein 
expression is delayed in CA1 neurons compared with 
CA3 neurons by a gap of 28 hrs33.  Expression of the 
HSP70 protein is pronounced in CA3 neurons already 
at 8 hr reperfusion after 10 min global brain ischemia, 
while HSP70 translation in CA1 neurons only begins 
after 36 hr of reperfusion (Figure 6)33.  This leads to 
the reasoning that translation of HSP70 early 
contributes to the survival in CA3 neurons, and  that  
Figure 6. HSP70 stain by immunofluorescence 
microscopy showing CA1 and CA3 regions of 
hippocampus in rat after 10 min global brain ischemia 
and indicated reperfusion time, from Jamison, 200833. 
 






















the inability to translate HSP70 contributes to the death in CA1 neurons.  The disjunction of 
transcription and translation of HSP70 will be the focus in current studies. 
c-Fos and c-Jun are nuclear proto-oncogenes, and they are members of the immediate 
early genes (IEG), which are activated transiently and rapidly after a wide variety of stimuli, 
including brain I/R.  Both of the product proteins are activated at a much earlier stage in I/R 
before the expression of HSP70.  In the gerbil hippocampus, expression of c-FOS was seen 1-6 
hrs after 15 min global ischemia in CA3 and CA4 regions, and expression of c-JUN was seen 4-
48 hrs in the same area.  The induction of both c-FOS and c-JUN protein expression was 
negligible or absent in CA164. 
Other proteins are also induced or down-regulated in brain I/R injury.  After global brain 
I/R in rats, brain derived neurotrophic factor (BDNF) is decreased significantly in CA1 neurons, 
with little change in CA3 neurons65.  The bcl-2 and bcl-x-long proto-oncogenes have been shown 
to suppress apoptosis in neurons in in vitro systems66 and neuron cell lines67.  After transient 
global brain I/R in rats, their mRNA is up regulated in both CA1 and CA3 neurons, but the 
protein expression only occurs in CA3 neurons68. 
As discussed previously, polysomes remain intact during brain ischemia, and they 
dissociate during reperfusion1,38.  Since the dissociated polysomes are inhibited at the initiation 
state, how the polysomes get reassembled and how specific transcripts are selectively translated 
in I/R resistant neurons is unknown and is a topic addressed by this thesis research. 
Ribosomal sequestration and TA  
Further investigations into the cause of prolonged TA discovered that brain I/R injury 
causes ribosomes sequestration into cytoplasmic complexes, which prevents translation69.  Both 
mRNA and translation machinery can be sequestered into cytoplasmic inclusions, and both 
conditions will lead to TA.  The particles can be viewed under light microscopy and studied by 
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fluorescence immunohistochemistry.  Two general classes of particles have been identified in 
reperfused neurons: (i) structures related to protein ubiquitination and (ii) structures related to 
mRNA metabolism70. 
Particles containing ubiquitin include ubiquitinated protein clusters and protein 
aggregates (PA)69, both of which accumulate during I/R and explain the robust heat shock 
response.  Ubiquitin is a small highly conserved regulatory protein which marks protein for 
degradation or proteolysis by proteasome system69.  These particles are aggregates of denatured 
proteins whose rate of production exceeds their rate of degradation during pathologic condition.  
Ubiquitinated protein clusters are present in all post ischemic neurons and are relatively large 
(2~5um), while PAs are only present in ischemic vulnerable CA1 neurons and are smaller 
(50~200nm)69,71.  PAs sequester ribosomal subunits, initiation factors, and co-translational 
chaperones in reperfused neurons72.  However, only 20% of ribosomal subunits are held in PAs 
and cannot fully explain the persistent TA in CA1 neurons70. 
Around a dozen particles have been identified in mRNA regulation. I will first generally 
describe mRNA regulatory complexes and then discuss the role they play in reperfused 
neurons70.  The general study of mRNA regulation is termed “ribonomics”. 
Ribonomics operon model  
Ribonomics is the study of mRNA regulation.  It is well known that mRNA is transcribed 
and processed in the nucleus, and it is transported out of the nucleus to be translated on 
polyribosomes.  From synthesis to degradation, mRNA is bound to a variety of different 
messenger ribonucleoprotein particles (mRNPs).  The function of the mRNPs includes 
biogenesis, transportation, silencing, translation and degradation of mRNAs73, 74.  mRNPs are 
collections of mRNA and protein, which regulate the bound mRNA.  Many mRNPs have been 
identified including heterogeneous nuclear ribonucleoprotein complexes (hnRNPs), polysomes, 
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RNA granules, stress granules, RNA-inducing silencing complex (RISC), processing bodies, and 
etc70.  Thus it is not surprising that the mRNA set in a cell does not correlate with the protein set 
in a cell75.  Regulation of mRNA stability and expression depends both on the various structure 
elements on the mRNA and the different mRNA binding proteins.  
Structure of mRNA 
A fully processed eukaryotic mRNA typically contains a 5’ cap, 5’ untranslated region 
(UTR), coding sequence, 3’ UTR, and a poly-A tail.  
The 5’ 7-methylguanosine cap is found at the 5’ end of mRNA, and it is connected to the 
mRNA via a 5’ to 5’ triphosphate linkage.  This 7-methylguanalyte cap provides the mRNA 
resistance to 5’ exonucleases.  It is recognized by eIF4E, which together with eIF4G and eIF4A, 
functions at positioning the ribosome at the start codon of the mRNA76. 
The 5’UTR is a non-coding region with variable length of nucleotides and contains 
regulatory elements that play important roles in mRNA regulation77.  The most famous is the 
internal ribosomal entry sites (IRES) in the 5’UTR, which mediates cap-independent translation 
initiation78.  The IRES sequence is identified in many key regulatory genes such as c-myc, BIP, 
eIF4G, whose protein products play important roles in processes during which cap-dependent 
translation is silenced or reduced, such as in viral infection79 in mitotic cycle80 and in DNA 
damage genotoxic stress81.  Many transcripts that contain IRES sequence can also be translated 
via the cap-dependent manner, thus IRES provide a switch that allow selective expression of 
essential protein in cell crisis77.  Small structural elements in the 5’UTR are also involved in 
mRNA regulation, and the best studied example is the iron response element (IRE), which is 
essential in iron homeostasis, and mutation of which has been implicated in human disease77.  
Long 5’UTR can form secondary structure, which can affect cap-dependent translation.  The 
size, stability and position relative to the 5’ cap of the secondary structure determine the extent 
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of the effect.  Many mRNAs containing highly structured 5’UTRs are involved in growth control 
and are in general translational suppression77. 
The 3’UTR follows termination codon and is also involved in mRNA regulation. 
Adenine Uridine-rich elements (AREs) are regions with frequent adenine and uridine bases in 
the 3’ UTR in mRNA.  They are commonly divided into five groups based on the number of 
motifs in the ARE82.  AREs are closely associated with mRNA degradation and stability82.  ARE 
containing mRNAs are short lived, and the ARE is considered a potent mRNA destabilizing 
factor83.  Those mRNAs containing the ARE element include proto-oncogenes (c-fos), cytokines, 
and transcription factors83.  ARE-binding proteins bind to the ARE region and regulates mRNA 
stability, for example, HuR, and this will be further discussed below.  
Most mRNAs in eukaryotic cells contain a 3’ poly (A) tail. Poly (A) tails are bound with 
the poly A- binding protein (PABP), which protects mRNAs from ribonuclease degradation84.  
The poly (A) tail also acts with the 5’ cap to increase translation initiation efficiency by forming 
a closed loop structure through the interaction between PABP and eIF4G subunit of eIF4F85.  
However, not all poly (A) tails are created equal.  Alternative polyadenylation results in 3’UTR 
of different length, and it is associated with different stages of cell proliferation and 
transformation86.  Deadenylation of mRNA is the common first step in mRNA degradation and is 
also a way to store mRNA in a stable and translation silenced manner, which occurs during 
embryogenesis86,87. 
mRNA binding proteins (RBPs) 
Cell function depends heavily on the ability to regulate mRNAs and coordinate between 
transcriptional and posttranscriptional events.  RBPs are at the core of posttranscriptional control, 
and they regulate the function and fate of their target mRNAs.  RBPs are involved in both 
nuclear and cytoplasmic RNA processing.  They regulate exportation, localization, translation 
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and stability of target mRNAs. RBPs contain RNA binding domain and interact with mRNAs 
cis-acting sequences.  These cis-acting regulatory RNA elements can be found in any region 
along the mRNA molecule, frequently the 5’UTR and 3’UTR.  Genome wide in-situ 
hybridization in developing mouse brain reveals that some RBPs are expressed in a neuron 
specific pattern, and most RBPs are expressed in a region specific pattern, suggesting their 
important regulatory role88.  
Mutation in RBPs have been implicated in many neurological diseases such as Fragile X 
syndrome, spinal muscular atrophy, paraneoplastic neurological syndromes, myotonic dystrophy, 
Fragile X tremor ataxia syndrome, and etc89.  For example, Fragile X syndrome is caused by the 
absence of RNA binding by fragile X mental retardation (FMR) protein, and the polysome-
bound mRNA population is changed drastically in fragile X cells compared with control cells90.  
Nova protein, is essential for neuronal viability and regulates mRNA flow, and is targeted in 
paraneoplastic opsoclonus myoclonus ataxia (POMA), an autoimmune neurologic disease91. 
Eukaryotic mRNA operon or regulon view 
Increasing evidence indicates that many RBPs associate with many mRNA targets92 in a 
combinatorial fashion.  This property has led to the mRNA operon model, proposed by Jack 
Keene’s group, where it is suggested that RBPs regulate mRNA as subpopulations analogous to 
DNA operons in prokaryotic cells92.  Prokaryotic organisms cluster genes into operons, which 
are under the influence of a single regulatory signal, thus allowing efficient and coordinate 
production of functionally linked genes in groups93.  In the mRNA operon model, eukaryotic 
monocistronic mRNAs are clustered into the functional equivalent of prokaryotic operons by 
binding to RBPs via common sequence.  Any given mRNA can also bind with other different 
RBPs, thus combinatorial regulation can occur in response to different stimuli, providing a 
flexibility and coordination analogous to prokaryotic operons (Figure 7)92,94. 
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Figure 7. Diagrammatic representation 
of combinatorial organization of 
mRNA subpopulations in eukaryotic 
ribonucleoproteins. A, prokaryotic 
polycistronic mRNA with four open 
reading frame; B, eukaryotic 
monocystronic mRNA containing 
combinatorial untranslated sequence 
elements for regulation (USER), 




Both ribonucleoprotein-immunoprecipitation (RIP) and UV crosslinking and 
immunoprecipitation (CLIP), followed by microarray analysis of bound mRNAs, revealed that 
different RBP bind to distinct subsets of mRNA in yeast, fruit fly and mammalian cells74,95,96 and 
these target mRNA subsets are functionally related96-98.  Further, mRNAs from different 
functional classes have distinct turnover rates99,100.  Transcription factor mRNAs have increased 
decay rates, while mRNAs for biosynthetic proteins have decreased decay rates100,101.  Even 
more, the stability or half-life of distinct mRNA subsets changes in coordination upon cell 
stimulus101,102. 
Normal neuronal development and organization requires coordination of RBPs and 
mRNA, thus it is highly likely that the neurons exhibit operon control.  I will now discuss two 
well-studied mRNPs: stress granules and HuR granules that have been shown in Dr. DeGracia’s 
lab to play a role during I/R injury. 
Stress granules 
Stress granules (SGs) are rapidly induced cytosolic structures into which mRNAs are 
sorted in mammalian cells in response to environmental stress (such as heat, UV irradiation, 
hypoxia)103.  SGs can be observed under fluorescence microscopy as small (< 1 m), circular 
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cytoplasmic foci with colocalization of poly (A) mRNA and mRNA binding protein T cell 
internal antigen (TIA-1) and TIA-1 related protein (TIAR)103.  SGs function as triage centers to 
route untranslated mRNA to other mRNA mRNPs. 
Components of SGs include the stalled 48S preinitiation complexes, which include the 
40S subunit with translation initiation factor eIF2, eIF3, eIF4E and eIF4G104 whereas 60S subunit 
is absent103.  It is estimated by in situ hybridization that approximately 50% of all poly (A) 
mRNA is sequestered in SGs during stress105.  SGs sequester housekeeping mRNAs, but exclude 
mRNAs coding stress protein105.  Thus SGs allow general suppression on translation of 
housekeeping genes, but foster selective translation of stress induced genes.  In addition, SGs 
contain many RNA-binding proteins that regulate RNA function, including HuR, tristetraprolin 
(TTP), staufen, TIA-1, TIAR, PABP1, FMRP, and etc73. 
The assembly of SGs is in close relation to translation inhibition during stress.  
Phosphomimetic eIF2α mutant (a mutant that mimics phosphorylated eIF2α, which as mentioned 
above, prevents the assembly of 43S PIC and leads to translation arrest) is sufficient to induce 
SGs formation in unstressed cells, while nonphosphorylated eIF2α mutant prevents and 
alleviates SGs formation even in the arsenite treated stress cells103.   TIA-1 plays important role 
in the assembly of SGs, as mutant TIA-1 which is incapable of binding RNA inhibits SGs 
formation103.  Proteins enter and leave SGs all the time, with rates ranging from milliseconds to 
seconds106.  The assembly of SGs, which is characterized as shuttling of TIA-1 and PABP, is in 
equilibrium with polysomes.  The assembly is inhibited by drugs that stabilize polysomes 
(ementine, cycloheximide), and is promoted by drugs that destabilize polysomes (puromycin)106. 
Whether SGs is reversible or not correlates with the severity of stress and the fate of the 
stressed cells.  SGs is reversible in DU145 cells subject to sub-lethal arsenite stress, but 
irreversible in cells under lethal stress103. 
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SGs were evaluated in rat hippocampal formation in different global brain ischemia 
models, and the results were animal model-dependent.  In the thoracic compression method of 
cardiac arrest model, after 10 min global ischemia, SGs formed at 10 min reperfusion, but were 
reversible and returned to control values by 90 min reperfusion in resistant neurons (CA3, DG, 
and hilus).  However, SGs persisted in CA1 neurons, and the S6 (40S marker) was sequestered 
within SGs at 4 hr reperfusion107.  Due to the fact that animals with cardiac arrest model have 
very poor survival rate, and that very few rats would survive further than 4 hr reperfusion, in 
order to look at further time points of reperfusion, 2VO/HT model was used as the model for 
global brain ischemia.  But sequestration of 40S did not occur following global brain ischemia 
via 2VO/HT model, and thus SGs behavior was model-dependent and not a common 
denominator of persistent TA33,108.  But in the 2VO/HT model, SGs did increase in number 
within 15 min reperfusion70 and there is convergence of SGs and PA at 2 day reperfusion after 10 
min global ischemia only in CA1, but not in CA3, which may contribute to the persistent TA in 
vulnerable neurons108. 
Hu granules and mRNA granules  
Hu granules are also mRNA containing structures, and they appear during cell stress and 
differentiation109.  HuR proteins are components of the Hu granules.  HuR belongs to the Hu 
RNA binding protein family, which contains the ubiquitous HuR (also called HuA) and the 
neuronal specific HuB (also called Hel-N1), HuC, and HuD protein110.  Hu proteins shuttle 
between nucleus and cytoplasm111 and are implicated in many biological functions, including 
neuronal development, neuronal plasticity, memory, and stress response.  The functions result 
from their ability to bind specific mRNAs.  
HuR consists of two N-terminal RNA recognition motifs (RRM1-2), a hinge region, and 
a C-terminal RRM (RRM3), and in most cases binds to adenine and uridine rich element (ARE) 
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on the 3’UTR of mRNA, promoting mRNA stability112.  HuR binds to the ARE sequence in the 
3’UTR of mRNA in many early response genes113,114.  Its expression is essential in progenitor 
cell survival in mice, and postnatal global deletion is lethal115. 
Besides increasing mRNA stability, HuR is also implicated in mRNA translation.  HuR 
binding to the 3’ ARE can increase recruitment of mRNA to polysomes, promoting translation 
initiation.  Examples are the translation of cytochrome c116 and p53117.  HuR also binds to the 3’ 
UTR of hypoxia-inducible factor 1  (HIF1) mRNA and promote its association with active 
polysomes and thus translation118.  Facilitating the export of mRNA from nucleus to cytoplasm is 
another mechanism by which HuR is able to up-regulate certain protein translation, and 
examples include CD83, C/EBP , and prothymosin 110. 
In reperfused neurons, mRNA granules were observed to form by 1 hr reperfusion as 
distinct granular structure.  Visualized by fluorescence in situ hybridization (FISH) microscopy, 
mRNA granules were a rearrangement of the cytoplasmic poly (A) mRNAs33.  The granules did 
not co-localize with TIA-1, S6 or TTP, indicating that mRNA granules are not SGs.  However, 
colocalization of mRNA granules with antisera that detected all 4 forms of Hu proteins suggested 
they were forms of Hu granules.  Using the 2VO/HT model, the reperfused hippocampus was 
observed out to 3 days after 10 min global brain ischemia.  The mRNA granules formed by 1 hr 
reperfusion in CA1 and CA3 neurons, and they abated in CA3 neurons after 16 h reperfusion, but 
persisted in CA1 neurons out to 48 h reperfusion (Figure 8).  In vivo protein synthesis 
measurements correlated with the mRNA granules, and thus mRNA granules offered a 
mechanism of prolonged TA in vulnerable neurons: mRNA is compartmentalized away from 
ribosomes. 
More confirming, pretreatment with cycloheximide (CHX), a drug which prevents the 
release of deacylated tRNA from the elongating ribosome119  freezing  mRNA in  place  with  the  
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Figure 8. FISH microscopy 
picture showing mRNA 
granules (arrowheads) in 
CA1 and CA3 neurons in 
rat hippocampus after 10 
min global brain ischemia 
and reperfusion time as 

















polysomes, inhibited the formation of mRNA granules at 1 hr reperfusion, if given 15 min before 
induction of ischemia.  However, CHX treatment at 15 min reperfusion, after polysomes had 
dissociated, had no effect on mRNA granule formation120, supporting that mRNA from 
polysomes were required to form the mRNA granules.  
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In both CA1 and CA3 neurons, Hu proteins were observed to colocalize with mRNA 
granules.  However, there is a delay of colocalization of Hu proteins and mRNA granules in CA1 
neurons compared with CA3 for at least 35 hrs, and this colocalization correlated with HSP70 
translation.  Further characterization of the mRNA granules showed no colocalization with 
endoplasmic reticulum, cis- or trans-Golgi apparatus, mitochondria, microtubules, intermediate 
filaments and 60S ribosomal subunits121  
Hu proteins and reperfused neurons 
hsp70 mRNA contains ARE element in the 3’ UTR122.  Hu proteins bind ARE sequences 
and colocalize with mRNA granules which correlated with HSP70 translation in reperfused 
neurons33.  This lead us to hypothesize that Hu proteins somehow promote the translation of 
HSP70 in reperfused neurons and thus provide protection in resistant neurons. 
To address this issue, our lab studied Hu proteins in reperfused neurons123.  We showed 
that Hu proteins bind to hsp70 mRNA but do not regulate its nuclear export; nor is there a 
change in the levels specifically of Hu associated with polysomal fractions during reperfusion123.  
However, this latter observation does not rule out the possibility that Hu proteins may associate 
with different binding partners on polysomes during I/R, and is something we proposed below to 
directly test. 
Translational state analysis, in which polysomes are isolated and the bound mRNAs 
identified by microarrays, of CA1 and CA3 after 10 min ischemia and 8 hr reperfusion indicated 
that CA1 and CA3 neurons were enriched in ARE-containing mRNA, suggesting potential 
ribonomic control123.  In this analysis, it was observed that the most abundant mRNA on 
polysomes at 8 hr reperfusion in CA1 and CA3 was hsp70 mRNA.  In total, 30 ARE-containing 
mRNAs were bound to polysomes in CA1 and CA3 at 8 hr reperfusion, and represented 4.5% of 
all polysome-bound mRNAs compared to non-ischemic controls. In contrast, it is estimated that 
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2% of all mRNAs in the rat transcriptome contain ARE sequences123.  Therefore, there was an 
overall enrichment of ARE-containing mRNAs at 8 hr reperfusion, compared to controls, and 
this, along with the fact that hsp70 was the most abundant polysome-bound transcript, suggests 
that Hu protein regulation of selective translation occurs during I/R.  Below I describe 
experiments to further understand the role of Hu proteins in selective translation during brain 
I/R. 
Summary of background 
I have reviewed different mechanism investigated in neuron I/R injury, and focused on 
correlation of prolonged TA with DND in ischemic vulnerable CA1 neurons.  I reviewed 
posttranscriptional regulation related to TA after I/R injury, including initiation factor studies, 
selective stress gene expression, ribosomal sequestration, and studies of SGs and Hu granules 
(mRNA granules).  I summarized the view of mRNA operon regulation.  These discussions show 
that posttranscriptional control of mRNA flow is closely related to prolonged-TA in CA1 
neurons.  The mechanism to survive and resume protein translation in ischemic resistant CA3 
cells after I/R injury compared with ischemic vulnerable CA1 cells may lie within the ability to 
coordinately regulate mRNA flow.  However, many details are still unclear.  
At present, the knowledge of translation regulation, based mainly on results from the 
2VO/hypotension model of global brain I/R, is summarized in Figure 9.  During ischemia, 
polysomes are kept intact because loss of ATP stops elongation.  Within minutes of reperfusion, 
eIF2 is phosphorylated and this causes polysomes to disaggregate by preventing translation 
initiation.  Breakdown of polysomes frees mRNA molecules, which cause formation of SGs 
within 10-15 min of reperfusion.  SGs return to control levels by 90 min reperfusion107, but by 1 
hr reperfusion, mRNA granules form in the neurons33.  In CA3, mRNA granules colocalize with 
Hu proteins and translate HSP70 protein and the mRNA granules disappear after 16 hr 
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reperfusion.  In CA1, Hu proteins do not colocalize with the mRNA granules until 36 hr 
reperfusion.  At this time the neurons are observed to translate HSP7033.  The selective 
translation occurs early in reperfusion in CA3 and late in CA1.  This time difference is thought to 
promote survival in CA3 and death in CA1.  The directing force behind the accessibility of stress 
gene mRNAs to polysomes, and what is preventing Hu proteins from acting in CA1 neurons as 
they do in CA3 neurons needs to be further investigated and forms the subject of the following 
hypotheses. 
 
Figure 9. Summary of 
translation regulation in neurons 






I therefore propose to investigate the following three hypotheses: 
Hypothesis 1: mRNA regulatory complexes bound to polysomes will differ in CA1 and CA3 
neurons at 8 hr reperfusion. 
This hypothesis will be tested by performing mass spectrometry (MS) proteomics on 
polysome pellets from microdissected CA1 and CA3 at 8 hr of reperfusion to detect RBP 
complexes interacting with polysomes, providing clues to the regulation of translation at this 
time point.   
Hypothesis 2: HuR binds to different mRNA binding proteins in CA1 and CA3 neurons at 8 hr 
of reperfusion.  
This hypothesis will be tested by performing MS proteomics on co-precipitating proteins 
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from HuR immunoprecipitation (IP) to compare HuR binding partners between vulnerable CA1 
and resistant CA3 to gain insight into the possible combinatorial interaction between RBPs. 
Hypothesis 3: mRNAs bound to polysomes isolated after reperfusion will indicate ARE 
regulation of selectively translated mRNAs. 
This hypothesis will be tested by running microarrays on mRNAs extracted from 





CHAPTER 2: INVESTIGATION OF POLYSOME PROTEOMICS AT 8 HOURS OF 
REPERFUSION 
Hypothesis 1: mRNA regulatory complexes bound to polysomes will differ in CA1 and CA3 
neurons at 8 hr reperfusion. 
Rationale  
At 8 hr reperfusion, global translation is still inhibited but selective translation of HSP70 
is detected in CA3 but not CA133.  The posttranscriptional regulation of mRNA determines 
which mRNAs get access to the polysomes.  In cultured human medulloblastoma cells, HuB 
(Hel-N1), a neuron specific form of Hu protein, co-purified with polysomes109.  Therefore it is of 
interest to determine the proteins that co-purify with polysomes to look for clues to mRNA 
regulatory events.  To study hypothesis 1, polysomes were purified by the sucrose pad method 
and assessed for the presence of RBPs by proteomics.  Because this procedure was worked-up 
for the present studies, a number of pilot and control studies will also be described along with the 
main findings. 
Experiment design overview 
The overall design is shown in Figure 10.  Aim 1 was tested using microdissected CA1 
and CA3 neurons from nonischemic controls (NIC) and at 8 hr reperfusion after 10 min global 
brain ischemia (8R), using n = 15 animals per experimental group.  CA subregions from n = 5 
animals were dissected and randomly pooled as one replicate for polysome pellet isolation, 
providing 3 pooled replicates per region per experimental group.  Polysome pellets from each 
replicate were isolated using ultracentrifugation.  The polysomal pellet was then resuspended, 
proteins extracted, and subject to either iTRAQ or LC-MS proteomics.   
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Figure 10. Experimental 
design for Aim 1 
proteomics of polysomes in 
CA1 and CA3 neurons 







The choice of the total number of animals and the number to be pooled per experimental 
group was based on the need to constitute 350 l of PMS to be loaded on the pad with the 
homogenization ratio unchanged.  Five pooled CA1 or CA3 were required to generate PMS of 
that much volume.  
Materials and methods 
Materials 
Antisera for PABP (ab21060), pyruvate dehydrogenase (ab110330), COX IV (ab16056), 
and cytochrome C (ab13575) were purchased from Abcam (Cambridge, MA, USA).  Antisera 
for S6 (2217 cell signaling) was purchased from cell signaling technology (Beverly, MA, USA).  
Antiserum for ribosome P antigen (RPA) (HPO-0100) was purchased from ImmunoVision 
(Springdale, AR, USA).  Antiserum for PDI (MA3-019) was purchased from Thermo Scientific 
(Rockford, IL, USA).  Antiserum for NeuN (MAB377) was purchased from Merk Millipore 
(Billerica, MA, USA). SYBR® Gold Nucleic Acid Gel Stain was purchased from Life 
technologies (Carlsbad, CA, USA).  HSP-70 (SPA-812) antiserum was purchased from Enzo 

























018), and RNaseZap® RNase Decontamination WipesZapwipe (AM9786) were purchased from 
Life technology (Carlsbad, CA, USA). iTRAQ® kit (4390811) was purchased from AB Siex 
(Framingham, MA, USA).  Protease inhibitor cocktail (P8340) and Diethyl pyrocarbonate 
(DEPC) (40718) was purchased from Sigma Aldrich (St. Louis, MO, USA).  All other chemicals 
were reagent grade.  Mass spectrometry related chemicals were MS grade. 
Animals 
All animal experimental protocols were approved by the Wayne State University Animal 
Investigation Committee and were conducted following the Guide for the Care and Use of 
Laboratory Animals (National research Council, revised 2011). All efforts were made to reduce 
animal suffering and minimize the total number of animal used. Male Long Evans rats are used 
in this study.  I am approved to perform the rat surgery under Protocol # A01-03-12, with Dr. 
DeGracia as PI on this protocol. 
Surgery: 2VO/HT Model 
Global brain ischemia was induced in experimental group animals via the 2VO/HT model 
of of Smith et al124.  Rats were induced with 5% halothane and anesthesia maintained at 2% 
halothane in 100% O2 using nose cone throughout the duration of the surgery.  Body temperature 
was monitored via rectal temperature probes.  A homeostatic blanket was used to maintain rat 
body temperature (37 ± 0.5°C) based on the readings of the rectal probe.  One catheter was 
introduced in the tail artery to measure mean arterial pressure (MAP) in real time.  Both common 
carotid arteries were isolated and lassoed.  One catheter was introduced in the right femoral 
artery. B efore the induction of ischemia, rats were first heparinized and 150 IU/kg heparin was 
administered via the right femoral artery.  After 5 min of steady state period after heparin 
injection, blood was withdrawn from the right femoral artery into a 10 ml syringe to produce a 
MAP of 50 mm Hg, and both isolated common carotid arteries were clamped using 
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microanueysm clips. MAP was maintained at 50 mm Hg in the ischemic period of 10 min by 
either withdrawing or infusing blood through the right femoral artery. For a rat of 350 g, it took 8 
to 10 ml of blood on average.  At the end of 10 min ischemia, the clips on the common carotids 
were released, and blood was infused back to the rat at a rate of 5 ml/min.  All wounds were 
sutured and halothane was discontinued.  Temperature control was maintained for 1 hr following 
surgery.  All post surgical animals were housed in a 12 hr light/dark cycle, and food and water 
access was provided in the reperfusion period.  At 8 hr of reperfusion rats were sacrificed and the 
brain was dissected.  Tissue processing and brain dissection is further described below. 
Microdissection of CA1, CA3 and forebrain 
RNAse contamination was minimized in all procedures by the following steps: 
consumables were RNAse-free and containers and surfaces were treated with RNase Zap 
(Invitrogen, Carlsbad, CA) then rinsed 5 times with DEPC-H2O.  All solutions were prepared 
with DEPC-H2O.  Procedures were performed under a laminar flow hood whenever possible. 
Masks and gloves were worn in all the procedures. 
Experimental and control animals were anesthetized with 5% halothane, decapitated, and 
the brains quickly dissected with a rongeur.  The whole brain was quickly rinsed in DEPC-H2O 
and snap frozen in dry ice-ethanol bath for 10 seconds.  Brains were then put in a brain blocker 
and allowed to thaw for five seconds.  A coronal section of the brain was taken at -2.44 mm to -
4.78 mm posterior to Bregma125,126.  The slice was then snap frozen again in dry ice-ethanol bath 
for about 5 seconds.  Hippocampal CA1 and CA3 were dissected on a dissecting stage under a 
dissecting microscope from the semi-frozen coronal slice.  The slice was maintained at a 
semifrozen state by application of dry ice to the dissecting stage.  
The CA3 region was separated by a vertical cut slightly medial to the curve of the CA3.  
The CA3 region was then isolated following its natural demarcation between hippocampus, 
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corpus callosum and cortex.  The CA1 region was separated by a horizontal cut just above the 
dentate gyrus and isolated following its natural demarcation.  For a single rat, bilateral dissection 
of CA1 and CA3 gave ~20 mg total wet wt.  The dissected CA1 and CA3 subregions were 
weighed in RNAse-free Eppendorf tubes and immediately frozen in dry ice-ethanol bath. 
Cerebral cortex (CTX) was taken from the rostral tissue of the slice.  All tissues were stored at -
80 °C until used for further processing.  
Validation of reperfusion by Western blot 
All reperfused animals were validated for translation of HSP70 in the CTX samples 
isolated during brain dissection.  CTX was homogenized at 1:10 (w/v) in cold buffer containing 
50 mM HEPES, pH 7.4, 150 mM NaCl, 1 mM EDTA, 25 mM DTT, 1% (v/v) Triton X-100, 
10% (v/v) glycerol, 5.2 µl/ml protease inhibitor cocktail (Sigma).  Nuclei and mitochondria were 
pelleted by 9000 g centrifugation for 15 min at 4 °C to generate post-mitochondrial supernatant 
(PMS).  Protein concentration was determined by Lowry assay.  50 µg of samples were loaded 
onto each lane on 10% SDS-PAGE gels, and electrophoresis was run at 25 mA/gel at constant 
current.  The gel was then transferred to nitrocellulose at a constant current of 100 mA overnight.  
Western blot condition were as follow: rabbit anti-HSP70 (SPA-812), 1:1000, 1hr, room 
temperature; horseradish peroxidase linked donkey anti-rabbit (NA934), 1:15,000, 45 min, room 
temperature.  Antibodies were incubated in Tris buffered saline with 2% Tween-20 (TTBS).  
Polysomes pellets  
All procedures were performed on ice and the measures described above were taken to 
prevent RNAse contamination.  Microdissected samples from 5 animals were pooled as one 
replicate and hand homogenized in a glass dounce at 1:8.5 (w/v) in cold homogenization buffer 
of 340 mM sucrose, 50 mM Tris, pH 7.4, 25mM NaCl, 5mM MgCl2, 300mM cycloheximide, 
1mM DTT, 5.2 µl/ml protease inhibitor cocktail (Sigma), and 80U/ml RNase inhibitor 
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(Invitrogen).  The glass dounce has a 150 µm clearance and to prevent nuclear rupture, only the 
A pestle was used.  Nuclei and mitochondria were pelleted by 9000 g centrifugation for 15 min 
at 4 °C to generate PMS. PMS was adjusted to have 1% final concentration of NP-40.  In a 
Beckman 800 µl ultracentrifuge tube, 350 µl of adjusted PMS was loaded carefully onto a 350 µl 
sucrose pad containing 20% w/v sucrose, 50 mM Tris, pH 7.4, 25 mM NaCl, 5 mM MgCl2, 300 
mM CHX, 1 mM DTT, 5.2 µl/ml protease inhibitor cocktail (Sigma), and 80 U/ml RNase 
inhibitor (Invitrogen).  The tubes were loaded in the SW55 rackets with adapters and centrifuged 
at 29,400 rpm for 1.5 hr at 4 °C (Beckman SW55 rotor).  After ultracentrifugation, the 
supernatant was carefully taken out by glass Pasteur pipets and discarded.  The pellet was either 
resuspended overnight for WB or agarose gel confirmation or further processed for MS 
proteomics as described below.  
Validation of polysomes pellet by Western blot 
To validate the polysomes pellet protocol, aliquot of crude homogenate (50 g), post-
mitochondrial supernatant (5 g), liquid above the pad (5 g), and the resuspended polysomes 
pellet (5 g) were run per lane on 10% SDS-PAGE gels, electroblot transferred to nitrocellulose.  
Protein concentration was determined by Lowry assay.  Nitrocellulose was stained for ribosomal 
markers: anti-ribosomal P antigen (1/300 in 5% milk, overnight at 4 °C), anti-S6 (1/1000 in 5% 
milk, overnight at 4 °C), anti-HuR (1/200 w/o block, 1 hr, room temperature) and anti-PABP 
(1ug/ml w/o block, overnight at 4 °C).  Nitrocellulose was also stained for organelle markers: 
anti-NeuN (1/1000 in 5% milk, overnight at 4 °C), anti-PDI (1/1000 in 2% milk, overnight at 
4 °C), anti-pyruvate dehydrogenase (1/1000 w/o block, overnight at 4 °C), anti-cytochrome C 
(1/1000 w/o block, overnight at 4 °C), and anti-COX IV (1/1000 in 5% milk, overnight at 4 °C).  
The nitrocellulose was stripped between antibody staining. 
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iTRAQ and LC-MS proteomics 
Mass spectrometry (MS) proteomics using the isobaric tag for relative and absolute 
quantitation (iTRAQ) method was used to analyze polysomes pellets.  Polysomes pellets were 
resuspended in 100 mM triethylammonium bicarbonate (TEAB), protein concentration measured 
with Bradford assay, reduced with tris (2-carboxyethyl)phosphine (TCEP), cysteines blocked 
with methyl methanethioulfonate (MMTS) and then trypsin digested at 37 °C overnight127,128.  
To quantitatively compare protein abundance in different samples, tryptic digests from 20 μg of 
polysomes pellet were labeled with iTRAQ reagents129.  iTRAQ proteomics does not require gel 
electrophoresis and allows detection and quantification of 8 samples simultaneously.  One fourth 
of the labeled tryptic digest were mixed and subjected to the first iTRAQ analysis using LC-
MS/MS with parameters as described above.  The rest were mixed and subjected to the second 
iTRAQ analysis.  For the second iTRAQ analysis, the iTRAQ-labeled peptide mixture was 
fractionated on SCX MicroSpin columns with sequential elution in 5 salt steps.  Salt fractions 
were analyzed by LC-MS/MS.  Finally, on the third attempt, the unlabeled tryptic digest of 
polysomes pellet was fractionated on SCX MicroSpin columns individually with sequential 
elution in 5 salt steps. Salt fractions were analyzed as the first two iTRAQ analysis by LC-
MS/MS in the reversed-phase C18 chromatography coupled to tandem mass spectrometry using 
an Ultimate nano-LC system and a QSTAR XL mass spectrometer.  Reverse-phase 
chromatography is performed using a PepMap100 C18 analytical column (flow rate = 150 
nl/min).  The QSTAR XL is operated in acquisition mode with 1s MS scans (400–1600 m/z) 
followed by 4s product ion scans (100–1580 m/z). QSTAR raw files are processed in MASCOT 
Distiller v2.3 and searched in Mascot against NCBI and SWISS-Prot databases.  
Gene ontology analysis 
Gene ontology (GO) analysis was performed in the Cytoscape plug-in ClueGo130.  This 
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software allows the user to test GO using the Gene Ontology Consortium, Kyoto Encyclopedia 
of Genes and Genomes (KEGG) and Reactome databases simultaneously.  For testing of 
proteomics, the Gene Ontology Consortium category of “cellular component” only was used. 
Statistical test was for hypergeometric sorting to the right, which represents enrichment of 
proteins in a category, and Bonferroni step-down correction of p values (the default settings).  
Number of genes per category was set to 10, and percent of genes in category compared to total 
number of genes in a category was set to 10%, to identify a category as statistically significant.  
For a given term accepted as statistically significant, the corrected p value was generally less 
than 10-7. 
Results 
Pilot studies and workup of polysome pellet procedure in cerebral cortex 
I began these studies using the sucrose gradient method to isolate polysome-containing 
fractions.  However, preliminary iTRAQ proteomics of the pooled polysomal fractions showed 
they contained only 4% in CA1 and 7% in CA3 of ribosomal subunit proteins (Table 1).  For 
counting “ribosomal proteins”, the 40S and 60S subunits, cotranslational chaperones, and 
ribosome-associated ubiquitination proteins were used.  
Table 1. Several pilot studies of ribosomal protein proteomics.   
 
Rows 1 and 2 used sucrose gradient method on CA1 and CA3 dissections.  
The remaining columns used sucrose pad method to isolate pp and tested 
either cortex or CA1 and CA3 dissections.  RP = ribosomal proteins. Protein 




Since the aim was to study polysome-associated proteins, a better method of 
concentrating polysomes was needed.  I found high-speed centrifugation to obtain polysome 
pellets gave more concentrated polysomes.  Below is preliminary data that polysome pellets: (1) 
contain ribosomal proteins by Western blot, (2) contains rRNAs by agarose electrophoresis, (3) 
were not contaminated by organelles protein determined by Western blots, and (4) consisted of 
~30% ribosomal proteins by proteomics.  
For first pilot studies I used cerebral cortex from NIC animals since it provided abundant 
wet weight of tissue as input material.  Figure 11 shows in two separate purifications that the 
polysomal pellet (pp) from the sucrose pad is enriched in ribosomal proteins by Western blot, 
including poly (A) binding protein (PABP), 60S protein ribosome P antigen (RPA), 40S protein 
S6.  The Hu proteins also came down in the cortical pp (Figure 11).  
 
Figure 11. WB for ribosomal protein from pilot studies of cerebral cortex: S6 (40S subunit 
marker), RPA (60S subunit marker) and PABP. Ribosomal protein is enriched in the 
resuspended polysomes pellet. 
In addition to ribosome proteins, Western blots were run for organelle markers to detect 
for organelle contamination (Figure 12), including protein disulfide isomerase (PDI) for 
endoplasmic reticulum (ER) and NeuN (Fox-3) for nucleus.  Since mitochondrial contamination 
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was a main worry, three markers were tested: mitochondrial pyruvate dehydrogenase, 
cytochrome oxidase subunit IV, and cytochrome C.  As seen in Figure 12, the organelle markers 
were not detected in Western blots of pp from cerebral cortex. 
Figure 12: Western blot tests for 
organelle contamination in 









To further demonstrate that the pellet contained polysomes, RNA was TRIzol extracted from the 
resuspended pellet from cortex of NIC animals, and ran on non-denaturing agarose gel ( 
Figure 13).  The two prominent 18S and 28S bands shows that the pellet has a major component 
of rRNA, and the background smear of mRNA in the lanes shows the pellet enriches polysomes. 
 
Figure 13: RNA TRIzol extracted from  




The cortical polysome pellet was subjected to MS analysis (Table 1, cortex 6/14/13 row).  
Sixty-nine proteins were detected by MS, of which 41 (59%) were ribosomal proteins, a large 
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improvement compared with the sucrose gradient method.  Complete lists of proteins detected in 
all pilot studies summarized in Table 1 are included in Appendix 1. 
Scaling down polysome pellet procedure for CA subregions 
Having validated polysome pellets from cerebral cortex, I was required to scale down the 
procedure for lesser weight of input material of CA subregions (~100 mg total wet weight of 
input tissue).  This required switching from the Beckman SW41 rotor to the SW55 rotor and 
from 10 ml tubes to 800 l tubes using tube adaptors.  The ultracentrifuge time was also adjusted 
based on keeping the k factor constant.  With this scaled down protocol, RNA using resuspended 
pellet from CA subregions showed the prominent 18S and 28S bands (Figure 14). 
 
Figure 14. Non-denaturing RNA agarose gel stained by SYBR 
gold, showing the prominent 18S and 28S rRNA bands. The input 
is the resuspended polysomes pellet from the CA subregions based 






Given the small amount of obtained polysome pellets (~10 g per resuspended pellet), 
Western blot validation was not performed on CA1 and CA3 polysome pellet isolations.  Instead, 
a series of pellets from CA subregions were analyzed by MS proteomics to determine ribosomal 
enrichment (Table 1).  The first test gave 22% and 18% ribosomal proteins (RP) for CA1 and 
CA3, respectively.  Adjusting centrifugation run time and speed to account for the smaller tube 
radii, led to an increase of 30% and 28% of RP isolated from CA1 and CA3, respectively.  With 
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the scaled down method, a last test of cerebral cortex gave 37% RP.  Again, the complete lists of 
proteins detected in all pilot studies summarized in Table 1 are included in Appendix 1. 
Therefore I concluded the scaled down procedure required for isolating polysome pellets 
from CA1 and CA3 produced results comparable to cerebral cortex and allowed assessing 
polysome pellets proteomics between CA1 and CA3 after brain I/R. 
iTRAQ polysome proteomics after brain ischemia and reperfusion 
After obtaining confidence in the scaled down sucrose pad procedure for isolating 
polysome pellets, polysome pellets were isolated from experimental groups as shown in Figure 
10.   
The first experiment on the isolated polysome pellets performed iTRAQ proteomics.  
Because of the number of samples, two 8-plex iTRAQ labelings were required (groups A and B).  
The first labeling detected 31% of proteins as RPs in group A, and detected 37% RPs in group B.  
In spite of the high percent of RPs, iTRAQ labeling did not detect any mRNA binding proteins 
(RBPs). 
Because the first iTRAQ run failed to detect any RBPs, the samples were subjected to 
additional strong cation exchange fractionation and the elutes were rerun through mass spec.  
The second run detected 25% RPs in both groups A and B, and in addition detected several RBPs 
(Table 2).  hnRNP Q and PABP were detected in both groups.  Group A also notably detected 
hnRNP D, also known as AUF1, an RBP that binds ARE-mRNAs and destabilizes them for 
degradation131.  The complete list of the 2nd iTRAQ run of groups A and B is provided in 
Appendix 2.  None of the proteins listed in Table 2 were quantified by iTRAQ and therefore it 





Table 2. RNA binding proteins detected in 2nd iTRAQ run following additional liquid 
chromato-graphy fractionation.  
Red fonts are RBPs detected in both groups A and B. 
LC-MS of polysome pellet proteins 
Given the serious limitations of the iTRAQ runs described above, the remaining 
individual samples of polysome pellet protein were subjected to LC-MS individually to 
determine the occurrence of RBPs by experimental group.  
All of the remaining samples gave ms detections of proteins. The complete lists of the 
individual sample LC-MS runs are provided in Appendix 3. Counts of percent RPs are shown in 
Table 3.  Percent of RPs ranged from 17.6% to 35.1%. When the percent of RBs per 
experimental group were tested by ANOVA, the p value = 0.11, indicating that the percent was 
not statistically different between groups.  The overall average %RP for all experimental groups 
was 25% + 4%. 
Group ID Name Description
A HNRPD_RAT  Heterogeneous nuclear ribonucleoprotein  AUF1; destabilizes ARE mRNAs
A PAIRB_RAT  Plasminogen activator inhibitor 1 RNA‐binding protein  Regulation of mRNA stability
A PRIO_RAT  Major prion protein Prion protein; component of stress granules
A HNRPQ_RAT  Heterogeneous nuclear ribonucleoprotein Q  Complex mRNA functions
A PABP1_RAT  Polyadenylate‐binding protein 1 Binds pA tail of mRNAs
B FA98A_RAT  Protein FAM98A  Human form binds polyA mRNAs 
B HENMT_RAT  Small RNA 2'‐O‐methyltransferase  Modifies piRNAs
B HNRPM_RAT  Heterogeneous nuclear ribonucleoprotein M Pre‐mRNA binding protein
B PRC2A_RAT  Protein PRRC2A  Regulation of pre‐mRNA splicing 
B HNRPQ_RAT  Heterogeneous nuclear ribonucleoprotein Q  Complex mRNA functions
B PABP1_RAT  Polyadenylate‐binding protein 1  Binds pA tail of mRNAs
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Table 3. Counts of ribosomal proteins (RPs) in individual samples of polysome pellets from 
experimental groups as indicated.   
 
Table 4 shows the detection of RBPs by individual sample.  No specific RBP was 
detected in all samples.  However, two RBPs were highly represented across the samples.  First 
was PAIRB_RAT, plasminogen activator inhibitor 1 RNA-binding protein, also known as 
SERBP1.  SERBP1 is thought to regulate mRNA stability and has been shown to be a 
component of stress granules132.  PAIRB_RAT was present in all NIC CA1 samples, and in two 
of the three 8R CA3 samples; this protein was also detected in the 2nd iTRAQ run (Table 2).  
Table 4. Left: RBPs detected in individual samples of polysome pellet proteins following LC-




Sample RPs total Percent AVE Stdev
N12 79 449 17.6%
N13 66 301 21.9% 21.3% 3.4%
N14 71 292 24.3%
N31 42 177 23.7%
N32 49 190 25.8% 28.2% 6.1%
N34 33 94 35.1%
R11 39 166 23.5%
R12 33 142 23.2% 22.8% 1.0%
R13 34 157 21.7%
R31 34 133 25.6%
R32 39 140 27.9% 28.0% 2.5%
R33 37 121 30.6%
Sample Hu Proteins RBP ID Description
N12  PAIRB_RAT AGO2_RAT RNA‐mediated gene silencing
N13  CELF2_RAT,  AGO2_RAT,  PAIRB_RAT CELF2_RAT CUGBP Elav‐like family member 2
N14  ELAV4_RAT  HNRH2_RAT,  RBM20_RAT,  PAIRB_RAT ELAV2_RAT HuB; neuron specific Hu form
N31 ELAV4_RAT HuD; neuron specific Hu form
N32  ELAV2_RAT  ROA2_RAT HNRH2_RAT Pre‐mRNA processing
N34  ELAV2_RAT HNRPD_RAT AUF‐1
R11 PAIRB_RAT A: regulation of mRNA stability
R12  ELAV2_RAT  RBM43_RAT, HNRPD_RAT PARK7_RAT Major prion protein; dysfunctionally binds mRNAs
R13  PARK7_RAT PRIO_RAT Prion protein: dysfunctional mRNA complexes
R31  ROA2_RAT RBM20_RAT Nuclear mRNA splicing
R32  ELAV2_RAT  PAIRB_RAT,  PRIO_RAT RBM43_RAT RNA binding protein




The second RBP found in many samples was ELAV2_RAT, a neuronal specific Hu 
protein, HuB, also known as Hel-N1 (human) or Rel-N1 (rat), which has been extensively 
studied in Dr. Keene’s lab at Duke University.  HuB was present in all the groups except NIC 
CA1. In NIC CA1, the Hu protein HuD was detected in one sample.  Several other mRNA 
binding proteins were detected including AUF1 (hnRNP D), DJ-1, and prion protein. DJ-1133,134 
and prion135 have both been implicated in dysfunctional mRNA binding in neurological 
disorders. 
Background contaminants of polysome pellet preparations 
Above I showed that Western blot for organelle markers indicated that ER, nucleus and 
mitochondria did not contaminate the polysome pellets obtains from the sucrose pad method 
(Figure 12).  However, as seen in Table 3, 75% of proteins detected by LC-MS were not 
classified as ribosomal proteins.  I performed gene ontology (GO) analysis to classify the 
background hits.   Using the software ClueGo I performed GO using the “cellular component” 
category. 
Representative NIC and 8R samples are shown in Figure 15.  There are several cell 
component categories, but they are reduced to a few broad categories.  These are: neuronal 
debris (growth cone, axonal growth cone, myelin sheath, neuronal projection, etc.), cytoskeleton 
(microtubule plus end, microtubule, cortical cytoskeleton, and etc.), internal membrane systems 
and plasma membranes of the cell (melanosome, clathrin-coated vesicle, perikaryon, membrane 
coat), and cytoplasmic contaminants.  
None of the markers used to work up the sucrose pad procedure tested for these possible 
contaminants.  Therefore, it is concluded that, even though accepted methods to determine purity 





Figure 15. Gene ontology analysis using “cellular component” to classify hits of representative 





CHAPTER 3: INVESTIGATION OF HU IMMUNOPRECIPITATES AT 8 HOURS 
OF REPERFUSION 
Hypothesis 2: Hu proteins bind with different mRNA binding proteins in CA1 and CA3 neurons 
at 8 hr of reperfusion. 
Rationale  
Hu proteins are mRNA binding protein with a sequence preference for ARE element112 
which is present in hsp70 mRNA122.  HuR RIP result showed that HuR binds with hsp70 mRNA 
from I/R brain homogenates121.  The colocalization of HuR with mRNA granules correlates with 
the translation of HSP70 protein121 which is related with the survival of neurons.  Given the 
combinatorial theory of mRNA regulation discussed in the Introduction, it is thus hypothesized 
that differences in HuR colocalization patterns at 8 hr reperfusion in CA1 and CA3 (Figure 16) is 
due to HuR binding different sets of proteins in each cell type.  This was in correlation with 
whether the stress genes are translated.  Hu binding proteins will be identified by 
immunoprecipitating Hu proteins, and identify co-precipitating proteins by MS proteomics.  
 
Figure 16. Hu proteins colocalize with mRNA in CA3 but not CA1 at 1 hr reperfusion33. 
Overall experiment design  
The overall protocol for Aim 2 is outlined in Figure 17 and is similar to the design of 
Aim 1.  Brain I/R was induced in male Long Evans rats utilizing the 2VO/HT model.  
Experimental groups were again 8R and NIC (n = 15 rats/experimental group).  CA1 and CA3 
were microdissected and pooled.  Regions were homogenized and post-mitochondrial 
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supernatant (PMS) prepared under conditions to preserve mRNAs. Dynabeads (magnetic beads) 
covalently coupled with anti-HuR antiserum were used to immunoprecipitate Hu proteins under 
conditions that retain Hu protein-mRNA interactions123,136.  The eluted protein complexes were 
subject to iTRAQ and LC-MS proteomics analysis.  Dynabeads covalently coupled with anti-
histone (an unrelated nuclear protein that should not be present in PMS), or lacking primary 
antibody, served as negative controls. 
 
Figure 17.  Experimental design for aim #2 proteomics for HuR RIP between NIC and 8hR 
animals. 
Materials and methods 
Materials 
HuR (sc-5261), hnRNP M (sc-20001), hnRNP K (sc-25373) antisera were purchased 
from Santa Cruz Biotechnology, Inc. (Santa Cruz CA, USA).  Histone (ab1791), hnRNP D 
(ab61193), anti-phospho-serine (ab1603) and anti-phospho-serine (ab6639) were purchased from 
Abcam (Cambridge, MA, USA).  Anti-phospho-threonine (9381) was purchased from Cell 
signaling technology (Beverly, MA, USA). HSP-70 (SPA-812) antiserum was purchased from 
Enzo Life Sciences (Farmingdale, NY, USA).  Dynabeads co-immunoprecipitation kit (14321D), 

























(15596-018), and RNaseZap® RNase Decontamination WipesZapwipe (AM9786) was 
purchased from Life technology (Carlsbad, CA, USA). iTRAQ® kit (4390811) was purchased 
from AB Siex (Farmingham, MA, USA). PlusOne Silver staining kit (17-1150-01) was 
purchased from GE Healthcare Life Sciences (Pittsburgh, PA, USA).  Protease inhibitor cocktail 
(P8340) and Diethyl pyrocarbonate/DEPC (40718) was purchased from Sigma Aldrich (St.Louis, 
MO, USA).  All other chemicals were reagent grade. Mass spectrometry related chemicals were 
MS grade.  Anti-mouse secondary antisera and mouse serum were purchased from Sigma 
Chemical Co. (St. Louis, MO, USA).  
Surgery: 2VO/HT Model 
The induction of ischemia and reperfusion are exactly as described in Methods of 
Chapter 2. 
Microdissection of CA1, CA3 and forebrain 
The microdissection of CA1 and CA3, and isolation of cerebral cortex are exactly as 
described in Methods of Chapter 2. 
Validation of reperfusion by Western blot 
The validation of the ischemia and reperfusion surgery by Western blot for HSP70 
protein are exactly as described in Methods of Chapter 2. 
Hu protein immunoprecipitation 
To prevent downstream contamination of primary antibody with mass spectrometry, this 
protocol used dynabeads to be covalently bound to primary antibody.  The dynabeads were 
prepared beforehand following manufacture protocol (Life technology).  Dynabeads were 
coupled with mouse anti-HuR (sc5261) and mouse anti-histone (ab1791) antibody (negative 
control) at 5 µg antibody per mg dynabeads.  According to manufacturer specifications sheet, 
anti-HuR (sc5261) detects all four forms of Hu proteins: HuA (most often called HuR), HuB 
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(Rel-N1), HuC and HuD.  Therefore, I will refer to the specific antisera as “HuR” but refer to 
what it detects as “Hu proteins”.  Dynabeads with no antibody coupled, anti-histone antibody 
coupled (two negative control) and mouse serum coupled (negative control) were also prepared 
in the same manner as those with antibody coupled dynabeads.  The beads were stored at 4 °C 
until use.  
All procedures were performed on ice or in cold room, and measures were taken to 
prevent RNAse contamination as described above. 
Microdissected CA1 and CA3 from n = 5 or 6 animals were pooled randomly to get one 
sample of around 100 mg weight.  The samples were pooled separately from NIC and 8R groups 
and were homogenized at 9:1 v/w ratio (0.9 ml) with extraction buffer B in glass Kontes dounce 
tissue grinder with 127 m clearance to preserve the nuclear membrane.  To maximally preserve 
the ribonucleoprotein complex, extraction buffer B contained 1X IP buffer (from Life 
technology, Dynabeads co-IP kit), 200 mM NaCl, 2 mM MgCl2, 1 mM DTT, 5.2 ul/ml protease 
inhibitor cocktail (Sigma, P8340), 80 U/ml Rnase I (Life technology, AM 2684), and 160U/ml 
Superase RnaseI (Life technology, AM 2694).  Nucleus was pelleted by 2500 g centrifugation 
for 15 min, and the supernatant was then subjected to 25,000 g centrifugation for 25 min to pellet 
the mitochondria.  Post-mitochondria supernatant (PMS) from each 100 mg starting tissue was 
used as input for one IP reaction.  For each IP reaction, 1.5 mg of antibody coated dynabeads 
were used, and they were washed with extraction buffer B first and then incubated with the PMS 
for 10 min on rotator at 4 °C.  The liquid was put on magnet for one min, and the supernatant 
was removed and discarded. For washes and elution of dynabeads, extraction buffer B was used.  
Following 3 times washes in extraction buffer B. First wash contained proteinase inhibitor 
cocktail, RNaseI and Superase RnaseI; the second and third did not.  The fourth and final wash 
used LWB buffer (provided in kit) with 0.02% Tween 20.  Ribonucleoprotein complex was then 
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eluted with 60 µl of EB buffer (provided in kit).  Eluted proteins were then subjected to acetone 
precipitation.  For one volume of eluted protein containing liquid, it was mixed with 6 volume of 
acetone chilled at -20 °C and incubated overnight at -20°C.  The mixture was then centrifuged at 
13,500 rpm for 10 min, and the precipitate was washed with cold acetone, air dried and stored at 
-80 °C before subjected to further preparation.  
Hu protein immunoprecipitation and Western blot  
For IP-Western blot confirmation after proteomics, eluted protein from each IP reaction 
was run per lane on 10% SDS-PAGE, electroblot transferred to nitrocellulose and Western 
blotted with HuR antiserum (1/200 in TTBS, 1 hr, room temperature), hnRNP K (1/100 in 
TTBS, 2 hr, room temperature), hnRNP M (1/250 in TTBS, 2 hr, room temperature), hnRNP D 
(1/250 in TTBS 2 hr, room temperature).  Nitrocellulose was stripped between antibody stain at 
55°C using strip solution of 100 mM 2-mercaptoethanol, 2% SDS, 62.5 mM Tris-HCl, pH 6.7. 
iTRAQ and LC-MS/MS proteomics 
Mass spectrometry (MS) proteomics using the iTRAQ method was used to analyze the 
Hu protein IP elutions.  Protein samples were washed with cold acetone twice, air-dried, then 
resuspended in 100 mM triethylammonium bicarbonate (TEAB), protein concentration measured 
with Bradford assay, reduced with tris(2-carboxyethyl)phosphine (TCEP), cysteines blocked 
with methyl methanethiosulfonate (MMTS) and then trypsin digested at 37 °C overnight127,128.  
Bradford result suggested that total protein in each pellets ranged from 1.7 g to 2.7 g.  The 
protein amount limited the number of fractions obtained from strong cation exchange (SCX).  
The tryptic digest of HuR IP elution was labeled with iTRAQ reagent.  One third of the labeled 
digest from each sample was taken and mixed.  
For liquid chromatography (LC)-MS/MS analysis, the iTRAQ-labeled peptide mixture 
were analyzed by reversed-phase C18 chromatography coupled to tandem mass spectrometry 
52 
 
using an Ultimate nano-LC system and a QSTAR XL mass spectrometer.  The parameters of LC-
MS/MS were set as described above in Chapter 2.  The remaining two thirds of the labeled digest 
were not mixed and run individually in LC-MS/MS. 
Gene ontology analysis 
Gene ontology analysis was performed exactly as described in Methods of Chapter 2. 
Results 
Pilot studies to validate and optimize IP procedures 
Hu IP using magnetic dynabeads was tested and confirmed with Western blot that no 
primary antibody eluted from the covalently linked dynabeads and this was tested in two buffer 
conditions: RIP buffer or the kit-supplied IP buffer.  No heavy or light IgG chains at 55 and 25 
kDa were observed (lanes “IP PMS” Figure 18A).  In contrast, Hu protein IP using Protein A 
Sepharose beads showed elution of primary antibody, with the heavy and light chains seen at 55 
and 25 kDa (Figure 18B).  Therefore, using dynabeads eliminated contamination by IgG for 
subsequent proteomics. 
 
Figure 18. (A) Western blot for Hu IP (IP PMS) from cerebral cortex, showing no primary 
antibody contamination in the elution of IP from dynabeads.  Lanes 1-6 are not IPs but show Hu 
proteins staining in various fractions: uFH: unfractionated homogenate; PNS: post-nuclear 
supernatant; PMS, post-mitochondrial supernatant. (B) Hu IP from NIC and 8R cortex using 
Sepharose beads, showing eluted IgG heavy and light chains. 
 
In additions, several other controls were performed to optimize the Hu protein IP 
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conditions to obtain maximum recovery of Hu proteins, and to test various buffers to optimize 
extraction of Hu proteins from the beads and to ensure the extraction buffer was compatible with 
subsequent proteomic procedures.  All of control experiments are shown in Figure 19.   
First was shown covalent binding of an unrelated antisera (anti histone) did not 
precipitate Hu proteins.  As seen in Figure 19A, anti-histone did not precipitate Hu proteins from 
PMS, but did do so from unfractionated homogenate.  Therefore, PMS was always used as input 
to IP reactions.   
Figure 19. Various controls and optimization for Hu protein immunoprecipitation. All Western 
blots in A-E are Hu Westerns using Hu antisera sc-5261. (A) Dynabeads covalently linked to 
anti-histone did not pull down Hu Proteins from PMS but did so from unfractionated 
homogenate (uFH). (B) Test of whether buffers A or B in combination with 100 mM or 200 mM 
NaCl led to best Hu protein recovery. (C) Test of NaCl concentration in buffer B to obtain 
highest Hu protein recovery.  (D) Test of elution buffers compatible with subsequent proteomics: 
EB buffer obtained best quantitative recovery. (E) Test of Hu protein recovery in IP supernatant 
(IP super) vs bead elution (IP), and whether SDS added to buffer EB eluted dynabeads could still 
recover Hu proteins. 
Next, based on the manufacture protocol for Dynabeads co-IP (Life technology), IP 
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buffer condition (A or B) was first tested.  The difference between buffer A and buffer B is that 
buffer B contained 2 mM MgCl2 and 1mM DTT, while buffer A did not.  They were tested at 
NaCl concentration of 100 mM.  The elution from anti HuR bound dynabeads under both IP 
condition was run on SDS-PAGE, and the gel was silver stained.  Silver stain suggested that the 
yield of bands of buffer A and B are similar (not shown here), as did Hu IP Western (Figure 
19B).  Since buffer B contained DTT and MgCl2, which is a common component in RNA 
immunoprecipitation buffer136, we decided to choose buffer B over buffer A. 
Once buffer B was chosen, the NaCl concentration was investigated to optimize the ionic 
stringency of the IP reaction.  Figure 19C shows that 200 mM NaCl gave the strongest yield of 
Hu proteins compared to 50, 100 and 150 mM NaCl.   
After incubation conditions were optimized, I tested which was the best buffer to elute 
the dynabead-bound Hu proteins, including ammonium hydroxide (NH4OH 0.5 M), HPH EB 
(NH4OH 0.5 M, EDTA 0.5 mM) and EB buffer (from dynabeads kit).  As seen in Figure 19D, 
EB buffer eluted the greatest amount of Hu protein, from IP reactions that all had been loaded 
with equal amount of input PMS protein. 
Finally, after determining EB to be the optimal elution buffer, I tested whether having 
0.01% SDS in the elution buffer increased the yield.  As seen in Figure 19E, after the dynabeads 
were eluted with EB buffer, SDS was still able to elute some Hu down.  In addition, it was 
observed that very little Hu protein remained in the IP supernatant compared to that recovered 
from the dynabeads (Figure 19E, compare lanes “IP super” to “IP”).  
Pilot MS was run to determine if acetone precipitation could clean SDS from the solution 
so that SDS would not interfere with MS detection.  However, samples eluted with SDS had very 
bad signal in MS even after acetone precipitation compared with sample eluted with only EB 
buffer (data not shown).  Thus EB buffer was finally chosen as the elution buffer. 
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Therefore, from the conducting of the various controls shown here, we were confident the 
IP was optimized to yield the highest recovery of Hu proteins from the IP incubation and after 
when the proteins were extracted from the dynabeads without interference of MS detection. 
Hu protein phosphorylation at 8 hr reperfusion 
Because it is known that the phosphorylation status of Hu proteins can regulate their 
function137, once the Hu protein IP had been optimized, a pilot study tested by phospho-threonine 
(pT) and phospho-serine (pS) antisera if we could detect changes in Hu protein phosphorylation.  
Hu proteins were immunoprecipitated from NIC and 8R cerebral cortex (n = 2 per group).  We 
evaluated cerebral cortex initially because there was abundant tissue.   Also, cortex  survives  10 
Figure 20. Western blots of Hu protein 
IPs for pT (thrP) and with two different 
pS (serP 1 and 2) antisera.  PMS from 
cerebral cortex (50 g); Hu IPs are 
dynabead elutions after Hu IP.  The two 
NIC (N) and 8 hr reperfused (8R) 








min ischemia like CA3, so the test would give an indication of what is likely to occur in CA3.  
Eluted proteins were run on SDS-PAGE and stained for Hu proteins, pT and pS, with stripping 
of the membrane at 55oC in SDS and beta mercaptoethanol solution between Western blots.  The 
results are shown in Figure 20 where no change in phosphorylation patterns was seen between 
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the NIC and 8R samples in either the PMS or after Hu IP for pS and pT had no signal after Hu 
IP. To conclude, no gross change in Hu protein phosphorylation occurred after brain I/R. 
Pilot proteomics of Hu immunoprecipitations 
After optimizing Hu IPs as described above, the last test was to determine if the Hu IP 
provided enough protein to successfully do proteomics.  Therefore, a pilot study was undertaken 
using cerebral cortex PMS as input to the Hu IP, and using a quantity of tissue comparable to 
hippocampal dissections (100 mg wet weight, the weight of 5 pooled CA1 or CA3).  As 
mentioned above what was also evaluated was if adding SDS to the elution buffer with 
subsequent acetone precipitation aided or hindered the subsequent proteomics.  IPs were 
performed and run through LC-MS/MS.  The result of this pilot study was that no-SDS elution 
resulted in ~150 proteins detected by mass spec verses ~60 proteins detected when SDS was 
included.  The no-SDS samples also detected known RBPs, including hnRNP D, hnRNP K and 
hnRNP A2, and these were not detected in the SDS containing elutions.  Therefore, it was 
concluded to omit SDS from the elution step and that enough protein was IP’d to be detected by 
proteomics. 
Proteomics of Hu immunoprecipitations from experimental groups 
Experimental groups for NIC and 8R were performed and processed as shown in the flow 
chart and design of Figure 17.  In addition to the Hu IPs of the experimental animals, two 
negative control IPs were performed: (1) an IP lacking antisera, and (2) an IP where anti-histone 
was bound to the dynabeads.  Ten additional NIC animals were sacrificed to give enough CA1 
and CA3 PMS that both negative controls could be done for NIC CA1 and NIC CA3, giving a 
total of four negative controls.  No negative controls were performed for the 8R group as all the 
samples were used for Hu IPs. 
The proteins eluted from Hu IPs were subjected to iTRAQ labeling, followed by mass 
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spec proteomics.  However, the amount of protein eluted from Hu IPs (~2 g per sample) was 
below the recommended protein concentration for iTRAQ labeling (~10 g per sample).  In spite 
of recommendation, it was attempted to run the iTRAQ labeling.  
After the labeling reaction, 1/3rd of each of the individual iTRAQ-labeled samples was 
mixed to give two eight-plex samples (group A containing NIC and 8R CA1 samples and the two 
negative NIC CA1 controls, and group B containing NIC and 8R CA3 samples and the two 
negative NIC CA3 controls).  The mixed eight-plexes were run on mass spec. But after mass 
spec, no iTRAQ labeling was detected.  Therefore, I was unable to successfully perform iTRAQ 
proteomics of the Hu IPs of CA1 and CA3 because not enough protein could be isolated from the 
Hu IPs to be labeled by the iTRAQ reagent. 
Since there was still 2/3rds of the original iTRAQ-labeled samples, these were used to 
perform LC-MS on each individual sample.  At this point, two poolings were necessary to ensure 
enough material for LC-MC: (1) NIC CA3-1 and -3 were pooled and (2) 8R CA1-1 and -3 were 
also pooled. 
The LC-MS runs on the individual samples were successful. The results now described 
are those of LC-MS of the Hu IPs. 
Counting detected proteins for LC-MS of Hu IPs 
The number of detected proteins in Hu IP samples and negative controls are shown in 
Table 5.  Reactions lacking primary antibody gave 108 and 140 hits in CA1 and CA3, 
respectively.  The anti-histone negative controls gave 150 and 185 detected proteins in CA1 and 
CA3, respectively.  In CA1, 63 of the background proteins were identical between no primary 
and anti-histone.  In CA3, 79 of the background proteins were identical between no primary and 
anti-histone.  The two lists were combined for each region to give background lists, which 
contained 258 proteins for CA1 and 325 for CA3. 
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Table 5. Counting protein hits after LC-MS/MS of Hu IPs 
 
The total numbers of proteins detected (“# proteins” column) in the Hu IPs for each 
individual sample are shown in Table 5.  When proteins on the respective background lists were 
subtracted from each individual sample, this gave the number of unique hits for each sample.  
Dividing the number of unique hits by the total gave very similar proportions for samples in each 
brain region.  CA1 averaged 44.8% + 2.4%, and CA3 averaged 31.4% + 3.4%. These were 
statistically different by ANOVA (p = 9.7 x 10-5).  Therefore, CA3 had more background than 
CA1 (~ 69% vs 56% of detected proteins, respectively).  All 14 protein hit lists are provided in 
Appendix 4. 
Gene ontology of background proteins from Hu IPs 
To understand the background lists, gene ontology was performed using the GO 
classification of “cellular component”.  The background lists between CA1 and CA3 and 
between no primary and the histone primary antisera were similar.  Similar to the polysome 
profile background contamination, there was neuronal debris (axon, synaptic vesicles, 
melanosomes, SNARE components), internal membranes (coated vesicles, sodium-potassium 
exchanger), mitochondrial membrane (proton transport proteins) and cytoskeleton (brush border 
membrane, intermediate filaments).  The extent of contamination in the Hu IPs is explained 
further in the next section. 
Negative Controls
CA1 # proteins unique overlap CA3 # proteins unique overlap
no primary 108 45 63 no primary 140 61 79
anti‐histone 150 87 63 anti‐histone 185 106 79
unique bkgrnd hits 258 325
Hu IP Samples
Samples CA1 # proteins unique ‐bkgrnd
% 
unique/total Samples CA3 # proteins unique ‐bkgrnd
%
unique/total
N11 91 40 51 44.0% N31+N33 134 35 99 26.1%
N12 159 66 93 41.5% N32 199 68 131 34.2%
N13 182 82 100 45.1% R31 196 68 128 34.7%
R11+R13 170 77 93 45.3% R32 188 58 130 30.9%
R12 220 106 114 48.2% R33 163 51 112 31.3%




Figure 21. Gene ontology analysis of background hit lists in CA1 and CA3, as indicated.  For 
“No primary” colors are similar and for “histone primary” colors are similar.  
Qualitative identification of RBPs detected after LC-MS of Hu IPs 
There were no RBPs on the background lists.  When the unique lists for the individual 
samples were inspected for RBPs, the lists shown in Table 6 were found.   
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HuB (ELAV2_RAT) was the main Hu protein detected in the sample IPs.  The main 
observation of this study was that HuB was present in all samples except the NIC CA1 samples.  
This is an amazing finding when it is considered that the samples were IP’d for Hu proteins.  For 
one sample 8R CA1-2, HuD (ELAV4_RAT) was also found. 
In addition to HuB, several other RBPs were found. The specific RBPs and short 
descriptions are listed in Table 6.  No specific RPB was found in more than one sample.  The 
unique hits ranged from 35 to 106 amongst the samples.  But RBPs ranged from zero to four in 
the samples.  Therefore, the contamination ranged from 100% in NIC CA1-1 (N11 in Table 6) to 
96% in CA1 8R-2 (R12 in Table 6). 
IP/Western of Hu IPs 
Since HuB or any other Hu isoform was not detected in NIC CA1 samples following Hu 
protein IP, it was necessary to confirm this result by IP/Western.  Therefore, 10 additional NIC 
and 10 additional 8R rats had CA1 and CA3 dissected, and pooled PMS from 5 rats per sample 
were subject to Hu protein IP, followed by SDS-PAGE and Western blot.   
The results are shown in Figure 22. Normally when staining with the Hu protein antisera, 
three bands are detected at molecular weights (MW) of 36, 38, and 42 kDa.  For NIC CA3 and 
8R CA1 and CA3, all three bands were observed.  However, the 38 kDa and 42 kDa bands were 
absent in NIC CA1, consistent with both the polysome pellet and Hu IP proteomics that failed to 
detect HuB in any NIC CA1 samples.  
Based on amino acid sequences from rat gene sequences obtained from Uniprot, HuR has 
a calculated MW of 36 kDa, HuB and HuC have calculated MWs of 39.5 kDa, and HuD has 
calculated MW of 41 kDa.  This would suggest the middle band is HuB and the top band is HuD.  
However,  different  labs  show  variability  in  MWs  for  Hu  proteins,  depending  on  cell type,  
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Figure 22: Western blots 
for Hu proteins (A), 
AUF1/hnRNP D (B), 
hnRNP M and hn RNP K 
(C) after Hu protein IP 
with corresponding 
densitometry analysis 
results by ANOVA and 






















species, or tissue, suggesting post-translational modifications affect the apparent MW of Hu 
proteins separated by SDS-PAGE.  Furthermore, Dr. Keene’s lab has shown that HuB in rat has 
a specific alternative splicing isoform that is about 2 kDa difference in size, based on predicted 
amino acid sequence.  Therefore, these uncertainties in the literature prevent unambiguous 
assignment of the two bands lacking in CA1 NIC following Hu protein IP.  The most 
conservative conclusion is that loss of the two bands is consistent with lack of detection of HuB 
by proteomics of the Hu IPs (Table 6) and the polysome pellets (Table 4). 
Co-IP of RPBs with Hu protein IP 
Following Hu Western blot, the membrane was stripped and reprobed three times with 
antisera directed against AUF1, hnRNP M and hnRNP K (Figure 22).  All three proteins were 
detected at the expected MWs of ~38 kDa (AUF1), 72/72 kDa (hnRNP M) and 65 kDa (hnRNP 
K), indicating these proteins co-IPs with the Hu proteins.  In support of this conclusion, each of 
the three signals was missing from the NIC CA1 samples. 
In addition, AUF1 is known to have 3 bands on SDS-PAGE, where the p37 band is most 
destabilizing to ARE-mRNAs and the p42 band is least destabilizing138 .  In 8R CA1, only p37 
was observed, but all three AUF1 forms were observed in NIC CA3 and 8R CA3.  Finally, as 
mentioned the signal for hnRNP K is absent in NIC CA1, but is also weak in NIC CA3, and is 
stronger in both the 8R CA1 and CA3 samples.   
Therefore, in spite of large backgrounds shown by proteomics, the combined data from 
the proteomics and IP/Western suggest that Hu proteins are bound differentially to the 3 detected 
RBPs between the NIC and 8R condition and between CA1 and CA3, where HuB, and the three 




CHAPTER 4: INVESTIGATION OF MRNAS BOUND TO POLYSOMES AT 8 HR 
REPERFUSION 
Hypothesis 3: mRNAs bound to polysomes isolated after brain ischemia and reperfusion will 
indicate ARE regulation of selectively translated mRNAs.  
Rationale  
RBPs regulate all aspects of mRNAs which include transcription, transport, translation 
and degradation.  Translation is the main function of mRNAs where genetic instructions convert 
into proteins and proteins carry out functions in the cells.  A method to understand RBP function 
is to study the mRNA populations bound to the ribosomes.  This tells about the end point of 
mRNA regulation by RBPs.  There are only two studies of which mRNAs are bound to 
polysomes, called translational state analysis (TSA), in the brain ischemia literature.   
MacManus studied TSA after focal brain ischemia139, using a mouse model of occlusion 
stroke.  This study looked for mRNAs with short 5’ UTRs for selective translation because 
degrading of eIF4G would favor short 5’ UTR-mRNA needing less scanning.  But the mRNAs 
found on polysomes did not show the short 5’UTRs.  This study was limited because the stroke 
model is heterogeneous in brain damage since blood flow makes a gradient from zero at the site 
of occlusion to 100% far from the occlusion.  Also, the study used cerebral cortex as input, and 
cortex is heterogeneous with more cell types than hippocampus.  
The second study was performed in the DeGracia lab by Dr. Szymanski, and I helped 
perform those studies140.  Here, we were isolating polysomes using the sucrose gradient method 
from CA1 and CA3 at 8 hr reperfusion after 10 min global ischemia in the rat.  There were two 
main findings: (1) ARE-mRNAs were enriched on the ribosomes, including hsp70, Atf3, and 
Hmox1 mRNAs, and (2) At 8R, CA3 polysomes had 591 mRNAs increase over controls but 
CA1 had 186. 
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The previous study of TSA used the sucrose gradient preparation of polysomes but no 
study of proteomics on polysomes was performed.  I have now measured and showed above 
(Table 1) that polysomes prepared from sucrose gradients contained only 4% ribosome proteins 
(RPs) in CA1 and 7% in CA3.  Also shown above, the sucrose pad method of isolating 
polysomes had 25% RPs.  The difference in the amount of detected RPs between the two 
polysome isolation methods is suggesting two possibilities: (1) both methods isolate the same 
polysome structures except the sucrose gradient method has more contaminations, or (2) each 
method is isolating different structures that contain RPs.  These two possibilities can be tested by 
measuring the mRNAs bound to polysomes isolated from the sucrose pad method and comparing 
to mRNAs already identified from the sucrose gradient method.  If the two methods isolated the 
same structure, then mRNA populations will be the same.  If the two methods isolated different 
structures containing RPs, then the mRNA populations will not be the same.  
Because the proteomics of the two methods was different, it was important to test the 
mRNAs isolated from both methods and the studies now describe the isolation and 
characterization of mRNA from polysomes isolated by the sucrose pad method.  I hypothesize 
that the mRNA populations will be the same and that ARE-mRNAs will be concentrated on 
polysomes isolated from the sucrose pad method. 
Overall experiment design  
The overall protocol for Aim 3 is outlined in Figure 23 and is similar to the design of 
Aims 1 and 2.  Brain I/R was induced in male Long Evans rats utilizing the 2VO/HT model. 
Experimental groups were again NIC and 8R (n = 15 rats/experimental group).  CA1 and CA3 
were microdissected and randomly pooled from n = 5 animals as one replicate for polysome 
pellet isolation, providing 3 pooled replicates per region per experimental group.  Polysome 
pellets from each replicate were isolated using sucrose pad ultracentrifugation.  The polysomal 
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pellet was then resuspended, mRNA extracted by TRIzol method, and run on Affymetrix 
GeneChip Rat Gene 2.0 ST microarrays. 
 
Figure 23. Overall Experimental Design for Aim 3: Translational State Analysis of CA1 and 
CA3 at 8 hr reperfusion. 
Materials and methods 
Materials 
GeneChip Rat Gene 2.0 ST microarrays were purchased from Affymetrix (City, State).  
Rat Gene 2.0 ST array measure all 28,407 rat mRNA transcripts where each rat gene is 
represented by a median of 22 probes taken across the entire 5’ to 3’ extent of the message. 
TRIzol and GlycoBlue were purchased from Life Technologies (Carlsbad, CA, USA).  RNeasy 
Mini Kit was purchased from Qiagen (Valencia, CA). All other chemicals were reagent grade. 
Surgery: 2VO/HT Model 
The induction of brain I/R were exactly as described in Methods of Chapter 2. 
Microdissection of CA1, CA3 and forebrain 
The microdissection of CA1 and CA3, and isolation of cerebral cortex were exactly as 

























Validation of reperfusion by Western blot 
The validation of brain I/R surgery by Western blot for HSP70 protein was exactly as 
described in Methods of Chapter 2. 
Polysomes pellets  
Polysome pellets were obtained by the sucrose pad method exactly as described in 
Chapter 2. 
RNA extraction 
RNA was extracted from resuspended polysome pellets using the methods previously 
described140.  All work was done under RNAse-free conditions as described in Chapter 2.   RNA 
extraction from polysome pellets was using the TRIzol reagent exactly as per vendor manual.  
For the final isopropanol precipitation, GlycoBlue co-precipitant was added as per vender 
instructions, to visualize RNA pellets. Following wash steps, RNA pellet was dissolved and then 
run thru an RNeasy mini kit exactly as manufacturer instructed.  All final RNA preparations had 
A260/A280 >1.8.  Washed RNA pellets were suspended in sterile water and shipped to Genome 
Explorations (Memphis, Tennessee) overnight on dry ice. 
RNA quality testing at Genome Explorations 
Prior to synthesis of cDNA, RNA purity and concentrations was estimated from A260/A280 
readings on a dual beam UV spectrophotometer.  In addition, integrity of RNA was assessed by 
capillary electrophoresis using an RNA 6000 Nano Lab-on-a-Chip kit and Bioanalyzer 2100 
(Agilent Technologies, Santa Clara, CA) as per manufacturer’s instructions. 
Synthesis of cDNA and labeling 
5-25 ng RNA/sample was converted to cDNA, amplified, fragmented, and biotin labeled 
by an Ovation Pico WTA, Ovation Exon Module, and Encore Biotin Module kits following 
exactly the instructions of the manufacturer (NuGEN, San Carlos CA). 
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Oligonucleotide array hybridization and analysis 
Biotin-labeled fragmented cDNA was hybridized for 17 hr at 45oC to GeneChip Rat 
Gene 2.0 ST Arrays (Affymetrix, Santa Clara CA).  Arrays were then washed.  Next they were 
stained with phycoerythrin-conjugated streptavidin (Life Technologies, Carlsbad, CA) in a 
Fluidics Station 450 (Affymetrix) according to manufacturer’s instructions.  A GCS 3000 7G 
high-resolution confocal laser scanner measured fluorescence intensities, which were recorded 
and analyzed using Affymetrix GeneChip Operating Software suite, v.3.2.  Data provided by 
Genome Explorations included the 16-bit pixel intensity image files (DAT), and probe intensity 
files (CEL) generated by Affymetrix software.  
Data analysis 
Data analysis was performed in the DeGracia lab using Affymetrix Expression Console 
for preprocessing of CEL files.  Preprocessing of CEL files included: probe set summarization 
by PLIER, PM-CGBG background correction and sketch quantile normalization. Sketch quantile 
uses a subset of all probes ('sketch') to shift probe values to the average ranked values for each 
probe set across chips.  Sketch quantile maintains the original signal distributions for each chip.  
Expression Console was also used to generate box plots and intensity histograms of normalized 
and unnormalized chips. 
Differential expression and class comparisons were performed in BRB-ArrayTools 
v.4.2.1, a free Microsoft Excel plug-in developed by BRB-ArrayTools Development Team and 
Dr. Richard Simon at the National Institute of Cancer.  Filter criteria for class comparisons were: 
(1) x-fold > 2; (2) univariate p < 0.01; and (3) exclude genes below the 75th percentile in ranked 
variance of log ratio of 8R/NIC (this excludes probe sets with smallest differences across chips). 
Starting with 29,489 probe sets, 7372 probe sets passed the three filters.  Gene ontology was 
performed in ClueGo as described in Chapter 2.  ARE-containing mRNA were determined by 
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searching gene lists at ARED, ARE Database (http://brp.kfshrc.edu.sa/ared/)141. 
Results 
Quality control of microarrays 
Representative capillary electrophoresis results are shown in Figure 24A. 
 
Figure 24. Quality control of microarrays. (A) Capillary electrophoresis of NIC and 8R CA1 and 
CA3 representative samples. (B) Intensity histograms of all microarrays after preprocessing. (C) 
Intensity box blots before (left) and after (right) preprocessing of chip CEL files. 
RNA extracted from polysome pellets showed intact rRNA.  Preprocessing of the CEL 
files of all chips showed same after normalizations.  Intensity histograms (Figure 24B) from all 
chips aligned following same curves.  Intensity box plots, showing the inter-quartile range, 
median, and maximum and minimum intensities for each chip, are an alternative way to display 




For criteria of x-fold > 2 and p < 0.01, the NIC vs. 8R class comparison show results in 
Table 7.  For mRNAs isolated from CA1 polysomes (CA1p) purified from sucrose pad method, 
243 probe sets changed, with 202 increasing and 41 decreasing at 8R compared to NIC. For CA3 
mRNAs (CA3p), 285 probe sets changed, with 232 increasing and 53 decreasing at 8R compared 
to NIC. For CA1 and CA3, 45% and 41% of hits were identified transcripts. Therefore, over half 
of each set were unknown transcripts. All probe sets meeting criteria are shown in volcano plots 
(Figure 25). The full lists of significant hits are provided in Appendix 5. 
 










Group # hits increased decreased known % known
CA1p 243 202 41 110 45%
CA3p 285 232 53 116 41%
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The list of the top ten hits for CA1p and CA3p are shown in Table 8.  
Table 8. Top ten hits for CA1 p and CA3 p.  
Highlighted transcripts are ARE-containing mRNAs. 
For CA1p, two of the top ten probe sets were unidentified, and for CA3p, four were 
unknown. For both regions, the most highly expressed mRNA bound to polysomes was the two 
mRNAs for HSP70 (Hspa1a, Hspa1b).  The other transcripts shared in common were Atf3, a 
stress-activated transcription factor142, Rpl13, the mRNA for large ribosomal subunit 13 protein, 
and the mRNA for HSP27.  Studies from other labs have shown HSP70 to be expressed in 
neurons143 and HSP27 to be expressed in astrocytes144 at 8 hr reperfusion. 
ARE-containing transcripts on polysomes 
From the top ten lists, four hits were ARE-containing mRNAs in CA1 and three were in 
CA3 (highlighted rows, Table 8).  Each list of identified mRNAs (110 for CA1p; 116 for CA3p) 
were run at ARE database ARED to determine all ARE-containing mRNAs for each hits list. For 
CA1p and CA3p, respectively, 23 (9% of all significant hits) and 10 (4% of significant hits) ARE 
mRNAs were identified (Table 9).  These are both enrichments over the ~ 2% of ARE-mRNAs 
in the entire rat genome145.  As seen in Table 9, all ARE transcripts increased at 8R over NIC 



























Table 9. ARE-containing mRNA from CA1p and CA3p hit lists determined form ARED search. 
 
Comparing mRNA from sucrose pad and sucrose gradient RNA preparations 
To compare the above results with the previously published microarrays study, the 
previous CEL files for the microarray data140 were reanalyzed using the data processing steps 
described above.  These microarrays were from RNA isolated from the sucrose gradients 
Region x‐fold ProbeSet Symbol Name
CA1p 2.13 17711471 Aadat aminoadipate aminotransferase
6.64 17687609 Atf3 activating transcription factor 3
2.43 17843026 Cdon cell adhesion associated, oncogene regulated
2.44 17664369 Cxadr coxsackie virus and adenovirus receptor
3.38 17765931 Dusp2 dual specificity phosphatase 2
2.73 17853273 Glce glucuronic acid epimerase
8.55 17728071 Hmox1 heme oxygenase (decycling) 1
46.43 17756503 Hspa1a heat shock 70kD protein 1A
0.4 17700161 Kctd4 K+ channel tetramerisation domain containing 4
2.35 17827861 Kitlg KIT ligand
2.25 17768956 Mmp9 matrix metallopeptidase 9
8.46 17731745 Mt1a metallothionein 1a
9.26 17717103 Mt1a metallothionein 1a
2.43 17880740 Mthfd2 methylenetetrahydrofolate dehydrogenase 2
2.34 17684954 Pla2g4a phospholipase A2 (cytosolic, calcium‐dependent)
2.54 17809625 Plk3 polo‐like kinase 3
4.18 17632926 Ppp1r15a protein phosphatase 1, regulatory subunit 15A
2.05 17833977 Ptbp1 polypyrimidine tract binding protein 1
5.9 17680795 Ptgs2 prostaglandin‐endoperoxide synthase 2
2.72 17684906 Rgs2 regulator of G‐protein signaling 2
2.17 17679473 Serpinb2 serpin peptidase inhibitor, member 2
3.94 17821305 Sox11 SRY (sex determining region Y)‐box 11
2.37 17661537 Stat3 signal transducer and activator of transcription 3
CA3p 2.05 17711471 Aadat aminoadipate aminotransferase
9.95 17687609 Atf3 activating transcription factor 3
3.11 17765931 Dusp2 dual specificity phosphatase 2
7.68 17728071 Hmox1 heme oxygenase (decycling) 1
27.99 17756503 Hspa1a heat shock 70kD protein 1A
2.12 17745208 Il31ra interleukin 31 receptor A
2.13 17809625 Plk3 polo‐like kinase 3
2.13 17717140 Pter phosphotriesterase related
2.37 17630418 PVR poliovirus receptor
2.37 17821305 Sox11 SRY (sex determining region Y)‐box 11
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method, and fractions containing ribosome proteins were pooled as shown in Figure 26. 
 
Figure 26: Illustration of fractions pooled from sucrose 
gradient method for isolating polysomes, and RNA 
extracted for microarrays in CA1 and CA3. Adopted from 





Shown in Table 10 are comparison of the number of probe sets meeting class comparison 
criteria, numbers of increased and decreased transcripts, number of known transcripts, and 
number and percent of ARE-containing mRNAs between the microarrays from RNAs isolated 
from polysomes prepared by the sucrose pad (pink rows, Table 10) and sucrose gradient (blue 
rows, Table 10) methods.  The numbers of hits in CA1 were comparable: 243 for Pad and 263 
for Gradient.  The numbers of hits from CA3 by the sucrose gradient method (683, CA3B) were 
greater than by the pad method (285, CA3p).   
Table 10. Comparing hits from microarrays of RNA isolated from sucrose pad or sucrose 
gradient methods.   
 
CA1p and CA3p refer to results from sucrose pad method, and CA1B and CA3B refer to sucrose 
gradient method. Up and down arrows are increased and decreased transcripts. ARE refers to 
number of ARE-containing mRNAs. 
For CA1 14% for gradient CA1B mRNAs were ARE verses 9% for pad CA1p.  
ARE-mRNAs were higher in gradient CA3B (13%) verses pad CA3p (4%).  Both methods led to 
enrichment of ARE-mRNAs.  Appendix 6 contains full hit lists for CA1B and CA3B.  Appendix 
Method Grp # hits ↑ ↓ known % known ARE % ARE
Pad CA1p 243 202 41 110 45% 23 9%
Gradient CA1B 263 260 3 181 69% 38 14%
Pad CA3p 285 232 53 116 41% 10 4%
Gradient CA3B 683 649 34 522 76% 90 13%
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7 contains ARED results for ARE-mRNAs from CA1B and CA3B. 
mRNA identities compared between both polysome isolation methods 
The lists of identified mRNAs were very different between the two experimental 
methods.  For CA1 and CA3, only 19 and 17 identified transcripts were shared in common.  
Therefore, it is concluded that different populations of mRNAs were isolated by the two 
methods.  Table 11 shows top 10 hits from sucrose gradient isolated mRNAs.  Also shown is 
when an mRNA was also isolated by pad method, showing x-fold for pad and gradient method 
when both detected the same mRNAs.  For pad method, mRNA was not from top 10 list, but 
could appear anywhere on hit list.  For the CA1 gradient top ten, six were in common with pad 
method, but for CA3 gradient top 10, only three common transcripts were found for both pad and 
gradient methods. 
Table 11. Top 10 hit lists of mRNAs identified from sucrose gradient method.   
 
X-fold of 8R to NIC for sucrose pad (pad x-fold) and sucrose gradient (grad x-fold) are listed along 
with mRNA symbols and names for CA1 (top table) and CA3 (bottom table). 
 
CA1 pad x‐fold grad x‐fold symbol name
56.14 183.77 Hspa1b heat shock 70kD protein 1B (mapped)
8.46 145.99 Atf3 activating transcription factor 3
56.14 77.72 Hspa1b heat shock 70kD protein 1B (mapped)
3.24 63.27 Inhba inhibin beta‐A
30.93 58.4 Hspb1 heat shock protein 1
‐‐ 55.02 Pcdh8 protocadherin 8
8.55 44.21 Hmox1 heme oxygenase (decycling) 1
‐‐ 44.04 Vps37b vacuolar protein sorting 37 homolog B (S. cerevisiae)
3.4 43.93 Gadd45a growth arrest and DNA‐damage‐inducible, alpha
‐‐ 34.07 Wsb1 WD repeat and SOCS box‐containing 1
‐‐
CA1 pad x‐fold grad x‐fold symbol name
9.95 93.48 Atf3 activating transcription factor 3
28.04 74.54 Hspb1 heat shock protein 1
34.89 58.64 Hspa1b heat shock 70kD protein 1B (mapped)
‐‐ 37.66 Ttr transthyretin
‐‐ 36.23 Inhba inhibin beta‐A
‐‐ 27.52 Tmem27 transmembrane protein 27
‐‐ 23.13 Cdkn1a cyclin‐dependent kinase inhibitor 1A
‐‐ 22.61 Ptgs2 prostaglandin‐endoperoxide synthase 2
‐‐ 20.47 Mfrp membrane frizzled‐related protein
‐‐ 17.56 S100a8 S100 calcium binding protein A8
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When x-fold were compared from pad to gradient methods, it was observed that gradient 
isolation of polysome RNAs always have greater x-fold in all cases.  Gradient isolated mRNAs 
were from ~1.5-fold (Hspa1b) to ~20-fold (Inhba) range of increase over pad isolated mRNAs.  
Therefore, in addition to lists being different populations of mRNA, the x-fold quantity was also 
different between lists.   
Gene ontology comparison of polysome mRNAs from sucrose pad and gradient 
To compare hit lists from mRNAs isolated by sucrose pad or gradients methods, gene 
ontology (GO) was used to find categories of “Molecular function” for the transcripts of both 
lists. GO used right-side hypergeometric testing which detects enrichments of transcripts.  This is 
justified by more than 80% of mRNAs increasing at 8R relative to NIC (Table 10).  The general 
pattern was less GO categories were found for mRNA from sucrose pad method, and more 
categories for mRNA from sucrose gradients.  Many categories were identified but I could group 
them into six main groups, shown as color key on Figure 27 and Figure 28: (1) protein 
folding/heat shock, (2) cell signaling, (3) DNA-related, (4) lipid metabolism, (5) miscellaneous 
protein-related functions, and (6) general metabolic or biochemical pathways.  Figure 27 shows 
mRNAs from sucrose pads had predominant heat shock and cell signaling pathways, and CA1 
had DNA-related mRNAs.  Figure 28 shows mRNAs isolated from sucrose gradient method had 
more categories.  This is interesting for CA1 because pad (243) and gradient (263) had about 
same number of significant hits.  Protein folding/heat shock and cell signaling, which was over 
75% of pad mRNAs, was less than 50% in mRNAs from gradient method. 
GO analysis indicates more mRNAs isolated from pad method were more related to 
stress responses, but mRNAs from gradient method had stress responses and in addition more 
general cell functions.  Therefore it is concluded that pad and gradient methods isolated different 














CHAPTER 5: DISCUSSION 
Summary 
In this study I investigated polysome and Hu protein IP proteomics and mRNA on 
polysomes isolated from sucrose pad method.  The notable findings are now summarized.  The 
main finding was that no Hu proteins were detected on CA1 NIC polysomes or following IP of 
Hu proteins, and this finding was consistent with loss of Hu-antibody reactive bands after Hu IP-
Western.  The second finding was that several RPBs copurified with polysomes and Hu IPs 
suggesting different RBP complexes occur in the NIC and 8R CA1 and CA3.  The third finding 
was the mRNA population found on polysomes isolated from sucrose pad method was different 
from mRNA population found from sucrose gradient method.  Below is discussed each finding.   
In addition to the main findings, an important technical finding was due to proteomics.  
Samples that seemed pure by Western blot markers were found by proteomics to be very 
contaminated.  This limitation and other limitations will be discussed below. Future directions to 
follow the studies described in this Thesis are also discussed and conclusions stated. 
Discussion of findings 
Lack of detection of HuB in NIC CA1 
There are four members in the highly conserved ELAV/Hu family. HuB, HuC, and HuD 
are predominantly cytoplasmic and expressed specifically in neurons, therefore they are called 
neuronal Hu proteins, while HuR is primarily expressed in the nucleus ubiquitously110,147.  
Expression distribution of mRNA of the four homologs in the developing brain is widely 
variable148, suggesting different function.  Yet, all these homologs protein contain three RNA 
recognition motif with greater than 90% similarity in amino acids sequence and specifically 
binds to ARE in the 3’-UTR148.  The antibody for Hu that I used in the Hu IP experiments (sc-
5261) was the same used in immunofluorescence colocalization33 , and this antibody recognizes 
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HuR, HuB, HuC, and HuD.  
It is concluded HuB was missing from Hu IP reactions (Table 6) and polysomes (Table 4) 
by proteomics.  Western blot showed loss of two bands that react with Hu antiserum (Figure 22). 
But identifying the two bands is not possible with data given here.  From amino acid sequences 
from rat gene sequences obtained from Uniprot, HuR has a calculated MW of 36 kDa, HuB and 
HuC have calculated MWs of 39.5 kDa, and HuD has calculated MW of 41 kDa.  This would 
suggest the middle band is HuB and the top band is HuD.  However, different labs show 
variability in MWs for Hu proteins, depending on cell type or tissue, suggesting post-
translational modifications affects the apparent MW of Hu proteins separated by SDS-PAGE.   
Furthermore, Dr. Keene’s lab has shown that HuB has a specific alternative splicing isoform that 
is about 2 kDa difference in size, based on predicted amino acid sequence114.  In addition, I have 
tried many antiserums to find the ones that can specifically detect homologs of Hu family but 
found no competent antiserum (data not shown).  Therefore, these uncertainties in the literature 
prevent us to identify the two bands lacking in CA1 NIC following Hu protein IP (Figure 22).  
To be conservative, it is concluded that the loss of the two bands is consistent with the lack of 
detection of HuB by proteomics in the Hu IPs (Table 6) and the polysome pellets (Table 4). 
In a 1994 paper that looked at HuB in the rat (also called Rel-N1), the Keene laboratory 
performed in situ hybridization for the mRNA of HuB and found that it was almost undetectable 
in CA1 compared to CA3 and dentate gyrus149.  It was not attempted in this paper to measure the 
HuB protein content of the various hippocampal regions.  When Dr. Keene’s results are 
combined with my results showing that HuB is not detected by proteomics of polysome pellets 
or Hu IP in NIC CA1, this supports that HuB is at a much lower level in CA1 compared to CA3.  
Implication of low levels of HuB in NIC CA1 
The lack of HuB in NIC CA1 is considered the main finding because it may relate to 
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selective vulnerability of CA1 discussed in Background (see Figure 2).  If HuB is required for 
neuron to organize mRNAs in stress response after brain I/R, it is possible low HuB slows this 
response.  By “organize” I mean that mRNA, after exit from the nucleus, may be grouped in 
mRNA operon (discussed in Background) to allow selective translation and selective access to 
ribosomes.  It is shown that mRNA for hsp70 in both CA1 and CA3 is very high by 8R (Table 8) 
but if HuB cannot be used for organizing mRNAs, this may explain delay in HSP70 protein 
translation in CA1 (Figure 6). 
However, one big mystery is the two Hu bands are lacking in CA1 NIC but are observed 
to be present by SDS-PAGE/Western after Hu IP at 8R CA1 (Figure 22).  If HuB is low in CA1 
NIC, how did it get in 8R samples?  The microarray data from both pad and gradient microarrays 
was searched for the HuB mRNA.  Shown in the following table is the individual sample 
intensities after preprocessing but before filters: 
Table 12. HuB mRNA levels from microarrays. 
 
For the pad microarrays (CA1p, CA3p) it is seen variance of the data is very small and 
this gene was filtered from criteria of log ratio >75 percentile from results presented above.  For 
gradient microarrays, CA1B NIC samples showed much variance and were filtered by p < 0.001.  
In both cases, HuB mRNA was filtered out.  
When x-fold was calculated CA1 and CA3 from pad method gave 8R/NIC ~ 1.0, 
showing no change in mRNA for HuB and would not pass x-fold > 2 filter.  However, for 
calculated gradient method x-fold, the CA1B sample had almost 5-fold increase in HuB mRNA.  
This data suggests HuB mRNA may increase in CA1 after reperfusion and was isolated 
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in fractions from gradient method but not pad method.  Combining with observation of return of 
bands at 8R in CA1 not seen in NIC CA1, this suggests HuB may actually be translated over the 
8 hrs of reperfusion.  Follow-up studies need to test this as discussed in Future Directions below. 
If it is true that HuB must be translated during reperfusion, this could explain why there 
is so long time delay of Hu signal colocalizing in mRNA granules (Figure 16) and delayed 
transcription of the ARE-mRNA of hsp70.   
The result overall can mean that CA1 starts from a weaker starting point than CA3, and 
this helps explaining the selective vulnerability of CA1.  This is a unique conclusion to reach 
because all theories of why CA1 is selectively vulnerable attribute CA1 death to damage 
incurred during reperfusion, and not to the starting position of the control.  As CA3 is subject to 
the exact same damage (10 min ischemia) as CA1, it is logical to consider that starting position 
of two cell types contributes to the outcome after I/R. 
Detection of RNA binding proteins 
Overall, I do not conclude that I isolated RBP complexes.  Even though both polysomes 
and Hu IP isolated other RBPs, the results were not consistent across the experimental groups 
and so it is not fair to conclude definite isolation of an RBP. 
Acknowledging this weakness of the data, there is still evidence that RBPs are different 
from all four conditions tested: NIC CA1, NIC CA3, 8R CA1 and 8R CA3.  The following 
observations support this.   
First, HuB was not detected in CA1, as discussed above, and this would be a difference in 
RBPs across conditions.   
Second, PAI1 RNA-binding protein 1 (PAIR_RAT) was seen in all three NIC CA1 
samples (Table 4) from polysome pellets and two of three 8R CA3 polysome pellets. PAIR_RAT 
was not detected by Hu IP indicating it may form a different RBP complex than those with Hu 
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proteins in them.  
Third, hnRNP D (AUF1) was detected in only in 8R CA1 in one polysome sample (Table 
4) and one Hu IP (Table 6).  Further AUF1 p37 form only was detected in 8R CA1 by 
IP/Western (Figure 22), whereas in NIC and 8R CA3 all three forms of AUF1 were detected. 
This points to a different binding between Hu proteins and AUF 1 in 8R CA1 compared to other 
conditions. 
Finally, the 8R CA1 and CA3 samples seemed to co-precipitate more hnRNP K than NIC 
CA3, and none was detected in NIC CA1.  This suggests Hu proteins and hnRNP K forms a 
complex specifically during reperfusion.  This is interesting because hnRNP K has shown to 
colocalize to dendritic spines150 and a complex of Hu proteins, and hnRNP K may be  involved in 
shuttling mRNAs to spines to express protective proteins such as hsp70 during I/R. 
Taken together, the above observations suggest, but do not conclusively prove, RBPs are 
regulated differently after brain I/R. 
Bound mRNA from two polysome isolation methods 
In my studies, I attempted to replicate the microarray findings of Szymanski et al, 2013123 
using a different method of isolating polysomes.  Here I used sucrose pad method vs. the pooling 
of fractions obtained from sucrose gradients.  Overall, I did not replicate the previous results 
because: (1) the number of mRNAs that passed the filters in the current study was about the 
same for CA1 and CA3, whereas CA3 had more detections than CA1 in Szymanski et al, and (2) 
the mRNA populations were about 90% different.  However, I replicated the previous findings 
showing a concentration of ARE-mRNAs on polysomes.  Two factors can contribute to the 
different mRNA populations isolated by each method: (1) the purity of each preparation, and (2) 
the physical methods of separation. 
First, it was shown using proteomics that the sucrose gradient method does not 
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concentrate ribosomal proteins (4-7%) as much as the pad method (~25%).  In Figure 15 is 
shown GO analysis of the sucrose pad polysome prep where contamination was mainly neuron 
debris, cytoskeleton, internal and plasma membranes.  A similar GO analysis of the proteomics 
of the sucrose gradient proteomics gives the following: 
 
Figure 29: GO analysis of proteomics of sucrose gradient isolated polysomes. 
Here is found similar items such as neuron debris, cytoskeleton and ER and plasma 
membranes.  The main difference is evidence of whole mitochondrial contamination 
(mitochondrial matrix), whereas with the pad method, there was evidence only for outer 
mitochondrial membrane.  Mitochondria have their own system of translation that could bias the 
results.  But the number of genes translated on mitochondrial ribosomes is small and 
mitochondrial ribosomes were detected by proteomics.  The additional contamination could 
provide more substrate for artificial binding sites for RNAs that might explain why a more 
diverse population of mRNAs was found in the microarrays of RNA from the sucrose gradient. 
Second, the physical methods of separation involved might be isolating different 
structures that contain ribosomal proteins.  The pad method is differential centrifugation where 
structures pellet at different times based on physical properties.  The sucrose gradient is 
isopycnic centrifugation where structures migrate until they reach the density of sucrose 
matching the density of the structure and then quit migrating.  For the pad-isolated RNAs the 
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results were similar between CA1 and CA3, but they mRNA populations were more diverse 
between CA1 and CA3 for the gradient method.  This suggests different ribosome-containing 
structures were isolated by the two methods and further study is required. 
Limits of the studies 
This section is the discussion of limits of the IP method, proteomic, and the fact that 
contaminants were so high as determined by proteomics. 
IP Limitations 
There is a possible confounder with HuR IP studies.  The Steitz lab showed that protein-
mRNA complex can spontaneously form in cell151.  They mixed lysates from FLAG-tagged HuR 
expressed in one cell population (lacking c-fos) with c-fos transfected in a different cell 
population151.  They observed c-fos-FLAG-tagged HuR complexes in the mixed lysates.  They 
showed co-IP does not always recapitulate the interaction of what is happening in vivo and may 
provide false positive results if protein-mRNA complexes form spontaneously in vitro151.  From 
this study it is possible to imagine that protein-protein complex could also form in the 
homogenization step and therefore not indicate what was present in vivo before homogenization. 
I attempted to overcome this limitation by using complimentary methods of IP detection 
of RBPs and detection of RBPs on polysomes.  Unlike smaller protein complexes, polysomes are 
large intricate ribonucleoprotein complexes that will not form spontaneously in cell extracts that 
do not provide substrates for translation initiation.  Further, polysomes present in the cell at the 
time of homogenization can be preserved by adding CHX to the homogenization buffer120.  
Therefore, Aim 1 complemented Aim 2 by assessing mRNA binding proteins associated with 
intact polysomes.  As discussed above, this helped adding some consistency, for example, in the 




Even though it is very powerful, proteomics technology has limits that were faced in the 
studies.  The main problem was protein concentration.  Because I tried to find protein complexes 
in small brain regions, this limited the amount of protein per animal.  Five animals had to be used 
to make one pooled sample.  Even then, for the Hu IPs, the amount of protein was below that 
needed for iTRAQ labeling, and the Hu IPs could not be detected by iTRAQ since the protein 
was too low concentration.  Also, because of the high amount of contaminants detected, the 
failure to consistently detect RBPs could be due to them being at low concentration in the 
samples relative to iTRAQ-labeled contaminants. 
The solutions would be to add more animals, but this becomes impractical. To double the 
amount of protein would require 30 animals per group instead of 15.  The time and cost of 
animals increase much more than the amount of protein obtained.  I could not use a more 
abundant brain region for the studies, such as cerebral cortex, because it is so heterogeneous and  
I then could not compare a selectively vulnerable region to a resistant region.  Cell culture could 
be used and not have such limitation.  But cell culture is artificial and cannot model real brain 
ischemia.  Therefore, the limit of protein concentration for proteomics cannot be easily 
overcome. Hopefully proteomic technology will continue to improve so one day to overcome 
these limits. 
Detection of contamination 
The most serious limit was contamination of the samples.  Recognizing the extent of 
contamination was a consequence of using the state of the art proteomics, and this does not affect 
only my studies, but has implications for accepted practices.  For the polysomes proteomics I 
tested 5 antisera for 3 organelles contaminating the samples, and all showed the samples to not 
be contaminated.  But proteomics showed the polysome pellets to only consist of 25% ribosomal 
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proteins.  In the IP reactions, even the no-antibody control showed over 100 proteins 
contaminating the beads, and the negative control using anti-histone had close to 200 proteins of 
contamination.  A number of controls were performed to optimize the IPs (Figure 19), but still 
such contamination was found.  As stated above, one consequence of the contamination is that it 
made the iTRAQ reactions less efficient because iTRAQ reagent was labeling the contaminants 
instead of the desired molecules.  Therefore, in both IPs and polysome pellets, I probably 
detected less than all the RBPs than were present because of interference from the contaminants. 
Generally, in the literature, when such studies are performed, the accepted practice is to 
Western blot for contaminants to show purity.  As I showed here, this does not appear to be a 
good criterion. It is impossible to guess beforehand all possible contaminants and then do 
Western blots for them.  My studies suggest that proteomics should become the accepted 
standard for determining the extent of contamination of purified fractions, especially when the 
fractions are isolated from whole animal tissues.  This experience has now made me very 
cautious when I read the literature. 
Possible function of “contaminant” protein 14-3-3 
14-3-3 protein family is detected in both Hu IP proteomics and polysomes proteomics.  
It’s detected in almost every samples including negative control.  It is possible that 14-3-3 may 
be background, but it’s also possible that 14-3-3 is serving a functional role. 14-3-3 is a family of 
highly homologous proteins and has been implicated in vital cellular processes, such as protein 
trafficking, cell signaling, and apoptosis, including many settings related to mRNA regulation.  
Immunoprecipitation of 14-3-3 sigma from mitotic U2OS cells, followed by mass spec, 
showed that many proteins involved in protein translation and RNA transcription, including 
initiation factors and many ribosomal proteins, were the binding targets of 14-3-3 sigma152.  
However, although many 14-3-3 proteins were detected in the proteomics results, 14-3-3 sigma 
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was not among them.  But we cannot rule out the possibility that 14-3-3 might be of a level to 
low to be detected.  Another study using MS on 14-3-3 zeta affinity column elute also detected 
many initiation factors, ribosomal proteins and RNA binding proteins153, and 14-3-3 zeta is 
detected in the proteomics.  Co-IP experiments have also shown that HuR binds with different 
isoforms of 14-3-3, and some of the binding contribute to the cellular localization of HuR137.  
Taken together, this suggests that 14-3-3 is unlikely a random background hit, but possible of 
functional significance. 
14-3-3 has implicated in mRNA regulation by binding with RBP either promoting or 
inhibiting ARE-mRNA degradation. 14-3-3 sigma binds with both p37 and p40 AUF-1, the two 
isoforms strongly associated with ARE-mRNA decay, promotes AUF-1 transport and ARE-
mRNA decay154.  The association of 14-3-3 with the phosphorylated KSRP, which also binds to 
ARE-mRNA, impairs KSRP’s ability to interact with the exosomes thus slows the degradation of 
ARE-mRNA155.  The association of 14-3-3 with TTP excludes TTP from stress granules and 
inhibits TTP dependent degradation of ARE-mRNA156. 
Given this large body of evidence, it is possible 14-3-3 proteins are not contaminants but 
in fact copurified with both the ribosomes and Hu IPs. 
Future Directions 
Even with the limits discussed above, when my results are combined with other results in 
the literature, I believe the conclusions reached are valid. HuB is missing from CA1 NIC, but is 
present at 8R; different RBPs were isolated from the four experimental conditions; and the 
mRNA populations were different from the pad and gradient methods.  Additional studies could 
strengthen these findings.  The main purpose of my PhD dissertation work was to gain molecular 
insight into the mRNA granules discovered in reperfused neurons.  To further this purpose and 
build on the work described here, the following future directions are proposed: 
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1. Seek to identify the two Hu antisera-reactive bands not detected in NIC CA1.  One 
method to accomplish this goal would be to excise the bands from nitrocellulose and 
subject them to LC-MS. Another method is to continue to test the commercial antisera for 
HuA, HuB, HuC and HuD. As mentioned above, I did preliminary work with other 
antisera, but these will require careful study to find the right conditions to obtain 
successful Western blot, which I was unable to obtain. 
2. The mystery of how the two bands can be absent from NIC CA1 and present in 8R CA1 
requires attention. The analysis of the microarray signal for HuB mRNA suggests that it 
is increasing during reperfusion, although the filter criteria applied in this study 
eliminated it from the significant hit list.   
One method to determine if HuB mRNA increases during reperfusion is to perform real-
time PCR with specific primers for the HuB mRNA and directly measure this mRNA.   
Another method would be to show de novo translation of HuB during reperfusion.  A 
way to accomplish this is to administer radioactive amino acids to reperfused animals and 
perform Hu protein IP.  If radioactive HuB can be isolated from reperfused homogenates, this is 
evidence it is being translated during reperfusion.  
Given the result that Hu antiserum-reactive proteins are delayed in the colocalization with 
mRNA granules, and this correlates with HSP70 translation, such studies could determine if the 
colocalization signal is HuB. 
3. Biochemical isolation of the mRNA granules.  This is the most important goal.  In the 
course of my PhD work, an attempt was made to isolate the mRNA granules.  Cortex 
from 8R animals containing mRNA granules was homogenized, fixed at various steps of 
fractionation, spread on microscope slides, and stained for polyA mRNAs using 
fluorescent in situ hybridization. Unfortunately, these pilot studies failed to detect 
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granular structures.  What is interesting is that, by substituting the microarray studies for 
the biochemical isolation of mRNA granules, I obtained the unexpected result that the 
sucrose pad and sucrose gradient polysome preparations isolated different mRNA 
populations. As discussed above, this suggested the two methods are isolating different 
ribosome protein-containing structures. It is possible that pad or gradients is isolating the 
mRNA granules. 
One way to get at testing this experimentally is to study the individual fractions from the 
sucrose gradient instead of pooling them.  They can be studied by proteomics to detect RPBs, 
possibly by first further purifying gradient fractions since I have now shown the gradient 
fractions have much contamination.  A method to see if the fractions contain particles is with 
light scattering to see if a fraction can be isolated that has a specific size particle.  Western blot 
of the fractions can also be used to detect proteins that have been identified to colocalize with the 
mRNA granules including eIF4E, eIF4G, PABP, and the Hu proteins.  This is one of the most 
exciting lines opened up by the studies described here and has the possibility of possibly 
isolating the mRNA granules. 
Conclusions 
The studies described here sought to identify RBP complexes that distinguished 
reperfused CA1 from CA3, to test the hypothesis that differences in mRNA regulation 
contributed to selective vulnerability of CA1. The work was a qualified success.  Technical 
limitations prevented obtaining clean experimental results. But the work I have done will make it 
easier for any future work along these lines.   
The work produced two unexpected results: HuB is lacking in NIC CA1, which might 
contribute to CA1 selective vulnerability, and (2) methods that are supposed to isolate polysomes 
gave very different results by proteomics and microarrays.  This second result may have 
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inadvertently found a method to study mRNA binding structures in reperfused neurons and will 
require further investigation.   
Finally, working with proteomics showed how “messy” the IP and polysome pad method 
were.  My work described here illustrates the important lesson that when doing science, “the 
devil is in the details”.  This was an eye-opening result that suggests that proteomic evaluation of 
purity should become the accepted standard for molecular studies of tissue.   
My dissertation did not solve the problem of mRNA granules, but it furthered the study 
of ribonomics after brain ischemia in a substantial way and moves steps closer to understanding 
why neurons die in a delayed fashion after brain I/R.  These are important results and give 
optimism that we will come to understand how and why the neurons die after I/R.  This will 
allow treating an important clinical condition that devastates the lives of millions of people 
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































APPENDIX 5: MICROARRAY HIT LISTS FROM SUCROSE PAD METHOD 
mRNA hit list CA1 from sucrose PAD 
   p‐value  FDR  x‐fold  ProbeSet  Symbol  Name 
1  1E‐07  0.000369  56.14  17752874  Hspa1b  heat shock 70kD protein 1B (mapped) 
2  1E‐07  0.000369  46.43  17756503  Hspa1a  heat shock 70kD protein 1A 
3  3E‐07  0.000737  8.55  17728071  Hmox1  heme oxygenase (decycling) 1 
4  9E‐07  0.00166  0.2  17850830     
5  3.4E‐06  0.00501  30.93  17676952  Hspb1  heat shock protein 1 
6  5.7E‐06  0.007  5  17615739     
7  7.9E‐06  0.00832  11.42  17869465     
8  1.63E‐05  0.015  3.51  17723019     
9  2.15E‐05  0.0164  5.12  17878998  Morc4  MORC family CW‐type zinc finger 4 
10  2.23E‐05  0.0164  5.66  17718415  Gadd45g  growth arrest and DNA‐damage‐inducible, 
gamma 
11  3.31E‐05  0.0222  2.71  17832266  Gpd1  glycerol‐3‐phosphate dehydrogenase 1 
(soluble) 
12  5.14E‐05  0.0284  2.51  17875520     
13  5.21E‐05  0.0284  10.19  17664420     
14  0.000059  0.0284  3.38  17765931  Dusp2  dual specificity phosphatase 2 
15  5.95E‐05  0.0284  5.36  17844027  Cryab  crystallin, alpha B 
16  6.17E‐05  0.0284  2.72  17684906  Rgs2  regulator of G‐protein signaling 2 
17  6.72E‐05  0.0291  5.48  17672229  Zfand2a  zinc finger, AN1‐type domain 2A 
18  7.39E‐05  0.0303  0.39  17880821     
19  8.04E‐05  0.0312  2.53  17868099     
20  9.83E‐05  0.0338  3.4  17773115     
21  0.000105  0.0338  2.46  17811536  Pnrc2  proline‐rich nuclear receptor coactivator 2 
22  0.000105  0.0338  4.29  17673512  Ubc  ubiquitin C 
23  0.000113  0.0338  2.86  17671497  Hsph1  heat shock 105/110 protein 1 
24  0.000117  0.0338  2.64  17867377     
25  0.000117  0.0338  2.64  17869668     
26  0.000124  0.0338  4.55  17731750  Mt2A  metallothionein 2A 
27  0.000125  0.0338  0.31  17791957     
28  0.000133  0.0338  3.18  17702048  LOC100362916  rCG61219‐like 
29  0.000142  0.0338  4.18  17632926  Ppp1r15a  protein phosphatase 1, regulatory subunit 
15A 
30  0.000151  0.0338  4.34  17828625  Ddit3  DNA‐damage inducible transcript 3 
31  0.000154  0.0338  3.23  17753672     
32  0.000156  0.0338  8.46  17731745  Mt1a  metallothionein 1a 
33  0.000158  0.0338  0.44  17619179  Olr162  olfactory receptor 162 
34  0.000163  0.0338  2.87  17717148  Vim  vimentin 
35  0.000164  0.0338  3.4  17833546  Gadd45b  growth arrest and DNA‐damage‐inducible, 
beta 
36  0.000165  0.0338  3.28  17752700     
37  0.000175  0.0339  2.46  17868246     
38  0.000177  0.0339  6.64  17687609  Atf3  activating transcription factor 3 
39  0.000182  0.0339  8.89  17730862  Rpl13  ribosomal protein L13 
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40  0.000184  0.0339  5.9  17680795  Ptgs2  prostaglandin‐endoperoxide synthase 2 
41  0.000213  0.0382  5.83  17621224  Bag3  Bcl2‐associated athanogene 3 
42  0.000235  0.0407  2.13  17674382  Hspb8  heat shock protein B8 
43  0.000237  0.0407  2.41  17867524     
44  0.000244  0.0408  2.11  17847005  Ryk  receptor‐like tyrosine kinase 
45  0.000267  0.0437  2.06  17824977     
46  0.000308  0.0481  2.26  17636799  Cdr2  cerebellar degeneration‐related 2 
47  0.000311  0.0481  0.47  17715365     
48  0.000313  0.0481  2.09  17845560     
49  0.000321  0.0483  2.73  17853273  Glce  glucuronic acid epimerase 
50  0.000336  0.0484  2  17843725  Mpzl3  myelin protein zero‐like 3 
51  0.00034  0.0484  0.49  17772385  Nr4a2  nuclear receptor subfamily 4, group A, 
member 2 
52  0.000343  0.0484  0.43  17707441     
53  0.00036  0.0484  0.37  17692312     
54  0.000365  0.0484  2.25  17715072  Nedd9  neural precursor cell expressed, 
developmentally down‐regulated 9 
55  0.000367  0.0484  6.56  17639411  Npas4  neuronal PAS domain protein 4 
56  0.000371  0.0484  4.93  17703273     
57  0.000381  0.0484  2.02  17880303     
58  0.000387  0.0484  2.34  17684954  Pla2g4a  phospholipase A2, group IVA (cytosolic, 
calcium‐dependent) 
59  0.000392  0.0484  2.4  17761562     
60  0.000394  0.0484  2.77  17868131     
61  0.000411  0.0496  2.35  17611516     
62  0.000417  0.0496  2.26  17728152     
63  0.000443  0.0505  5.99  17875665  Timp1  TIMP metallopeptidase inhibitor 1 
64  0.000443  0.0505  2.65  17669324     
65  0.00046  0.0505  2.74  17767319     
66  0.000479  0.0505  3.35  17756041  Rnf39  ring finger protein 39 
67  0.000513  0.0529  2.33  17735630  RGD1564606  similar to 60S ribosomal protein L23a 
68  0.000517  0.0529  2.67  17664730  Slc5a3  solute carrier family 5 (sodium/myo‐
inositol cotransporter), member 3 
69  0.000542  0.0546  2.47  17868037     
70  0.000548  0.0546  0.23  17621993  Olr305  olfactory receptor 305 
71  0.000563  0.0554  2.37  17696845     
72  0.000587  0.0569  2.31  17872261     
73  0.000608  0.057  3.41  17808756     
74  0.000611  0.057  4.52  17802844  Sesn2  sestrin 2 
75  0.000611  0.057  3.85  17791883     
76  0.000624  0.0575  2.13  17711471  Aadat  aminoadipate aminotransferase 
77  0.000653  0.0578  2.42  17867369     
78  0.000673  0.0578  2.67  17833162  Olr896  olfactory receptor 896 
79  0.000677  0.0578  2.16  17869664     
80  0.000681  0.0578  2.25  17697923  Samd4a  sterile alpha motif domain containing 4A 
81  0.000682  0.0578  0.49  17772363     
82  0.000688  0.0578  2.89  17675915  Nptx2  neuronal pentraxin II 
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83  0.000702  0.0582  2.88  17866859     
84  0.000719  0.0588  2.54  17648894  Rpl23a  ribosomal protein L23a 
85  0.000733  0.0588  3.24  17719769  Inhba  inhibin beta‐A 
86  0.000738  0.0588  0.28  17761763  Olr400  olfactory receptor 400 
87  0.000742  0.0588  3.19  17765084  Chac1  ChaC, cation transport regulator homolog 
1 (E. coli) 
88  0.000754  0.0591  2.06  17869622     
89  0.000767  0.0595  2.88  17870204     
90  0.000774  0.0595  2.43  17880740  Mthfd2  methylenetetrahydrofolate 
dehydrogenase (NADP+ dependent) 2, 
methenyltetrahydrofolate cyclohydrolase 
91  0.000802  0.0603  0.4  17721097     
92  0.000807  0.0603  2.37  17661537  Stat3  signal transducer and activator of 
transcription 3 (acute‐phase response 
factor) 
93  0.00081  0.0603  3.94  17821305  Sox11  SRY (sex determining region Y)‐box 11 
94  0.000856  0.0631  2.06  17778298  Trib3  tribbles homolog 3 (Drosophila) 
95  0.000891  0.0636  2.73  17634637     
96  0.000896  0.0636  2.23  17859277  Hspe1  heat shock protein 1 (chaperonin 10) 
97  0.000903  0.0636  2.99  17703301     
98  0.000906  0.0636  0.33  17688235     
99  0.000929  0.0646  2.4  17783943     
100  0.000943  0.0649  2.54  17856053     
101  0.000968  0.0661  2.44  17668398  Olr1537  olfactory receptor 1537 
102  0.000993  0.0666  9.26  17717103  Mt1a  metallothionein 1a 
103  0.001061  0.0705  2.55  17638715     
104  0.001078  0.0709  2.78  17826912  Vom1r108  vomeronasal 1 receptor 108 
105  0.001109  0.0724  2.74  17868148     
106  0.001142  0.0732  3.93  17877200  LOC100362769  hypothetical protein LOC100362769 
107  0.001163  0.0732  2.8  17682964     
108  0.001205  0.0748  2.33  17869596     
109  0.00122  0.0749  4.72  17685339     
110  0.001282  0.0776  2.69  17727551  Rrad  Ras‐related associated with diabetes 
111  0.001284  0.0776  2.1  17868207     
112  0.001375  0.0815  2.22  17820411     
113  0.001378  0.0815  3.88  17626509     
114  0.001387  0.0815  3.41  17665017     
115  0.001392  0.0815  2.23  17816328     
116  0.001421  0.0824  0.34  17803983     
117  0.001446  0.0824  2.89  17872868  Msn  moesin 
118  0.001464  0.0824  2.11  17748101  Fnip2  folliculin interacting protein 2 
119  0.001465  0.0824  2.1  17651421  Arl4d  ADP‐ribosylation factor‐like 4D 
120  0.001475  0.0824  3.65  17781033     
121  0.00151  0.0837  2.76  17818250     
122  0.001563  0.0843  0.31  17815318     
123  0.001576  0.0843  2.54  17809625  Plk3  polo‐like kinase 3 
124  0.001576  0.0843  0.32  17792025     
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125  0.001577  0.0843  2.03  17692307     
126  0.001579  0.0843  2.37  17703668     
127  0.001603  0.0844  2.24  17870257     
128  0.001747  0.0894  2.43  17843026  Cdon  cell adhesion associated, oncogene 
regulated 
129  0.001899  0.0953  2.35  17827861  Kitlg  KIT ligand 
130  0.001901  0.0953  2.15  17731681  Herpud1  homocysteine‐inducible, endoplasmic 
reticulum stress‐inducible, ubiquitin‐like 
domain member 1 
131  0.002126  0.104  2.46  17869467     
132  0.002126  0.104  2.46  17870157     
133  0.002313  0.11  0.41  17763629  Olr530  olfactory receptor 530 
134  0.002321  0.11  2.22  17752318  OLR1740‐PS // 
LOC100362200 
// ‐‐‐ 
135  0.002393  0.112  2.97  17769238  Dok5  docking protein 5 
136  0.002403  0.112  2.05  17833977  Ptbp1  polypyrimidine tract binding protein 1 
137  0.002408  0.112  2.4  17821927     
138  0.002511  0.115  0.4  17700161  Kctd4  potassium channel tetramerisation 
domain containing 4 
139  0.002537  0.115  2.1  17880291     
140  0.00265  0.117  2.85  17637216  Sult1a1  sulfotransferase family, cytosolic, 1A, 
phenol‐preferring, member 1 
141  0.002691  0.117  2.6  17838120  Arc  activity‐regulated cytoskeleton‐associated 
protein 
142  0.00279  0.12  2.89  17853950  Pigb  phosphatidylinositol glycan anchor 
biosynthesis, class B 
143  0.002822  0.12  2.43  17779781     
144  0.002827  0.12  2.25  17768956  Mmp9  matrix metallopeptidase 9 
145  0.002846  0.12  2.79  17633661  Mir344a‐2  microRNA mir‐344a‐2 
146  0.002869  0.12  2.12  17797676  RGD1562265  similar to ribosomal protein S12 
147  0.002873  0.12  2.87  17654073  Olr1376  olfactory receptor 1376 
148  0.002942  0.122  3.51  17795795  Tas2r110  taste receptor, type 2, member 110 
149  0.003068  0.122  3.23  17851234  Olr1257  olfactory receptor 1257 
150  0.003078  0.122  2.03  17867711     
151  0.003078  0.122  2.03  17870281     
152  0.003093  0.122  2.22  17699330     
153  0.003101  0.122  5.13  17764480     
154  0.003101  0.122  5.13  17860243     
155  0.003103  0.122  0.49  17703132     
156  0.003129  0.122  2.46  17815894     
157  0.003156  0.122  0.49  17746295  LOC361914  similar to solute carrier family 7 (cationic 
amino acid transporter, y+ system), 
member 12 
158  0.003166  0.122  2.44  17664369  Cxadr  coxsackie virus and adenovirus receptor 
159  0.003241  0.122  2.17  17658404  Spns2  spinster homolog 2 
160  0.00329  0.123  2.84  17693294  RGD1561226  similar to DNA segment, Chr 5, ERATO Doi 
577, expressed 
161  0.003418  0.126  2.09  17783185     
162  0.00351  0.128  0.47  17774126  Olr485  olfactory receptor 485 
163  0.003539  0.128  2.32  17829032     
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164  0.003751  0.134  0.49  17755248     
165  0.003878  0.137  0.43  17835175     
166  0.003915  0.137  0.36  17744380     
167  0.003946  0.138  2.06  17794096     
168  0.004039  0.139  2.19  17731173     
169  0.004098  0.14  2.55  17869518     
170  0.004106  0.14  2.77  17673385     
171  0.004299  0.143  3.38  17711336     
172  0.004339  0.143  2.31  17792677  Cd207  CD207 molecule, langerin 
173  0.004453  0.144  3.43  17812434  LOC691257  similar to Zinc finger protein 267 (Zinc 
finger protein HZF2) 
174  0.004463  0.144  2.04  17815281  Lamb1  laminin, beta 1 
175  0.004487  0.144  2.16  17751213     
176  0.004502  0.144  2.15  17613853     
177  0.004631  0.147  2.38  17818497     
178  0.004663  0.147  2.18  17843248  Olr1213  olfactory receptor 1213 
179  0.00492  0.151  2.07  17762021  LOC690840  similar to ribosomal protein L37 
180  0.004923  0.151  2.11  17808683  Jun  jun proto‐oncogene 
181  0.004928  0.151  2.32  17724318  Smad7  SMAD family member 7 
182  0.005032  0.154  2.69  17737218     
183  0.005126  0.155  2.62  17640939     
184  0.00518  0.156  0.3  17692790     
185  0.005185  0.156  0.35  17714226     
186  0.005204  0.156  3.77  17701208     
187  0.005218  0.156  2.06  17626435  Dusp5  dual specificity phosphatase 5 
188  0.005308  0.157  2.02  17797978     
189  0.005635  0.162  0.41  17683699  Htr5b  5‐hydroxytryptamine (serotonin) receptor 
5B 
190  0.005822  0.165  2.08  17648358     
191  0.005862  0.165  2.27  17671549  Slc7a1  solute carrier family 7 (cationic amino acid 
transporter, y+ system), member 1 
192  0.005879  0.165  2.57  17849817     
193  0.005946  0.166  0.37  17779805     
194  0.006168  0.171  2.23  17794683  RGD1307916  LOC362433 
195  0.006273  0.173  0.26  17784277     
196  0.006305  0.173  2.13  17868250     
197  0.006339  0.173  2.45  17825853  Olr907  olfactory receptor 907 
198  0.006368  0.173  3.64  17816457     
199  0.006421  0.173  0.49  17763974     
200  0.006443  0.173  0.38  17766487     
201  0.006517  0.174  2.13  17687846  Tmed11  transmembrane emp24 protein transport 
domain containing 11 
202  0.006712  0.177  4.95  17661197  Krt31  keratin 31 
203  0.00678  0.178  2.81  17832121  Tuba1c  tubulin, alpha 1C 
204  0.006801  0.178  0.29  17752277  Olr1670  olfactory receptor 1670 
205  0.006878  0.179  0.39  17784001     
206  0.006967  0.181  2.19  17866112     
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207  0.007115  0.182  0.49  17737823     
208  0.007136  0.182  4.32  17797986     
209  0.007155  0.182  2.01  17731112     
210  0.007284  0.184  2.37  17729887     
211  0.007297  0.184  2.32  17771736  Olr416  olfactory receptor 416 
212  0.007314  0.184  3.08  17875518     
213  0.007325  0.184  2.06  17741409     
214  0.007405  0.184  2.62  17702543     
215  0.007476  0.185  2.92  17724639     
216  0.007606  0.188  2.78  17876868     
217  0.007802  0.191  2.36  17854132     
218  0.007901  0.192  0.5  17682222  Olr1595  olfactory receptor 1595 
219  0.007911  0.192  0.48  17792019     
220  0.00795  0.193  2.06  17645342  Olr1389  olfactory receptor 1389 
221  0.007969  0.193  0.4  17726231     
222  0.00812  0.194  0.47  17703173     
223  0.008169  0.195  2.02  17868103     
224  0.008215  0.195  2.17  17679473  Serpinb2  serpin peptidase inhibitor, clade B 
(ovalbumin), member 2 
225  0.008225  0.195  2.54  17708174     
226  0.008273  0.195  2.33  17692732  Lrrc8c  leucine rich repeat containing 8 family, 
member C 
227  0.008397  0.197  3.18  17805948     
228  0.008596  0.2  2.3  17786978  Clec4b2  C‐type lectin domain family 4, member B2 
229  0.008699  0.2  2.17  17675680     
230  0.008881  0.202  2.61  17749614  Hist2h2ac  histone cluster 2, H2ac 
231  0.008981  0.203  0.34  17878683     
232  0.009074  0.204  2.37  17666518     
233  0.009074  0.204  2.37  17747511     
234  0.00917  0.204  2.04  17657603     
235  0.009208  0.204  0.49  17876494  Il13ra2  interleukin 13 receptor, alpha 2 
236  0.009349  0.205  2.4  17865389     
237  0.009434  0.205  2.21  17681325     
238  0.009456  0.205  2.01  17733326     
239  0.009473  0.205  2.18  17665771     
240  0.009706  0.208  2.6  17851521     
241  0.009721  0.208  3.05  17868678  Vom2r79  vomeronasal 2 receptor, 79 
242  0.009833  0.21  0.47  17880467     
243  0.009992  0.212  5.29  17869670     
 
mRNA hit list CA3 from sucrose PAD 
 p‐value  FDR  x‐fold  ProbeSet  Symbol  Name 
1  1E‐07  0.00073  8.72  17665491 
2  1.8E‐06  0.00663  10.28  17784575 
3  4.2E‐06  0.00958  34.89  17752874  Hspa1b  heat shock 70kD protein 1B 
4  5.2E‐06  0.00958  2.07  17689126 
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5  8.6E‐06  0.0127  3.78  17853671 
6  1.26E‐05  0.0142  2.35  17832266  Gpd1 
glycerol‐3‐phosphate 
dehydrogenase 1 (soluble) 
7  1.35E‐05  0.0142  7.42  17735609 
8  3.18E‐05  0.026  2.69  17626769  Pnliprp1 
pancreatic lipase‐related protein 
1 
9  6.06E‐05  0.0447  7.47  17613332  Vom1r53  vomeronasal 1 receptor 53 
10  6.97E‐05  0.0467  2.28  17780786  Slc26a5 
solute carrier family 26, member 
5 (prestin) 
11  0.000095  0.0539  2.78  17810979 
12  0.000095  0.0539  2.78  17810981 
13  0.000103  0.0541  2.16  17645248  LOC100359777  mCG12681‐like 
14  0.000113  0.0549  7.84  17724830 
15  0.000119  0.0549  27.99  17756503  Hspa1a  heat shock 70kD protein 1A 
16  0.000151  0.0574  5.79  17850030  Olr1177  olfactory receptor 1177 
17  0.000151  0.0574  9.46  17642957 
18  0.000155  0.0574  7.68  17728071  Hmox1  heme oxygenase (decycling) 1 
19  0.000156  0.0574  3.64  17742515 
20  0.00018  0.0582  2.57  17818613 
21  0.000187  0.0582  2.03  17870257 
22  0.000192  0.0582  2.32  17646559  Map2k3 
mitogen activated protein kinase 
kinase 3 
23  0.000195  0.0582  28.04  17676952  Hspb1  heat shock protein 1 
24  0.000205  0.0582  3.85  17824767 
25  0.000221  0.0598  3.36  17711299 
26  0.000236  0.0598  9.95  17687609  Atf3  activating transcription factor 3 
27  0.00024  0.0598  3.36  17774230  Olr587  olfactory receptor 587 




29  0.000293  0.0639  2.9  17623115  Fosl1  fos‐like antigen 1 
30  0.000294  0.0639  2.23  17867524 
31  0.000295  0.0639  2.16  17868246 
32  0.000323  0.0667  5.96  17628747 
33  0.000336  0.0667  2.54  17724601 
34  0.000352  0.0667  2.65  17862549 
35  0.000353  0.0667  2.03  17759437 
36  0.000427  0.0782  4.9  17844027  Cryab  crystallin, alpha B 
37  0.000435  0.0782  4.48  17871507 




39  0.000461  0.079  4.15  17618305 
40  0.000488  0.0817  2.5  17735630  RGD1564606 
similar to 60S ribosomal protein 
L23a 
41  0.000519  0.0827  2.21  17763566  Olr444  olfactory receptor 444 
42  0.000535  0.0827  2.41  17635975  Olr239  olfactory receptor 239 
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43  0.000538  0.0827  3.32  17665373 
44  0.000551  0.0828  7.38  17833185  Olr901  olfactory receptor 901 
45  0.000574  0.0836  0.37  17624808 
46  0.000578  0.0836  2.29  17844935  LOC691098  similar to ribosomal protein L37 
47  0.000608  0.0862  2.83  17635579  Olr115  olfactory receptor 115 
48  0.000648  0.0901  2.42  17728152 
49  0.000701  0.0922  2.08  17635422  Lrrc51  leucine rich repeat containing 51 
50  0.000735  0.0922  2.18  17704121  Adamdec1  ADAM‐like, decysin 1 
51  0.000751  0.0922  5.06  17772374 
52  0.000777  0.0922  2.65  17875518 
53  0.00078  0.0922  2.04  17845678 
54  0.00082  0.0922  7.85  17664420 
55  0.000836  0.0922  3.31  17869418 
56  0.000843  0.0922  7.51  17687455 
57  0.000846  0.0922  0.46  17708441 
58  0.000861  0.0922  3.6  17869467 
59  0.000861  0.0922  3.6  17870157 
60  0.000877  0.0922  2.65  17870204 
61  0.00089  0.0922  2.8  17742509 
62  0.000911  0.0922  6.21  17779805 
63  0.000913  0.0922  2.16  17635598  Olr128  olfactory receptor 128 
64  0.000929  0.0922  2.27  17647364 
65  0.000953  0.0922  2.05  17711471  Aadat  aminoadipate aminotransferase 
66  0.000956  0.0922  2.48  17643242 
67  0.00096  0.0922  4.2  17766256  RGD1561317  similar to ribosomal protein L31 
68  0.00098  0.0922  2.28  17740584  S100a10  S100 calcium binding protein A10 
69  0.001014  0.0922  3.11  17765931  Dusp2  dual specificity phosphatase 2 
70  0.00102  0.0922  2.9  17789520 
71  0.00102  0.0922  4.97  17835454 
72  0.001035  0.0922  2.5  17718415  Gadd45g 
growth arrest and DNA‐damage‐
inducible, gamma 
73  0.001042  0.0922  2.98  17752700 
74  0.001062  0.0922  0.27  17624349 
75  0.001064  0.0922  2.45  17619405  Olr242  olfactory receptor 242 
76  0.001087  0.0927  2.43  17793713 
77  0.001109  0.0927  0.23  17784180 
78  0.001121  0.0927  2.17  17799775  Mir3554  microRNA mir‐3554 
79  0.001126  0.0927  2.76  17621987  Olr300  olfactory receptor 300 
80  0.001132  0.0927  2.02  17868037 
81  0.00116  0.0933  0.44  17668766  Retnla  resistin like alpha 
82  0.0012  0.0933  3.13  17717148  Vim  vimentin 
83  0.001203  0.0933  2.39  17795006  Tuba3a  tubulin, alpha 3A 
84  0.001206  0.0933  5.76  17619045 




86  0.001259  0.0933  2.13  17809625  Plk3  polo‐like kinase 3 
87  0.001263  0.0933  5.24  17835750 
88  0.001297  0.0947  2.24  17618283 
89  0.001352  0.0977  0.24  17832683 
90  0.00139  0.099  0.19  17650171  RGD1304870  similar to Tceb2 protein 
91  0.001397  0.099  0.42  17879633  Mir463  microRNA mir‐463 
92  0.001461  0.103  3.56  17664532 
93  0.001484  0.103  3.39  17826910  Vom1r107  vomeronasal 1 receptor 107 
94  0.00153  0.104  0.37  17818677 
95  0.001557  0.105  2.45  17647137 






97  0.001608  0.107  2.39  17849826 








99  0.001655  0.107  5.05  17672229  Zfand2a  zinc finger, AN1‐type domain 2A 
100  0.001662  0.107  0.25  17624493 
101  0.001685  0.107  2.12  17655501 
102  0.001691  0.107  2.24  17795302  Klrb1a 
killer cell lectin‐like receptor 
subfamily B, member 1A 
103  0.001694  0.107  0.3  17696207 
104  0.001723  0.108  0.49  17742244 
105  0.001757  0.109  2.14  17756838 
106  0.001789  0.109  3.72  17799940 
107  0.001795  0.109  2.51  17809339 
108  0.001809  0.109  3.05  17777631 
109  0.00182  0.109  2.5  17624245 
110  0.00187  0.111  3.02  17797643 
111  0.00193  0.114  2.36  17815867 
112  0.001951  0.114  3.67  17753672 
113  0.002069  0.117  3.03  17868057 
114  0.002069  0.117  3.03  17868324 
115  0.002079  0.117  2.03  17781129  Abcb1b 
ATP‐binding cassette, subfamily B 
(MDR/TAP), member 1B 
116  0.002081  0.117  2.51  17636799  Cdr2  cerebellar degeneration‐related 2 
117  0.002105  0.118  2.17  17869596 
118  0.002155  0.119  3.99  17843361  Olr1265  olfactory receptor 1265 
119  0.002242  0.121  2.37  17821305  Sox11 
SRY (sex determining region Y)‐
box 11 
120  0.002268  0.121  5.2  17783091  Olr819  olfactory receptor 819 
121  0.002281  0.121  3.88  17637890 
122  0.00232  0.121  0.16  17791978 
123  0.002344  0.121  5.16  17629882  Vom2r35  vomeronasal 2 receptor, 35 
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124  0.002344  0.121  3.96  17859862 
125  0.002378  0.121  2.03  17867369 
126  0.00238  0.121  2.06  17622041  Scgb1c1 
secretoglobin, family 1C, member 
1 
127  0.002387  0.121  3.58  17818250 
128  0.002454  0.121  2.19  17765620 
129  0.00253  0.124  2.24  17873013 
130  0.002625  0.126  3.38  17644053 
131  0.002641  0.126  5.16  17741625 
132  0.002642  0.126  2.35  17880683 
133  0.002727  0.128  2.46  17621948 
134  0.002731  0.128  0.32  17850533 
135  0.002798  0.128  2.5  17779186  Slpi 
secretory leukocyte peptidase 
inhibitor 
136  0.002816  0.128  2  17869943 
137  0.002824  0.128  4.64  17749842  RGD1560000  similar to alpha tubulin 
138  0.002845  0.128  2.08  17754240 
139  0.002851  0.128  0.3  17879499 
140  0.002942  0.129  3.19  17716847 
141  0.003001  0.129  3  17621224  Bag3  Bcl2‐associated athanogene 3 
142  0.003013  0.129  0.23  17784641 
143  0.003054  0.13  7.56  17873683 
144  0.00308  0.13  0.35  17683259 
145  0.003154  0.133  5.93  17798721 
146  0.003177  0.133  2.08  17700646 
147  0.003209  0.133  2.18  17799795 
148  0.003227  0.133  2.1  17838143  RGD1308195 
similar to secreted Ly6/uPAR 
related protein 2 
149  0.003234  0.133  0.29  17664326 
150  0.003324  0.135  0.24  17698284 
151  0.003331  0.135  0.49  17771783 
152  0.003358  0.135  0.37  17767173 
153  0.003358  0.135  0.37  17767180 
154  0.003408  0.136  0.25  17635565  Olr104  olfactory receptor 104 
155  0.003547  0.14  4.18  17731745  Mt1a  metallothionein 1a 
156  0.003584  0.141  2.55  17878998  Morc4 
MORC family CW‐type zinc finger 
4 
157  0.003635  0.142  4.37  17634970 
158  0.003696  0.143  2.53  17629294  LOC365171 
similar to nitric oxide synthase 
interacting protein 
159  0.003768  0.145  4.29  17841786 
160  0.003813  0.146  2.12  17745208  Il31ra  interleukin 31 receptor A 
161  0.003854  0.146  3.77  17631491 
162  0.003944  0.149  2.15  17697116  Mss51 
MSS51 mitochondrial 
translational activator 
163  0.003969  0.149  2.17  17650036  Mir142  microRNA mir‐142 
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164  0.003985  0.149  0.45  17704845 
165  0.004064  0.151  3.01  17719265  Prl3d4 
prolactin family 3, subfamily d, 
member 4 
166  0.004118  0.152  0.48  17675139 
167  0.004199  0.154  0.42  17835409 
168  0.00423  0.154  0.5  17679011 
169  0.00435  0.155  2.47  17732255 
170  0.004354  0.155  2.27  17853630 
171  0.004366  0.155  2.68  17719272  Prl8a2 
prolactin family 8, subfamily a, 
member 2 
172  0.004383  0.155  2.55  17822169 
173  0.004402  0.155  0.41  17772840 
174  0.004412  0.155  2.53  17788927 
175  0.004438  0.155  2.23  17666056 
176  0.004481  0.155  3.34  17807271  Olr845  olfactory receptor 845 
177  0.004503  0.155  2.11  17747224 
178  0.004505  0.155  13.2  17804126 
179  0.004505  0.155  2.54  17868154 
180  0.004544  0.156  2.3  17833135  Olr878  olfactory receptor 878 
181  0.004698  0.16  3.21  17828625  Ddit3 
DNA‐damage inducible transcript 
3 
182  0.004753  0.16  4.25  17875052  RGD1565183  similar to ribosomal protein L28 
183  0.004753  0.16  2.3  17845560 
184  0.004771  0.16  0.43  17799873 
185  0.004796  0.16  11.91  17730862  Rpl13  ribosomal protein L13 
186  0.004877  0.161  0.33  17763762  Olr726  olfactory receptor 726 
187  0.004999  0.164  0.22  17695156 
188  0.005141  0.165  7.32  17808103 
189  0.005207  0.165  4.13  17797504 
190  0.005222  0.165  2.46  17773349 
191  0.005236  0.165  3.2  17875665  Timp1 
TIMP metallopeptidase inhibitor 
1 
192  0.005241  0.165  4.01  17833260  Olr1057  olfactory receptor 1057 
193  0.005247  0.165  3.11  17809417  Cyp4a2 
cytochrome P450, family 4, 
subfamily a, polypeptide 2 
194  0.005268  0.165  4.27  17766761 
195  0.005347  0.167  2.11  17866200  Alpp  alkaline phosphatase, placental 




197  0.005455  0.167  0.27  17692312 
198  0.005462  0.167  2.11  17869614 
199  0.005462  0.167  2.75  17637632 
200  0.005493  0.167  3.31  17731750  Mt2A  metallothionein 2A 
201  0.005495  0.167  2.14  17746004  RGD1564125  similar to Cln5 protein 
202  0.005521  0.167  2.23  17702085 




204  0.005677  0.169  10.55  17768155 
205  0.005715  0.169  2.42  17870212 
206  0.005864  0.17  0.41  17664274 
207  0.005884  0.17  0.32  17797651 
208  0.005896  0.17  0.16  17807875  Mup5  major urinary protein 5 
209  0.00605  0.173  0.46  17791785 
210  0.006081  0.173  2.17  17783085  Olr813  olfactory receptor 813 
211  0.00618  0.173  2.6  17750295 
212  0.006222  0.173  2.13  17864163 
213  0.006246  0.173  4.04  17837230 
214  0.006279  0.173  3.12  17878714 
215  0.00628  0.173  4.45  17792089 
216  0.00634  0.174  2.48  17787596  Klre1 
killer cell lectin‐like receptor, 
family E, member 1 
217  0.006423  0.174  0.4  17818655 
218  0.006491  0.174  2.05  17782616 
219  0.006552  0.174  0.43  17842225 
220  0.00657  0.174  2.13  17717140  Pter  phosphotriesterase related 
221  0.006587  0.174  2.06  17797599  Mms22l  MMS22‐like, DNA repair protein 
222  0.006609  0.174  2.31  17811631  C1qb 
complement component 1, q 
subcomponent, B chain 
223  0.006614  0.174  2.81  17720630 
224  0.006638  0.174  0.39  17844988 
225  0.006692  0.174  2.25  17644056  Zscan10 
zinc finger and SCAN domain 
containing 10 
226  0.006802  0.175  2.76  17720965  LOC100364106  Sec61 gamma subunit‐like 
227  0.006812  0.175  2.89  17838642  LOC100910811 
putative transmembrane protein 
C8orfK29‐like 
228  0.006876  0.175  4.28  17618009 
229  0.007  0.176  2.56  17682865  Tlr5  toll‐like receptor 5 
230  0.007004  0.176  3  17767175 
231  0.007012  0.176  2.37  17667228 
232  0.007064  0.176  4.01  17628506 
233  0.007079  0.176  2  17681861  Apoa2  apolipoprotein A‐II 
234  0.007158  0.177  0.36  17665038 
235  0.007189  0.177  2.37  17630418  PVR  poliovirus receptor 
236  0.007216  0.177  0.43  17773187 
237  0.007249  0.177  4.87  17806280 
238  0.007332  0.177  0.24  17732640 
239  0.007367  0.177  2.35  17624351  Olr367  olfactory receptor 367 
240  0.007453  0.178  2.62  17721795 
241  0.007537  0.179  3.58  17782681  Tas2r108 
taste receptor, type 2, member 
108 
242  0.007642  0.179  2.26  17813867  Rhoq  ras homolog family member Q 




244  0.007713  0.179  2.63  17653002 
245  0.007932  0.183  3.59  17805604 
246  0.008004  0.184  2.04  17834341  RGD1310212  similar to KIAA1111‐like protein 
247  0.008042  0.185  2.91  17877200  LOC100362769 
hypothetical protein 
LOC100362769 
248  0.008154  0.187  2.92  17880857  LOC680635 
similar to 40S ribosomal protein 
S10 
249  0.00822  0.188  2.09  17822627 
250  0.008268  0.188  2.1  17750982 
251  0.008272  0.188  0.37  17879614 
252  0.008337  0.188  2.47  17853950  Pigb 
phosphatidylinositol glycan 
anchor biosynthesis, class B 
253  0.008353  0.188  3.37  17835733 
254  0.008357  0.188  2.82  17684927  LOC100364404 
regulator of G‐protein signaling 2‐
like 
255  0.00847  0.188  2.59  17816034  Ctage5  CTAGE family, member 5 
256  0.008494  0.188  0.37  17689964 
257  0.008512  0.188  2.39  17825894 
258  0.008516  0.188  0.21  17790393 
259  0.00853  0.188  2.17  17872259 
260  0.008596  0.189  3.75  17856790  Ccr1l1 
chemokine (C‐C motif) receptor 
1‐like 1 
261  0.008715  0.191  0.29  17767283 
262  0.008854  0.193  2.11  17833546  Gadd45b 
growth arrest and DNA‐damage‐
inducible, beta 
263  0.00892  0.194  0.23  17834079  Olr1075  olfactory receptor 1075 
264  0.00896  0.194  0.46  17697179 
265  0.009008  0.194  0.46  17766487 
266  0.009017  0.194  2.78  17629876  Vom2r34  vomeronasal 2 receptor, 34 
267  0.009026  0.194  3.31  17716541 
268  0.009146  0.195  2.03  17686666  Ly9  lymphocyte antigen 9 
269  0.009159  0.195  4.04  17613328  Vom1r51  vomeronasal 1 receptor 51 
270  0.009223  0.195  3.47  17870224 
271  0.009242  0.195  2.31  17842144 
272  0.009268  0.195  2.47  17673512  Ubc  ubiquitin C 
273  0.009288  0.195  2.39  17654068  Olr1374  olfactory receptor 1374 
274  0.009324  0.195  3.64  17648329  Olr1466  olfactory receptor 1466 
275  0.009351  0.195  6.41  17781033 
276  0.009494  0.197  0.33  17629100  Vom2r15  vomeronasal 2 receptor, 15 
277  0.009521  0.197  2.2  17868099 
278  0.009616  0.197  2.25  17629433  Galp  galanin‐like peptide 
279  0.009622  0.197  3.14  17682452 
280  0.009656  0.197  2.61  17795373  RGD1564770 
similar to CD69 antigen (p60, 
early T‐cell activation antigen) 
281  0.009687  0.197  2.48  17680779  LOC689412  similar to CG4025‐PA 
282  0.009818  0.197  0.45  17743570 
251 
 
283  0.00982  0.197  0.32  17615462 
284  0.009926  0.199  0.3  17646207  Olr1449  olfactory receptor 1449 






APPENDIX 6: REANALYSIS OF MICROARRAY HIT LISTS FROM SUCROSE 
GRADIENT METHOD 
Reanalysis of CA1 mRNA from sucrose GRADIENT     
  p‐value  FDR  x‐fold  ProbeSet  Symbol  Name 
1  1.4E‐06  0.00957  8.04  10823075  Elf2  E74‐like factor 2 
2  0.000003  0.00957  17.23  10729213     
3  4.2E‐06  0.00957  9.42  10722427     
4  1.93E‐05  0.033  9.03  10817894     
5  5.78E‐05  0.06  9.6  10877206     
6  6.04E‐05  0.06  5.4  10763477  Mki67ip  Mki67 (FHA domain) interacting nucleolar 
phosphoprotein 
7  7.08E‐05  0.06  12.02  10749983  Cxadr  coxsackie virus and adenovirus receptor 
8  7.81E‐05  0.06  6.97  10873903     
9  0.000079  0.06  9.5  10796507  Slc39a12  solute carrier family 39 (zinc transporter), 
member 12 
10  0.000107  0.067  5.17  10907913  Mmp8  matrix metallopeptidase 8 
11  0.000108  0.067  7.77  10937020  Gripap1  GRIP1 associated protein 1 
12  0.000134  0.0765  9.12  10784416  Ints6  integrator complex subunit 6 
13  0.000208  0.109  10.91  10931717  C3  complement component 3 
14  0.000258  0.126  6.13  10762704  Srsf9  serine/arginine‐rich splicing factor 9 
15  0.000289  0.132  7.08  10824322  Lmna  lamin A/C 
16  0.000361  0.153  8.62  10838497  Katnbl1  katanin p80 subunit B‐like 1 
17  0.000405  0.153  145.99  10770710  Atf3  activating transcription factor 3 
18  0.000409  0.153  9.36  10895152  Kitlg  KIT ligand 
19  0.000434  0.153  6.84  10846966  Olr490  olfactory receptor 490 
20  0.000503  0.153  13.17  10880107     
21  0.000538  0.153  13.16  10862473     
22  0.00054  0.153  11.7  10855701  Aqp1  aquaporin 1 
23  0.000567  0.153  3.6  10853916     
24  0.000574  0.153  10.71  10894333  Myo1f  myosin IF 
25  0.000581  0.153  4.25  10818687     
26  0.000592  0.153  6.79  10764567  Pdc  phosducin 
27  0.000615  0.153  7.32  10717069  Pde7b  phosphodiesterase 7B 
28  0.000626  0.153  0.092  10707639     
29  0.000698  0.156  8.96  10856282  Rnf103  ring finger protein 103 
30  0.00073  0.156  43.93  10862867  Gadd45a  growth arrest and DNA‐damage‐inducible, 
alpha 
31  0.000748  0.156  9.76  10814146     
32  0.000762  0.156  12.83  10797929  Gcnt2  glucosaminyl (N‐acetyl) transferase 2, I‐
branching enzyme 
33  0.000785  0.156  5.21  10927838     
34  0.000809  0.156  7.76  10812922     
35  0.00082  0.156  12.84  10877538     
36  0.000909  0.156  4.05  10839579  Dusp2  dual specificity phosphatase 2 
37  0.00091  0.156  13.22  10821117  Nln  neurolysin (metallopeptidase M3 family) 
253 
 
38  0.000983  0.156  14.29  10926405     
39  0.001008  0.156  7.23  10906364  Syt10  synaptotagmin X 
40  0.001012  0.156  15.91  10828861     
41  0.001012  0.156  15.91  10850255     
42  0.001012  0.156  15.91  10874216     
43  0.001012  0.156  15.91  10875949     
44  0.001012  0.156  15.91  10910193     
45  0.001027  0.156  6.57  10830906  Znrd1as  ZNRD1 antisense RNA 




47  0.001134  0.161  9.23  10768339     
48  0.001196  0.161  9.97  10768332  Rgs2  regulator of G‐protein signaling 2 
49  0.001223  0.161  6.08  10934560     
50  0.001228  0.161  11.36  10864481  Cntn3  contactin 3 (plasmacytoma associated) 
51  0.001235  0.161  63.27  10798702  Inhba  inhibin beta‐A 
52  0.001261  0.161  7.04  10830932  Trim26  tripartite motif‐containing 26 
53  0.001261  0.161  58.4  10761128  Hspb1  heat shock protein 1 
54  0.001292  0.161  9.29  10730116     
55  0.001298  0.161  7.47  10866374  Lrp6  low density lipoprotein receptor‐related 
protein 6 
56  0.001341  0.164  9.29  10734828     
57  0.001411  0.166  8.6  10767763  Prelp  proline/arginine‐rich end leucine‐rich repeat 
protein 
58  0.001448  0.166  7.04  10858967  Tnfrsf1a  tumor necrosis factor receptor superfamily, 
member 1a 
59  0.001461  0.166  7.97  10765040     
60  0.001484  0.166  4.01  10877855     
61  0.001489  0.166  19.95  10901367     
62  0.00151  0.166  183.77  10828154  Hspa1b  heat shock 70kD protein 1B (mapped) 
63  0.001554  0.167  4.46  10724993  Rras2  related RAS viral (r‐ras) oncogene homolog 2 
64  0.001585  0.167  8.57  10788483     
65  0.00159  0.167  7.06  10910252  Snupn  snurportin 1 
66  0.001649  0.171  6.6  10823338  Siah2  seven in absentia 2 
67  0.00176  0.175  31.05  10797566     
68  0.001784  0.175  8.01  10793175  Usp19  ubiquitin specific peptidase 19 
69  0.001788  0.175  18.87  10933345  Tlr7  toll‐like receptor 7 
70  0.001795  0.175  13.85  10933903     
71  0.001832  0.176  8.58  10934666     
72  0.001923  0.18  9.6  10800442  Rnf138  ring finger protein 138, E3 ubiquitin protein 
ligase 
73  0.001948  0.18  5.35  10729996     
74  0.001987  0.18  6.41  10773004     
75  0.002043  0.18  22.66  10711401  Bag3  Bcl2‐associated athanogene 3 
76  0.002062  0.18  16.01  10924076  Rpe  ribulose‐5‐phosphate‐3‐epimerase 
77  0.002079  0.18  6.96  10804783  Fbxo38  F‐box protein 38 
78  0.00211  0.18  8.67  10788497  Eri1  exoribonuclease 1 
254 
 
79  0.00212  0.18  8.5  10885029  Frmd6  FERM domain containing 6 
80  0.002138  0.18  7.21  10872747  Ubxn11  UBX domain protein 11 
81  0.00216  0.18  6.13  10881820  Spsb1  splA/ryanodine receptor domain and SOCS box 
containing 1 
82  0.00221  0.18  6.06  10790725     
83  0.002261  0.18  9.68  10774383  Vps54  vacuolar protein sorting 54 homolog (S. 
cerevisiae) 
84  0.002278  0.18  6.22  10862453     
85  0.002294  0.18  11.97  10890354  Cdkl1  cyclin‐dependent kinase‐like 1 (CDC2‐related 
kinase) 
86  0.002309  0.18  14.67  10934631  Lpar4  lysophosphatidic acid receptor 4 
87  0.002325  0.18  6.85  10768726  Npl  N‐acetylneuraminate pyruvate lyase 
88  0.002326  0.18  22.61  10896793  Trib1  tribbles homolog 1 (Drosophila) 
89  0.00235  0.18  18.83  10853202  Phtf2  putative homeodomain transcription factor 2 
90  0.002478  0.181  3.49  10794477  Kif13a  kinesin family member 13A 
91  0.00249  0.181  6.75  10714348  Fam108b1  family with sequence similarity 108, member 
B1 
92  0.002504  0.181  6.6  10810811  Slc7a6os  solute carrier family 7, member 6 opposite 
strand 
93  0.002556  0.181  7.12  10719616  PVR  poliovirus receptor 
94  0.002559  0.181  6.72  10840396  Sec23b  Sec23 homolog B (S. cerevisiae) 
95  0.00256  0.181  7.04  10895988  Zbtb39  zinc finger and BTB domain containing 39 
96  0.002575  0.181  22.18  10781962     
97  0.002575  0.181  22.18  10864711     
98  0.002601  0.181  6.9  10803991  Cd14  CD14 molecule 
99  0.00262  0.181  15.36  10922962     
100  0.002709  0.182  13.62  10891548     
101  0.002709  0.182  34.07  10745323  Wsb1  WD repeat and SOCS box‐containing 1 
102  0.002712  0.182  6.6  10775519  Agpat9  1‐acylglycerol‐3‐phosphate O‐acyltransferase 9 
103  0.002824  0.187  14.9  10721050  Cebpg  CCAAT/enhancer binding protein (C/EBP), 
gamma 
104  0.00285  0.187  22.59  10892171     
105  0.002959  0.193  16.25  10844223  Ptges  prostaglandin E synthase 
106  0.003014  0.194  6.01  10785405     
107  0.003043  0.194  13.41  10915716  Zfp653  zinc finger protein 653 
108  0.003219  0.202  7.07  10812580     
109  0.003225  0.202  6.14  10868226  Ifnk  interferon kappa 
110  0.003272  0.202  6.72  10928254  Orc2  origin recognition complex, subunit 2 
111  0.003345  0.202  4.64  10932652     
112  0.00342  0.202  8.6  10898408     
113  0.00345  0.202  8.55  10730472     
114  0.00352  0.202  22.23  10903210     
115  0.00359  0.202  44.04  10758344  Vps37b  vacuolar protein sorting 37 homolog B (S. 
cerevisiae) 
116  0.003595  0.202  6.47  10772795     
117  0.003598  0.202  5.17  10745871  Ints2  integrator complex subunit 2 
118  0.003621  0.202  5.57  10703104  Pacrg  Park2 co‐regulated 
119  0.003624  0.202  6.89  10745340     
255 
 
120  0.00367  0.202  3.26  10912088  Nt5e  5' nucleotidase, ecto 
121  0.003673  0.202  7.45  10903466  Azin1  antizyme inhibitor 1 
122  0.003706  0.202  77.72  10831298  Hspa1b  heat shock 70kD protein 1B (mapped) 
123  0.003713  0.202  22.84  10767001  Mat2a  methionine adenosyltransferase II, alpha 
124  0.003716  0.202  7.97  10901752     
125  0.003751  0.202  9.25  10885906  Zfp410  zinc finger protein 410 
126  0.003753  0.202  7.24  10801260     
127  0.003762  0.202  9.04  10721925  Grwd1  glutamate‐rich WD repeat containing 1 
128  0.003801  0.203  8.58  10716984  Heca  headcase homolog (Drosophila) 
129  0.003892  0.204  10.85  10808103  Terf2ip  telomeric repeat binding factor 2, interacting 
protein 
130  0.003895  0.204  8.41  10780813  Fgf9  fibroblast growth factor 9 
131  0.003956  0.204  4.03  10774652  Pnpt1  polyribonucleotide nucleotidyltransferase 1 
132  0.00397  0.204  21.24  10727717  Npas4  neuronal PAS domain protein 4 
133  0.003999  0.204  14.87  10880404  Ptafr  platelet‐activating factor receptor 
134  0.004005  0.204  14.47  10712340  Cd151  CD151 molecule (Raph blood group) 
135  0.004045  0.205  8.37  10812589  F2rl2  coagulation factor II (thrombin) receptor‐like 2 
136  0.004076  0.205  9.9  10903482  Slc25a32  solute carrier family 25 (mitochondrial folate 
carrier) , member 32 
137  0.004116  0.205  6.6  10776646  Guf1  GUF1 GTPase homolog (S. cerevisiae) 
138  0.004133  0.205  20.87  10889415  Sox11  SRY (sex determining region Y)‐box 11 
139  0.004201  0.206  31.8  10785461  Pcdh8  protocadherin 8 
140  0.004215  0.206  7.87  10714576  Vldlr  very low density lipoprotein receptor 
141  0.004264  0.207  11.09  10733045     
142  0.004358  0.207  9.64  10920860  Myd88  myeloid differentiation primary response 88 
143  0.004364  0.207  10.93  10701663  LOC292449  similar to hypothetical protein 
144  0.004411  0.207  21.87  10842500  Dok5  docking protein 5 
145  0.004434  0.207  6.77  10818218  Dram2  DNA‐damage regulated autophagy modulator 2 
146  0.00445  0.207  5.87  10890210  Mdga2  MAM domain containing 
glycosylphosphatidylinositol anchor 2 
147  0.004475  0.207  7.4  10727493     
148  0.004529  0.207  7.69  10789042     
149  0.004563  0.207  17.95  10733047     
150  0.00459  0.207  7.56  10815393  Supt20  suppressor of Ty 20 
151  0.004592  0.207  15.28  10845095  Orc4  origin recognition complex, subunit 4 
152  0.004599  0.207  17.45  10847932  Depdc7  DEP domain containing 7 
153  0.004686  0.208  6.87  10740959  Kctd5  potassium channel tetramerisation domain 
containing 5 
154  0.004695  0.208  16.96  10787212  Myo9b  myosin IXb 
155  0.00476  0.21  7.66  10763284  Zcchc2  zinc finger, CCHC domain containing 2 
156  0.004783  0.21  7.1  10776807  Mcart1  mitochondrial carrier triple repeat 1 
157  0.00482  0.21  11.3  10866926  Asun  asunder, spermatogenesis regulator 
158  0.004967  0.211  5.57  10890626  Gphb5  glycoprotein hormone beta 5 
159  0.00499  0.211  28.4  10708672  Prcp  prolylcarboxypeptidase (angiotensinase C) 
160  0.005047  0.211  14.79  10714973  Hectd2  HECT domain containing 2 
161  0.005061  0.211  8.63  10719956  Nemf  nuclear export mediator factor 
162  0.005062  0.211  12.61  10813984  LOC64038  sertolin 
256 
 
163  0.005096  0.211  7.05  10887826  Tmem196  transmembrane protein 196 
164  0.005116  0.211  8.64  10789709     
165  0.005156  0.211  8.11  10903195  Mterfd1  MTERF domain containing 1 
166  0.005168  0.211  13.07  10713602     
167  0.005192  0.211  7.32  10703508     
168  0.005228  0.211  21.64  10868302     
169  0.005271  0.212  24.27  10796673     
170  0.005298  0.212  7.33  10867761  Mmp16  matrix metallopeptidase 16 
171  0.005363  0.212  4.7  10792863  Atp11a  ATPase, class VI, type 11A 
172  0.005371  0.212  22.01  10827686  RT1‐M6‐1  RT1 class I, locus M6, gene 1 
173  0.005422  0.212  6.82  10872291  Yars  tyrosyl‐tRNA synthetase 
174  0.005427  0.212  8.3  10908205  Olr1165  olfactory receptor 1165 
175  0.005464  0.212  11.68  10855187  Zfp398  zinc finger protein 398 
176  0.005496  0.212  44.21  10806122  Hmox1  heme oxygenase (decycling) 1 
177  0.00551  0.212  16.32  10894115     
178  0.005695  0.215  4.41  10910768     
179  0.005764  0.215  6.14  10727464  Rps6kb2  ribosomal protein S6 kinase, polypeptide 2 
180  0.00577  0.215  11.44  10808764  Urb2  URB2 ribosome biogenesis 2 homolog (S. 
cerevisiae) 
181  0.005794  0.215  13.71  10781100  Zfp395  zinc finger protein 395 
182  0.005808  0.215  14.13  10875939  Zfp292  zinc finger protein 292 
183  0.005808  0.215  9.11  10794599  Nedd9  neural precursor cell expressed, 
developmentally down‐regulated 9 
184  0.005856  0.215  7.64  10817989     
185  0.005866  0.215  12.72  10832460  Zfp280b  zinc finger protein 280B 
186  0.005889  0.215  6.8  10792278  Whsc1l1  Wolf‐Hirschhorn syndrome candidate 1‐like 1 
(human) 
187  0.005969  0.216  20.08  10865349  Slc2a3  solute carrier family 2 (facilitated glucose 
transporter), member 3 
188  0.006002  0.216  8.21  10766521  Eprs  glutamyl‐prolyl‐tRNA synthetase 
189  0.006032  0.216  55.02  10781715  Pcdh8  protocadherin 8 
190  0.006037  0.216  13.86  10937834  Rai2  retinoic acid induced 2 
191  0.00607  0.216  13.89  10846286  Nfe2l2  nuclear factor, erythroid derived 2, like 2 
192  0.006133  0.217  10.31  10729970  Rbp4  retinol binding protein 4, plasma 
193  0.0062  0.217  13.07  10846762  Calcrl  calcitonin receptor‐like 
194  0.006214  0.217  5.24  10702792  Cldn20  claudin 20 
195  0.00625  0.217  13.77  10805100  LOC361346  similar to chromosome 18 open reading frame 
54 
196  0.006305  0.217  6.98  10705485  Fbl  fibrillarin 
197  0.006337  0.217  21.48  10908089  Taf1d  TATA box binding protein (Tbp)‐associated 
factor, RNA polymerase I, D 
198  0.006376  0.217  7.06  10913866     
199  0.006381  0.217  13.63  10875936  Zfp292  zinc finger protein 292 
200  0.006432  0.218  11.74  10877943  Ptplad2  protein tyrosine phosphatase‐like A domain 
containing 2 
201  0.006527  0.22  9.24  10877431  Hdhd3  haloacid dehalogenase‐like hydrolase domain 
containing 3 
202  0.006738  0.224  7.1  10767067     
203  0.00675  0.224  6.63  10743318  Shmt1  serine hydroxymethyltransferase 1 (soluble) 
257 
 
204  0.006816  0.224  11.89  10928229  Clk1  CDC‐like kinase 1 
205  0.006826  0.224  7.56  10822043  Cdh6  cadherin 6 
206  0.006905  0.224  7.9  10720215  Zfp36  zinc finger protein 36 
207  0.006928  0.224  7.41  10859264  Ddx47  DEAD (Asp‐Glu‐Ala‐Asp) box polypeptide 47 
208  0.00697  0.224  14.4  10935021     
209  0.006987  0.224  6.85  10732113     
210  0.007019  0.224  7.18  10883716  E2f6  E2F transcription factor 6 
211  0.007023  0.224  17.41  10867093     
212  0.007046  0.224  7.08  10871133  Mknk1  MAP kinase‐interacting serine/threonine kinase 
1 
213  0.007104  0.224  32.87  10757082  Zfand2a  zinc finger, AN1‐type domain 2A 
214  0.007149  0.224  6.39  10730428  Fbxw4  F‐box and WD repeat domain containing 4 
215  0.00718  0.224  6.69  10935949  Abcd1  ATP‐binding cassette, subfamily D (ALD), 
member 1 
216  0.007295  0.224  8.32  10801606  Dmxl1  Dmx‐like 1 
217  0.007301  0.224  8.95  10861890  Creb3l2  cAMP responsive element binding protein 3‐
like 2 
218  0.007365  0.224  8.62  10737344  Srsf1  serine/arginine‐rich splicing factor 1 
219  0.007428  0.224  4.27  10848908     
220  0.007466  0.224  8.68  10887016     
221  0.007466  0.224  8.68  10887020     
222  0.007466  0.224  8.68  10887024     
223  0.007466  0.224  8.68  10887028     
224  0.007466  0.224  8.68  10887032     
225  0.007466  0.224  8.68  10887036     
226  0.007466  0.224  8.68  10887040     
227  0.007546  0.225  6.21  10729350  Smc5  structural maintenance of chromosomes 5 
228  0.007565  0.225  11.59  10797992  Riok1  RIO kinase 1 
229  0.007592  0.225  5.73  10833366     
230  0.007689  0.226  8.46  10856673  Slc4a5  solute carrier family 4, sodium bicarbonate 
cotransporter, member 5 
231  0.007705  0.226  9.35  10759342  Noc4l  nucleolar complex associated 4 homolog (S. 
cerevisiae) 
232  0.007859  0.23  5.94  10775113  Mtf2  metal response element binding transcription 
factor 2 
233  0.007896  0.23  18.52  10797527  Gadd45g  growth arrest and DNA‐damage‐inducible, 
gamma 
234  0.007973  0.23  5.15  10886714  Ccnk  cyclin K 
235  0.00803  0.23  12.4  10823462  Slc33a1  solute carrier family 33 (acetyl‐CoA 
transporter), member 1 
236  0.008041  0.23  9.39  10891364  Alkbh1  alkB, alkylation repair homolog 1 (E. coli) 
237  0.008053  0.23  0.17  10846974  Olr495  olfactory receptor 495 
238  0.008176  0.232  12.04  10772330     
239  0.008206  0.232  7.1  10936365  Il13ra1  interleukin 13 receptor, alpha 1 
240  0.008217  0.232  16.84  10742464  Zfp2  zinc finger protein 2 
241  0.008287  0.232  12.92  10805202     
242  0.008312  0.232  10.18  10811531  Slc7a5  solute carrier family 7 (amino acid transporter 
light chain, L system), member 5 
243  0.008337  0.232  6.78  10854086  Lep  leptin 
258 
 
244  0.008388  0.232  7.62  10908764  Snx19  sorting nexin 19 
245  0.0084  0.232  5.64  10886036  Jdp2  Jun dimerization protein 2 
246  0.008406  0.232  29.46  10778568  Pno1  partner of NOB1 homolog (S. cerevisiae) 
247  0.008568  0.235  4.68  10868718  Dcaf10  DDB1 and CUL4 associated factor 10 
248  0.008579  0.235  3.17  10927840     
249  0.008621  0.235  6.4  10707824  Vimp  VCP‐interacting membrane protein 
250  0.00866  0.235  12.28  10753533  Mina  myc induced nuclear antigen 
251  0.008791  0.237  9.6  10881167  Ddi2  DNA‐damage inducible protein 2 
252  0.00883  0.237  8.82  10891324  Zdhhc22  zinc finger, DHHC‐type containing 22 
253  0.008889  0.237  6.63  10752592  Yars2  tyrosyl‐tRNA synthetase 2 (mitochondrial) 
254  0.008895  0.237  0.18  10847215  Olr712  olfactory receptor 712 
255  0.009045  0.241  6.77  10701697     
256  0.009129  0.242  28.47  10857314  Slc6a6  solute carrier family 6 (neurotransmitter 
transporter, taurine), member 6 
257  0.009266  0.245  7.64  10868627     
258  0.009434  0.248  12.36  10750296  Clic6  chloride intracellular channel 6 
259  0.009531  0.25  9.6  10911352  RGD1307526  similar to modulator of estrogen induced 
transcription 
260  0.009737  0.254  17.67  10832905  Sirt1  sirtuin 1 
261  0.009804  0.255  14.4  10936993  Pim2  pim‐2 oncogene 
262  0.009911  0.256  6.6  10908521  Ldlr  low density lipoprotein receptor 
263  0.009964  0.256  18.58  10772580     
 
Reanalysis of CA3 mRNA from sucrose GRADIENT     
  p‐value  FDR  x‐fold  ProbeSet  Symbol  Name 
1  2E‐07  0.00137  58.64  10828154  Hspa1b  heat shock 70kD protein 1B  
2  6E‐07  0.00205  74.54  10761128  Hspb1  heat shock protein 1 
3  1.8E‐06  0.00359  13.66  10803991  Cd14  CD14 molecule 
4  2.1E‐06  0.00359  93.48  10770710  Atf3  activating transcription factor 3 
5  3.3E‐06  0.00427  17.37  10831298  Hspa1a  heat shock 70kD protein 1A 
6  3.8E‐06  0.00427  8.76  10809392  Mt1a  metallothionein 1a 
7  4.9E‐06  0.00427  8.42  10796411  Mt1a  metallothionein 1a 
8  0.000005  0.00427  9.36  10937867     
9  1.08E‐05  0.00752  7.24  10853916     
10  1.18E‐05  0.00752  10.52  10808167     
11  1.21E‐05  0.00752  0.073  10862359     
12  1.36E‐05  0.00775  0.074  10855946     
13  1.66E‐05  0.00873  16.21  10900358  Gadd45b  growth arrest and DNA‐damage‐
inducible, beta 
14  0.000018  0.00879  27.52  10937762  Tmem27  transmembrane protein 27 
15  0.000021  0.00957  6.48  10740869  Tnfrsf12a  tumor necrosis factor receptor 
superfamily, member 12a 
16  2.82E‐05  0.012  8.91  10711401  Bag3  Bcl2‐associated athanogene 3 
17  3.34E‐05  0.0129  9.11  10936482  Timp1  TIMP metallopeptidase inhibitor 1 
18  3.41E‐05  0.0129  0.12  10932269     




20  4.08E‐05  0.013  12.05  10727717  Npas4  neuronal PAS domain protein 4 
21  4.12E‐05  0.013  7  10939174     
22  0.000042  0.013  5.04  10838813  Dll4  delta‐like 4 (Drosophila) 
23  5.92E‐05  0.0176  5.98  10909892  Cryab  crystallin, alpha B 
24  7.49E‐05  0.0191  9.54  10797527  Gadd45g  growth arrest and DNA‐damage‐
inducible, gamma 
25  7.63E‐05  0.0191  15.58  10892173     
26  7.84E‐05  0.0191  6.55  10868718  Dcaf10  DDB1 and CUL4 associated factor 10 
27  7.96E‐05  0.0191  12.77  10840791  Srxn1  sulfiredoxin 1 
28  0.000081  0.0191  10.47  10757082  Zfand2a  zinc finger, AN1‐type domain 2A 
29  8.79E‐05  0.0191  4.31  10794599  Nedd9  neural precursor cell expressed, 
developmentally down‐regulated 9 
30  9.09E‐05  0.0191  7.28  10750296  Clic6  chloride intracellular channel 6 
31  9.19E‐05  0.0191  4.69  10907324     
32  9.35E‐05  0.0191  20.47  10909428  Mfrp  membrane frizzled‐related protein 
33  9.55E‐05  0.0191  9.68  10896793  Trib1  tribbles homolog 1 (Drosophila) 
34  9.68E‐05  0.0191  6.67  10736697  Ccl2  chemokine (C‐C motif) ligand 2 
35  9.84E‐05  0.0191  5.35  10812580     
36  0.000101  0.0191  36.23  10798702  Inhba  inhibin beta‐A 
37  0.000103  0.0191  4.27  10717331  Sgk1  serum/glucocorticoid regulated kinase 1 
38  0.000107  0.0193  6.65  10817552  Txnip  thioredoxin interacting protein 
39  0.000113  0.0198  6.87  10891679  Gpr68  G protein‐coupled receptor 68 
40  0.000121  0.0207  7.08  10920977     
41  0.000131  0.0216  37.66  10800426  Ttr  transthyretin 
42  0.000133  0.0216  6.45  10732652  Dusp1  dual specificity phosphatase 1 
43  0.000139  0.0219  5.13  10885400  Hspa2  heat shock protein 2 
44  0.000141  0.0219  6  10768332  Rgs2  regulator of G‐protein signaling 2 
45  0.000164  0.0249  9.36  10899187  Gpd1  glycerol‐3‐phosphate dehydrogenase 1 
(soluble) 
46  0.000195  0.0281  6.58  10760290  Nptx2  neuronal pentraxin II 
47  0.000196  0.0281  6.21  10756343  Hsph1  heat shock 105/110 protein 1 
48  0.000209  0.0281  3.47  10806527     
49  0.000211  0.0281  7.79  10775519  Agpat9  1‐acylglycerol‐3‐phosphate O‐
acyltransferase 9 
50  0.000216  0.0281  4.78  10865081  Adipor2  adiponectin receptor 2 
51  0.000222  0.0281  6.56  10713583  Wdr74  WD repeat domain 74 
52  0.000224  0.0281  3.99  10868289  Dnaja1  DnaJ (Hsp40) homolog, subfamily A, 
member 1 
53  0.000226  0.0281  5.59  10819347     
54  0.000227  0.0281  12.38  10759762  Kl  Klotho 
55  0.000228  0.0281  3.65  10774274  Egfr  epidermal growth factor receptor 
56  0.00023  0.0281  3.6  10794225  Nfil3  nuclear factor, interleukin 3 regulated 
57  0.000237  0.0284  7.47  10884274  Sostdc1  sclerostin domain containing 1 
58  0.000267  0.0304  3.79  10752758  Btg3  BTG family, member 3 
59  0.000275  0.0304  4.45  10875532  Pdp1  pyruvate dehyrogenase phosphatase 
catalytic subunit 1 




61  0.000283  0.0304  6.2  10867731  Calb1  calbindin 1 
62  0.000287  0.0304  8.83  10745323  Wsb1  WD repeat and SOCS box‐containing 1 
63  0.000295  0.0304  4.65  10807473  Slc7a6  solute carrier family 7 (amino acid 
transporter light chain, y+L system), 
member 6 
64  0.000296  0.0304  3.65  10844587  Psmd5  proteasome (prosome, macropain) 26S 
subunit, non‐ATPase, 5 
65  0.000299  0.0304  3.11  10751255  Arhgap31  Rho GTPase activating protein 31 
66  0.000306  0.0304  17.56  10817071  S100a8  S100 calcium binding protein A8 
67  0.000306  0.0304  4.92  10720813  Mag  myelin‐associated glycoprotein 
68  0.00031  0.0304  3.92  10863221  Mat2a  methionine adenosyltransferase II, 
alpha 
69  0.00031  0.0304  3.31  10892184  Hsp90aa1  heat shock protein 90, alpha (cytosolic), 
class A member 1 
70  0.000311  0.0304  5.56  10734853  Aurkb  aurora kinase B 
71  0.000337  0.0317  7.29  10810295  Dnajb1  DnaJ (Hsp40) homolog, subfamily B, 
member 1 
72  0.000339  0.0317  4  10884205  Twistnb  TWIST neighbor 
73  0.000341  0.0317  5.9  10928522     
74  0.000343  0.0317  5.77  10871417     
75  0.000349  0.0317  4.56  10813643     
76  0.000352  0.0317  6.18  10820613  Sv2c  synaptic vesicle glycoprotein 2c 
77  0.000365  0.032  5.85  10721865  Ppp1r15a  protein phosphatase 1, regulatory 
subunit 15A 
78  0.000365  0.032  4.41  10767605  Cntn2  contactin 2 (axonal) 
79  0.000417  0.0355  0.21  10850440     
80  0.000419  0.0355  3.98  10906608  Slc38a2  solute carrier family 38, member 2 
81  0.000424  0.0355  4.2  10879516  Mfsd2a  major facilitator superfamily domain 
containing 2A 
82  0.000426  0.0355  3.28  10902547  Lyz2  lysozyme 2 
83  0.000434  0.0356  3.17  10774470     
84  0.000452  0.0356  4.42  10755013  Il1rap  interleukin 1 receptor accessory protein 
85  0.000454  0.0356  5.74  10725387  Cdr2  cerebellar degeneration‐related 2 
86  0.000461  0.0356  4.04  10820282  Vcan  versican 
87  0.000467  0.0356  6.61  10726682  Ifitm3  interferon induced transmembrane 
protein 3 
88  0.00047  0.0356  6.24  10744766  Aspa  aspartoacylase 
89  0.000473  0.0356  5.27  10812922     
90  0.000474  0.0356  4.01  10860900  Pdk4  pyruvate dehydrogenase kinase, 
isozyme 4 
91  0.000479  0.0356  4.66  10809328  Herpud1  homocysteine‐inducible, endoplasmic 
reticulum stress‐inducible, ubiquitin‐like 
domain member 1 
92  0.000482  0.0356  3.49  10896992  Ptp4a3  protein tyrosine phosphatase type IVA, 
member 3 
93  0.000484  0.0356  3.3  10796673     
94  0.000491  0.0357  5.18  10897428  Csf2rb  colony stimulating factor 2 receptor, 
beta, low‐affinity (granulocyte‐
macrophage) 
95  0.000507  0.0363  0.19  10856024     
96  0.000509  0.0363  6.56  10817183  S100a11  S100 calcium binding protein A11 
261 
 
97  0.000515  0.0363  5.18  10764540     
98  0.000523  0.0363  4.01  10765744  Pigm  phosphatidylinositol glycan anchor 
biosynthesis, class M 
99  0.000531  0.0363  3.54  10901231  Timp3  TIMP metallopeptidase inhibitor 3 
100  0.000531  0.0363  22.61  10764551  Ptgs2  prostaglandin‐endoperoxide synthase 2 
101  0.000543  0.0367  5.28  10881820  Spsb1  splA/ryanodine receptor domain and 
SOCS box containing 1 
102  0.000563  0.0372  5.08  10921120  Slc6a20  solute carrier family 6 (proline IMINO 
transporter), member 20 
103  0.000571  0.0372  3.64  10885417     
104  0.000574  0.0372  4.5  10767001  Mat2a  methionine adenosyltransferase II, 
alpha 
105  0.000574  0.0372  5.08  10827450     
106  0.000576  0.0372  3.62  10796991  Npepo  aminopeptidase O 
107  0.000594  0.0379  6.84  10927840     
108  0.000599  0.0379  5.47  10788374  Mtus1  microtubule associated tumor 
suppressor 1 
109  0.000609  0.0381  3.1  10719432     
110  0.000614  0.0381  2.96  10899248  Atf1  activating transcription factor 1 
111  0.000626  0.0385  3.38  10817894     
112  0.000648  0.0392  6.74  10903736  Enpp2  ectonucleotide 
pyrophosphatase/phosphodiesterase 2 
113  0.000649  0.0392  4.13  10887939  Cdc42ep3  CDC42 effector protein (Rho GTPase 
binding) 3 
114  0.000654  0.0392  3.67  10831940  Fkbp5  FK506 binding protein 5 
115  0.000673  0.0394  6.05  10761394  Psph  phosphoserine phosphatase 
116  0.000677  0.0394  3.97  10861565  Zc3hc1  zinc finger, C3HC‐type containing 1 
117  0.000679  0.0394  4.46  10855449  Gpnmb  glycoprotein (transmembrane) nmb 
118  0.00068  0.0394  4.2  10911287  Anxa2  annexin A2 
119  0.000688  0.0395  3.69  10871511  Lao1  L‐amino acid oxidase 1 
120  0.000732  0.0415  3.06  10877907  Plin2  perilipin 2 
121  0.000734  0.0415  6.88  10880107     
122  0.00075  0.0417  5.69  10772472  Nfxl1  nuclear transcription factor, X‐box 
binding‐like 1 
123  0.000751  0.0417  3.46  10808362  Usp10  ubiquitin specific peptidase 10 
124  0.000768  0.0421  2.94  10763685     
125  0.00077  0.0421  3.05  10767067     
126  0.000798  0.0423  12.73  10827686  RT1‐M6‐1  RT1 class I, locus M6, gene 1 
127  0.000799  0.0423  4.66  10712317  Pnpla2  patatin‐like phospholipase domain 
containing 2 
128  0.000814  0.0423  3.07  10871521  Slc2a1  solute carrier family 2 (facilitated 
glucose transporter), member 1 
129  0.000817  0.0423  3.78  10721232  Isg20l2  interferon stimulated exonuclease gene 
20‐like 2 
130  0.00082  0.0423  16.98  10797566     
131  0.000821  0.0423  3.94  10723884  Serpinh1  serpin peptidase inhibitor, clade H (heat 
shock protein 47), member 1, (collagen 
binding protein 1) 
132  0.000826  0.0423  4.93  10862453     
133  0.000829  0.0423  3.51  10890650     




135  0.000838  0.0423  3.39  10836394  41705  membrane‐associated ring finger 
(C3HC4) 7, E3 ubiquitin protein ligase 
136  0.000842  0.0423  3.8  10862473     
137  0.000866  0.0432  5.9  10785461  Pcdh8  protocadherin 8 
138  0.000886  0.0439  4.69  10928154  Hspd1  heat shock protein 1 (chaperonin) 
139  0.000892  0.0439  3.55  10822627  Tmem212  transmembrane protein 212 
140  0.000907  0.0439  3.26  10811531  Slc7a5  solute carrier family 7 (amino acid 
transporter light chain, L system), 
member 5 
141  0.000913  0.0439  0.22  10818571     
142  0.000913  0.0439  0.22  10908096     
143  0.000919  0.0439  4.35  10909382  Vof16  ischemia related factor vof‐16 
144  0.000927  0.0439  4.46  10796149  Pfkfb3  6‐phosphofructo‐2‐kinase/fructose‐2,6‐
biphosphatase 3 
145  0.000931  0.0439  3.67  10781361  Lgi3  leucine‐rich repeat LGI family, member 
3 
146  0.000978  0.0452  4.11  10895589  Cpm  carboxypeptidase M 
147  0.000988  0.0452  4.13  10801884  Slc12a2  solute carrier family 12 
(sodium/potassium/chloride 
transporters), member 2 
148  0.000988  0.0452  2.74  10805335  Slc14a1  solute carrier family 14 (urea 
transporter), member 1 
149  0.000991  0.0452  15.56  10929656  Kcnj13  potassium inwardly‐rectifying channel, 
subfamily J, member 13 
150  0.000992  0.0452  4.55  10765042     
151  0.001  0.0453  3.73  10822631  Cldn11  claudin 11 
152  0.001043  0.0464  2.54  10901752     
153  0.001048  0.0464  5.42  10908102     
154  0.001052  0.0464  6.06  10914019     
155  0.001053  0.0464  6.05  10912614  Slco2a1  solute carrier organic anion transporter 
family, member 2a1 
156  0.001075  0.0471  4.44  10834022  Arrdc3  arrestin domain containing 3 
157  0.00109  0.0473  3.63  10765534  Adamts4  ADAM metallopeptidase with 
thrombospondin type 1 motif, 4 
158  0.001093  0.0473  3.92  10812470  Serinc5  serine incorporator 5 
159  0.00111  0.0477  2.55  10823049     
160  0.001137  0.0485  6.48  10753423     
161  0.001147  0.0485  3.42  10872291  Yars  tyrosyl‐tRNA synthetase 
162  0.001165  0.0485  4.19  10880524     
163  0.00117  0.0485  2.68  10871909  Gnl2  guanine nucleotide binding protein‐like 
2 (nucleolar) 
164  0.001172  0.0485  3.5  10792863  Atp11a  ATPase, class VI, type 11A 
165  0.001172  0.0485  2.8  10863866  Cnbp  CCHC‐type zinc finger, nucleic acid 
binding protein 
166  0.001179  0.0486  3.69  10712706  Chka  choline kinase alpha 
167  0.001208  0.0489  0.16  10703224     
168  0.00121  0.0489  3.99  10868428  Dnajb5  DnaJ (Hsp40) homolog, subfamily B, 
member 5 
169  0.001215  0.0489  6.03  10847761  Cd44  Cd44 molecule 
170  0.001217  0.0489  4.25  10899263  Mettl7a  methyltransferase like 7A 
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171  0.001251  0.0497  5.55  10853852  ST7  suppression of tumorigenicity 7 
172  0.001252  0.0497  4.58  10886846     
173  0.001288  0.0503  2.98  10859371  Strap  serine/threonine kinase receptor 
associated protein 
174  0.001288  0.0503  23.13  10828827  Cdkn1a  cyclin‐dependent kinase inhibitor 1A 
175  0.001295  0.0503  7.74  10856673  Slc4a5  solute carrier family 4, sodium 
bicarbonate cotransporter, member 5 
176  0.001303  0.0503  2.9  10725253     
177  0.001306  0.0503  4.84  10858967  Tnfrsf1a  tumor necrosis factor receptor 
superfamily, member 1a 
178  0.001315  0.0503  3.42  10716080  Dusp5  dual specificity phosphatase 5 
179  0.001319  0.0503  8.06  10838823  Chac1  ChaC, cation transport regulator 
homolog 1 (E. coli) 
180  0.00133  0.0503  3.36  10768726  Npl  N‐acetylneuraminate pyruvate lyase 
181  0.001331  0.0503  3.57  10897683  Ddx17  DEAD (Asp‐Glu‐Ala‐Asp) box 
polypeptide 17 
182  0.001347  0.0504  4.71  10885959  RGD1563216  similar to HESB like domain containing 1 
183  0.001349  0.0504  5.65  10938209     
184  0.001378  0.0511  2.98  10707824  Vimp  VCP‐interacting membrane protein 
185  0.001382  0.0511  3.29  10749704  Sirt7  sirtuin 7 
186  0.001412  0.0519  8.08  10811126  Fa2h  fatty acid 2‐hydroxylase 
187  0.001433  0.0524  4.35  10818059     
188  0.001454  0.0529  7.48  10772580     
189  0.001464  0.0529  3.72  10724228  Bcl2l1  Bcl2‐like 1 
190  0.001473  0.053  2.71  10782764     
191  0.001481  0.053  4.73  10728647  Myrf  myelin regulatory factor 
192  0.001496  0.0531  5.48  10899756  Coq10a  coenzyme Q10 homolog A (S. 
cerevisiae) 
193  0.001508  0.0531  2.68  10746014     
194  0.00151  0.0531  2.71  10713045  Fosl1  fos‐like antigen 1 
195  0.001514  0.0531  4.08  10789653  Irs2  insulin receptor substrate 2 
196  0.001542  0.0538  11.71  10935177  Cldn2  claudin 2 
197  0.001559  0.0539  3.01  10862505  LOC500124  similar to RIKEN cDNA 4921507P07 
198  0.001563  0.0539  3.2  10909733  Zfp259  zinc finger protein 259 
199  0.001572  0.054  3.14  10816400  Isg20l2  interferon stimulated exonuclease gene 
20‐like 2 
200  0.001629  0.0554  2.86  10811493  Cox4nb  COX4 neighbor 
201  0.00163  0.0554  2.89  10851952  B4galt5  UDP‐Gal:betaGlcNAc beta 1,4‐
galactosyltransferase, polypeptide 5 
202  0.001688  0.0571  2.74  10889728  Arl4a  ADP‐ribosylation factor‐like 4A 
203  0.001697  0.0571  4.38  10791677  Acsl1  acyl‐CoA synthetase long‐chain family 
member 1 
204  0.001724  0.0575  3.15  10790002  Gnl3  guanine nucleotide binding protein‐like 
3 (nucleolar) 
205  0.001743  0.0575  3.66  10730884  Smndc1  survival motor neuron domain 
containing 1 
206  0.001755  0.0575  3.25  10924223  Igfbp2  insulin‐like growth factor binding 
protein 2 
207  0.001762  0.0575  2.33  10914580  Sacm1l  SAC1 suppressor of actin mutations 1‐
like (yeast) 
208  0.001769  0.0575  2.7  10707656     
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209  0.00177  0.0575  3.27  10822043  Cdh6  cadherin 6 
210  0.001803  0.0575  4.64  10826837  Cyp2u1  cytochrome P450, family 2, subfamily u, 
polypeptide 1 
211  0.001807  0.0575  3.67  10750080  Bach1  BTB and CNC homology 1, basic leucine 
zipper transcription factor 1 
212  0.001813  0.0575  3.67  10739204  Smndc1  survival motor neuron domain 
containing 1 
213  0.001819  0.0575  3.16  10894999  Tmcc3  transmembrane and coiled‐coil domain 
family 3 
214  0.00182  0.0575  16.28  10830908  Rnf39  ring finger protein 39 
215  0.00184  0.0575  0.28  10750426  Ttc3  tetratricopeptide repeat domain 3 
216  0.001851  0.0575  7.19  10807464  Pla2g15  phospholipase A2, group XV 
217  0.001853  0.0575  3.36  10824059     
218  0.001856  0.0575  3.22  10890156  Fbxo33  F‐box protein 33 
219  0.001858  0.0575  3.15  10902564  Mdm2  p53 E3 ubiquitin protein ligase 
220  0.001871  0.0575  3.29  10803238     
221  0.001871  0.0575  3.74  10908133  Chordc1  cysteine and histidine‐rich domain 
(CHORD)‐containing 1 
222  0.001879  0.0575  2.95  10847562  Tspan18  tetraspanin 18 
223  0.001882  0.0575  2.55  10881167  Ddi2  DNA‐damage inducible protein 2 
224  0.001886  0.0575  2.35  10726679  Ifitm2  interferon induced transmembrane 
protein 2 
225  0.001893  0.0575  3.2  10906323  Chkb  choline kinase beta 
226  0.001908  0.0575  2.73  10916768  Vps11  vacuolar protein sorting 11 homolog (S. 
cerevisiae) 
227  0.001911  0.0575  2.59  10823119     
228  0.001948  0.0577  3.57  10865855     
229  0.001948  0.0577  3.17  10878034     
230  0.001957  0.0577  2.9  10900753  Ptbp1  polypyrimidine tract binding protein 1 
231  0.001964  0.0577  2.68  10831135  Ddx39b  DEAD (Asp‐Glu‐Ala‐Asp) box 
polypeptide 39B 
232  0.00197  0.0577  2.98  10874866  Noc2l  nucleolar complex associated 2 
homolog (S. cerevisiae) 
233  0.001971  0.0577  2.72  10743318  Shmt1  serine hydroxymethyltransferase 1 
(soluble) 
234  0.001983  0.0577  3.26  10792441  Slc20a2  solute carrier family 20 (phosphate 
transporter), member 2 
235  0.001986  0.0577  10.66  10765212  F5  coagulation factor V (proaccelerin, 
labile factor) 
236  0.002001  0.0577  3.88  10934794  Isg20l2  interferon stimulated exonuclease gene 
20‐like 2 
237  0.002001  0.0577  3.06  10885396  Zbtb1  zinc finger and BTB domain containing 1 
238  0.002016  0.0577  5.51  10789059  Agpat6  1‐acylglycerol‐3‐phosphate O‐
acyltransferase 6 
239  0.002033  0.0577  2.72  10706635  Nup62  nucleoporin 62 
240  0.002039  0.0577  2.76  10889263  Trib2  tribbles homolog 2 (Drosophila) 
241  0.002045  0.0577  2.55  10901367     
242  0.002056  0.0577  3.45  10908968  Cdon  cell adhesion associated, oncogene 
regulated 
243  0.002057  0.0577  3.44  10874193  Errfi1  ERBB receptor feedback inhibitor 1 
244  0.002059  0.0577  4.52  10885015     




246  0.002105  0.0582  2.78  10859108  Clec2g  C‐type lectin domain family 2, member 
G 
247  0.002111  0.0582  3.51  10871711  Trit1  tRNA isopentenyltransferase 1 
248  0.002112  0.0582  6.12  10772330     
249  0.002164  0.0593  5.6  10914823  LOC654482  hypothetical protein LOC654482 
250  0.002171  0.0593  16.09  10855701  Aqp1  aquaporin 1 
251  0.002179  0.0593  3.72  10787517  Gdf15  growth differentiation factor 15 
252  0.002198  0.0596  2.44  10713760  Mta2  metastasis associated 1 family, member 
2 
253  0.002209  0.0596  3.12  10918364     
254  0.002214  0.0596  4.56  10803851  Hspa9  heat shock protein 9 
255  0.002239  0.0597  4.35  10903061  Shmt2  serine hydroxymethyltransferase 2 
(mitochondrial) 
256  0.002242  0.0597  8.74  10903459  Klf10  Kruppel‐like factor 10 
257  0.002243  0.0597  4.25  10834162  Tprn  taperin 
258  0.002279  0.0604  4.4  10861793  Slc13a4  solute carrier family 13 (sodium/sulfate 
symporters), member 4 
259  0.002303  0.0608  3.53  10912495  Dbr1  debranching enzyme homolog 1 (S. 
cerevisiae) 
260  0.00233  0.0613  3.15  10906574     
261  0.00235  0.0613  0.16  10919074     
262  0.002364  0.0613  3.56  10920632  Pdcd6ip  programmed cell death 6 interacting 
protein 
263  0.002364  0.0613  5.78  10762709  Coq5  coenzyme Q5 homolog, 
methyltransferase (S. cerevisiae) 
264  0.002367  0.0613  5.92  10891364  Alkbh1  alkB, alkylation repair homolog 1 (E. 
coli) 
265  0.002377  0.0613  3.15  10833005  Slc29a3  solute carrier family 29 (nucleoside 
transporters), member 3 
266  0.002397  0.0615  5.39  10726669  Cox8b  cytochrome c oxidase, subunit VIIIb 
267  0.002404  0.0615  3.63  10754939  Fam43a  family with sequence similarity 43, 
member A 
268  0.00241  0.0615  2.73  10927230  Bag2  Bcl2‐associated athanogene 2 
269  0.002432  0.0615  3.32  10718001  Agpat4  1‐acylglycerol‐3‐phosphate O‐
acyltransferase 4 (lysophosphatidic acid 
acyltransferase, delta) 
270  0.00244  0.0615  3.88  10703465  Taf5l  TAF5‐like RNA polymerase II, p300/CBP‐
associated factor (PCAF)‐associated 
factor 
271  0.002441  0.0615  3.61  10864662  Emc3  ER membrane protein complex subunit 
3 
272  0.002461  0.0615  2.67  10763740  Yod1  YOD1 OTU deubiquinating enzyme 1 
homolog (S. cerevisiae) 
273  0.002464  0.0615  3.24  10852671     
274  0.002468  0.0615  2.49  10926658  Rcan2  regulator of calcineurin 2 
275  0.002483  0.0615  3.44  10825472  Atp1a1  ATPase, Na+/K+ transporting, alpha 1 
polypeptide 
276  0.002493  0.0615  3.61  10803947  Hbegf  heparin‐binding EGF‐like growth factor 
277  0.002507  0.0615  3.29  10936537  Gtpbp4  GTP binding protein 4 
278  0.002507  0.0615  2.89  10824655  Npr1  natriuretic peptide receptor 
A/guanylate cyclase A (atrionatriuretic 
peptide receptor A) 




280  0.002524  0.0616  3.53  10864874  Rassf4  Ras association (RalGDS/AF‐6) domain 
family member 4 
281  0.002533  0.0616  3.35  10798856  Cul2  cullin 2 
282  0.002573  0.0623  4.02  10881630  Tardbp  TAR DNA binding protein 
283  0.002583  0.0623  6.5  10931308  P4ha1  prolyl 4‐hydroxylase, alpha polypeptide 
I 
284  0.002617  0.0623  2.6  10889772     
285  0.002618  0.0623  11.49  10844223  Ptges  prostaglandin E synthase 
286  0.002624  0.0623  4.29  10865347     
287  0.002625  0.0623  3.77  10769672  Rgs4  regulator of G‐protein signaling 4 
288  0.002637  0.0623  2.7  10807430  Pskh1  protein serine kinase H1 
289  0.002644  0.0623  3.11  10938091     
290  0.002644  0.0623  4.07  10859342  Ptpro  protein tyrosine phosphatase, receptor 
type, O 
291  0.00266  0.0625  2.45  10925810  Ppp4r1  protein phosphatase 4, regulatory 
subunit 1 
292  0.002709  0.0632  2.67  10749789  LOC619574  hypothetical protein LOC619574 
293  0.002715  0.0632  2.26  10905909     
294  0.002726  0.0632  2.8  10904169  Ndrg1  N‐myc downstream regulated 1 
295  0.00273  0.0632  4.31  10750282  Slc5a3  solute carrier family 5 (sodium/myo‐
inositol cotransporter), member 3 
296  0.002743  0.0633  3.53  10881648  Pex14  peroxisomal biogenesis factor 14 
297  0.002758  0.0633  5.82  10840396  Sec23b  Sec23 homolog B (S. cerevisiae) 
298  0.00276  0.0633  2.52  10846821  Tmx2  thioredoxin‐related transmembrane 
protein 2 
299  0.002776  0.0635  5.3  10825100  Car14  carbonic anhydrase 14 
300  0.002805  0.0635  0.23  10767380     
301  0.002832  0.0635  4.42  10801260     
302  0.002836  0.0635  2.28  10932162     
303  0.002837  0.0635  0.44  10857435     
304  0.00285  0.0635  2.38  10887821     
305  0.002862  0.0635  3.5  10727373     
306  0.002865  0.0635  7.06  10730472     
307  0.002866  0.0635  3.99  10719977  Mia  melanoma inhibitory activity 
308  0.002872  0.0635  3.03  10889064  Seli  selenoprotein I 
309  0.002878  0.0635  2.62  10890365     
310  0.002882  0.0635  3.06  10763547     
311  0.002892  0.0636  3.57  10727643     
312  0.002935  0.0636  0.4  10797584     
313  0.002936  0.0636  3.93  10884853  Prpf39  PRP39 pre‐mRNA processing factor 39 
homolog (S. cerevisiae) 
314  0.002938  0.0636  2.77  10863698  Dusp11  dual specificity phosphatase 11 
(RNA/RNP complex 1‐interacting) 
315  0.002942  0.0636  6.1  10713602     
316  0.002944  0.0636  2.65  10818173  Wdr77  WD repeat domain 77 
317  0.00295  0.0636  5.95  10799187  Dip2c  DIP2 disco‐interacting protein 2 
homolog C (Drosophila) 
318  0.003003  0.0644  3.86  10711357  Armc5  armadillo repeat containing 5 
319  0.003004  0.0644  2.66  10921527     
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320  0.003048  0.065  4.49  10754218  Fstl1  follistatin‐like 1 
321  0.003067  0.065  3.76  10739399     
322  0.00307  0.065  3.28  10785773  Spry2  sprouty homolog 2 (Drosophila) 
323  0.003071  0.065  2.37  10711433  Sec23ip  SEC23 interacting protein 
324  0.003084  0.065  3.02  10767631  Nfasc  neurofascin 
325  0.00309  0.065  0.41  10871127  Mob3c  MOB kinase activator 3C 
326  0.003099  0.065  7.01  10827691  RT1‐M6‐2  RT1 class I, locus M6, gene 2 
327  0.003111  0.065  4.86  10924076  Rpe  ribulose‐5‐phosphate‐3‐epimerase 
328  0.00316  0.0658  3.99  10935131  Rnf128  ring finger protein 128, E3 ubiquitin 
protein ligase 
329  0.003184  0.0661  2.31  10884738     
330  0.0032  0.0663  9.84  10749983  Cxadr  coxsackie virus and adenovirus receptor 
331  0.00322  0.0663  2.58  10791902  Slc7a2  solute carrier family 7 (cationic amino 
acid transporter, y+ system), member 2 
332  0.003228  0.0663  4.34  10915885     
333  0.003229  0.0663  3.08  10909691  Bace1  beta‐site APP cleaving enzyme 1 
334  0.003259  0.0666  3.61  10859774     
335  0.003265  0.0666  2.84  10812390     
336  0.003305  0.0672  2.54  10875420  LOC502940  pro‐histogranin 
337  0.003311  0.0672  2.53  10795200  LOC502940  pro‐histogranin 
338  0.003332  0.0674  2.43  10850199  Tmx4  thioredoxin‐related transmembrane 
protein 4 
339  0.003386  0.0682  2.87  10720430  Psmd8  proteasome (prosome, macropain) 26S 
subunit, non‐ATPase, 8 
340  0.003391  0.0682  3.88  10728028     
341  0.003435  0.0686  0.36  10807881     
342  0.003435  0.0686  3.05  10805895  Gtl3  gene trap locus 3 
343  0.003519  0.0699  16.42  10806122  Hmox1  heme oxygenase (decycling) 1 
344  0.00352  0.0699  2.37  10869355  Rgs3  regulator of G‐protein signaling 3 
345  0.003531  0.0699  3.46  10742236  Thg1l  tRNA‐histidine guanylyltransferase 1‐
like (S. cerevisiae) 
346  0.003548  0.0701  2.17  10827916  Ddr1  discoidin domain receptor tyrosine 
kinase 1 
347  0.003588  0.0707  3.66  10835757  Gsn  gelsolin 
348  0.003636  0.0714  2.53  10747692  Dusp3  dual specificity phosphatase 3 
349  0.003655  0.0716  3.59  10871479  Elovl1  ELOVL fatty acid elongase 1 
350  0.003673  0.0717  2.16  10766161  Itpkb  inositol‐trisphosphate 3‐kinase B 
351  0.003702  0.072  3.73  10714973  Hectd2  HECT domain containing 2 
352  0.003717  0.072  6.39  10776667     
353  0.003718  0.072  4.86  10736873     
354  0.003732  0.0721  2.37  10829976  Psap  prosaposin 
355  0.003774  0.0727  3.73  10797657  Omd  osteomodulin 
356  0.003787  0.0727  2.55  10873303  Ddost  dolichyl‐diphosphooligosaccharide‐
protein glycosyltransferase 
357  0.003813  0.073  3.93  10889462     
358  0.003846  0.0734  4.18  10835692  Hspa5  heat shock protein 5 
359  0.003856  0.0734  5.79  10757489  Vgf  VGF nerve growth factor inducible 




361  0.003884  0.0735  2.21  10871117  Atpaf1  ATP synthase mitochondrial F1 complex 
assembly factor 1 
362  0.003901  0.0737  6.67  10925291  Cxcr7  chemokine (C‐X‐C motif) receptor 7 
363  0.003936  0.0739  2.24  10798434     
364  0.003937  0.0739  2.39  10820795     
365  0.003955  0.0741  0.16  10729065     
366  0.004009  0.0743  2.43  10765503  RGD1562658  similar to RIKEN cDNA 1700009P17 
367  0.004031  0.0743  3.25  10795927  Gtpbp4  GTP binding protein 4 
368  0.00405  0.0743  3.18  10820666  Hmgcr  3‐hydroxy‐3‐methylglutaryl‐CoA 
reductase 
369  0.004053  0.0743  3.35  10798831  Mtpap  mitochondrial poly(A) polymerase 
370  0.004062  0.0743  2.5  10778620  Slc1a4  solute carrier family 1 
(glutamate/neutral amino acid 
transporter), member 4 
371  0.004063  0.0743  2.23  10793397  Hiatl1  hippocampus abundant transcript‐like 1 
372  0.004065  0.0743  2.66  10811185  Bcar1  breast cancer anti‐estrogen resistance 1 
373  0.004069  0.0743  3.41  10799133  Smarca5  SWI/SNF related, matrix associated, 
actin dependent regulator of chromatin, 
subfamily a, member 5 
374  0.004076  0.0743  3.54  10786624  Nt5dc2  5'‐nucleotidase domain containing 2 
375  0.004076  0.0743  6.6  10740519  Pmm2  phosphomannomutase 2 
376  0.004108  0.0745  4.99  10719616  PVR  poliovirus receptor 
377  0.004112  0.0745  3.4  10914937     
378  0.004121  0.0745  2.67  10885524  Plekhh1  pleckstrin homology domain containing, 
family H (with MyTH4 domain) member 
1 
379  0.004152  0.0749  4.03  10869106  Slc44a1  solute carrier family 44, member 1 
380  0.004184  0.0751  2.61  10863777  Antxr1  anthrax toxin receptor 1 
381  0.004188  0.0751  3.39  10763587  Slc35f5  solute carrier family 35, member F5 
382  0.004201  0.0752  0.29  10714632     
383  0.004241  0.0754  2.35  10821115     
384  0.004246  0.0754  3.01  10742968  Plod1  procollagen‐lysine, 2‐oxoglutarate 5‐
dioxygenase 1 
385  0.00427  0.0754  3.94  10812589  F2rl2  coagulation factor II (thrombin) 
receptor‐like 2 
386  0.004272  0.0754  3.68  10859264  Ddx47  DEAD (Asp‐Glu‐Ala‐Asp) box 
polypeptide 47 
387  0.004278  0.0754  2.29  10872003  Stk40  serine/threonine kinase 40 
388  0.004295  0.0754  2.63  10724042  P2ry2  purinergic receptor P2Y, G‐protein 
coupled, 2 
389  0.004298  0.0754  5.08  10739353  Kcnj2  potassium inwardly‐rectifying channel, 
subfamily J, member 2 
390  0.004306  0.0754  2.82  10854108  Calu  calumenin 
391  0.004328  0.0754  3.19  10759409  Pgam5  phosphoglycerate mutase family 
member 5 
392  0.004335  0.0754  2.73  10798878     
393  0.004355  0.0754  2.72  10756692  Aimp2  aminoacyl tRNA synthetase complex‐
interacting multifunctional protein 2 
394  0.004362  0.0754  2.14  10832299  Pttg1ip  pituitary tumor‐transforming 1 
interacting protein 
395  0.004369  0.0754  2.89  10887981  Srsf7  serine/arginine‐rich splicing factor 7 
396  0.004371  0.0754  2.29  10726979  Ctsd  cathepsin D 
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397  0.004378  0.0754  2.43  10803577  Syt4  synaptotagmin IV 
398  0.004396  0.0755  2.63  10767985     
399  0.004441  0.0761  3.86  10762600  Gcn1l1  GCN1 general control of amino‐acid 
synthesis 1‐like 1 (yeast) 
400  0.004512  0.0768  3.98  10937302  Htr2c  5‐hydroxytryptamine (serotonin) 
receptor 2C, G protein‐coupled 
401  0.004514  0.0768  2.42  10714667  Jak2  Janus kinase 2 
402  0.004547  0.0768  2.96  10907793  Mettl7a  methyltransferase like 7A 
403  0.00455  0.0768  3.74  10811875  Taf5l  TAF5‐like RNA polymerase II, p300/CBP‐
associated factor (PCAF)‐associated 
factor 
404  0.004564  0.0768  2.59  10714103  Mpeg1  macrophage expressed 1 
405  0.004566  0.0768  2.71  10714788  Cstf2t  cleavage stimulation factor, 3' pre‐RNA, 
subunit 2, 64kDa, tau variant 
406  0.004573  0.0768  3  10852106     
407  0.004582  0.0768  2.9  10827531  Srsf11  serine/arginine‐rich splicing factor 11 
408  0.004587  0.0768  4.41  10808103  Terf2ip  telomeric repeat binding factor 2, 
interacting protein 
409  0.00461  0.077  3.28  10919433     
410  0.00465  0.0775  2.36  10764678     
411  0.004677  0.0778  3.21  10862131  Clec5a  C‐type lectin domain family 5, member 
A 
412  0.00469  0.0778  2.68  10919637  Tf  transferrin 
413  0.004721  0.0781  2.81  10901536     
414  0.004735  0.0782  2.63  10822184     
415  0.004765  0.0782  2.35  10835355  Ass1  argininosuccinate synthase 1 
416  0.004782  0.0782  2.9  10716667  Ust  uronyl‐2‐sulfotransferase 
417  0.004786  0.0782  3.85  10781197  Stmn4  stathmin‐like 4 
418  0.004801  0.0782  4.06  10765335  Creg1  cellular repressor of E1A‐stimulated 
genes 1 
419  0.004808  0.0782  3.07  10791631  Enpp6  ectonucleotide 
pyrophosphatase/phosphodiesterase 6 
420  0.004815  0.0782  2.19  10817898  Tspan2  tetraspanin 2 
421  0.004837  0.0782  3.06  10830270     
422  0.004859  0.0782  3.08  10727321  Gal  galanin/GMAP prepropeptide 
423  0.00486  0.0782  3.36  10885006  Tmx1  thioredoxin‐related transmembrane 
protein 1 
424  0.004866  0.0782  0.24  10756530     
425  0.004871  0.0782  2.6  10724529  Tpp1  tripeptidyl peptidase I 
426  0.004874  0.0782  2.35  10794257     
427  0.004897  0.0784  2.07  10702768     
428  0.00491  0.0784  2.22  10829191  Pdxk  pyridoxal (pyridoxine, vitamin B6) 
kinase 
429  0.00496  0.079  2.16  10754337  Iqcb1  IQ motif containing B1 
430  0.004978  0.0791  2.68  10718486     
431  0.005016  0.0795  3.68  10719956  Nemf  nuclear export mediator factor 
432  0.005033  0.0796  2.52  10867163  Rbpj  recombination signal binding protein 
for immunoglobulin kappa J region 
433  0.005062  0.0797  9.27  10720215  Zfp36  zinc finger protein 36 




435  0.005094  0.0799  2.68  10761329  Tmem248  transmembrane protein 248 
436  0.005094  0.0799  0.25  10742192     
437  0.005115  0.08  2.76  10787212  Myo9b  myosin IXb 
438  0.005128  0.08  4.99  10749495  Lgals3bp  lectin, galactoside‐binding, soluble, 3 
binding protein 
439  0.005184  0.0807  4.26  10831802     
440  0.005192  0.0807  2.27  10890402  Nin  ninein (GSK3B interacting protein) 
441  0.005224  0.0807  3.84  10804127  Fgf1  fibroblast growth factor 1 (acidic) 
442  0.005237  0.0807  2.78  10797681  Ippk  inositol 1,3,4,5,6‐pentakisphosphate 2‐
kinase 
443  0.005241  0.0807  3.34  10833013  Unc5b  unc‐5 homolog B (C. elegans) 
444  0.005252  0.0807  2.49  10765683  Copa  coatomer protein complex subunit 
alpha 
445  0.005256  0.0807  2.4  10863197  Usp39  ubiquitin specific peptidase 39 
446  0.005293  0.0811  2.77  10886816  RGD1566401  similar to GTL2, imprinted maternally 
expressed untranslated 
447  0.005313  0.0812  2.53  10738576  Grn  granulin 
448  0.005328  0.0813  2.69  10812656     
449  0.005347  0.0813  2.43  10844747  Rbm18  RNA binding motif protein 18 
450  0.005353  0.0813  2.4  10758940  Prkab1  protein kinase, AMP‐activated, beta 1 
non‐catalytic subunit 
451  0.005385  0.0814  2.32  10832905  Sirt1  sirtuin 1 
452  0.005398  0.0814  2.39  10724494  Trim3  tripartite motif‐containing 3 
453  0.005403  0.0814  5.26  10929536  Slc16a14  solute carrier family 16, member 14 
(monocarboxylic acid transporter 14) 
454  0.005415  0.0814  0.17  10817191     
455  0.005422  0.0814  2.38  10721191  Pop4  processing of precursor 4, ribonuclease 
P/MRP subunit (S. cerevisiae) 
456  0.005453  0.0817  0.32  10803824  Cdc25c  cell division cycle 25C 
457  0.005485  0.0818  2.2  10891293  Tmed10  transmembrane emp24‐like trafficking 
protein 10 (yeast) 
458  0.005488  0.0818  2.09  10799241  Idi1  isopentenyl‐diphosphate delta 
isomerase 1 
459  0.005492  0.0818  3.55  10928275  Fam126b  family with sequence similarity 126, 
member B 
460  0.005518  0.0819  3.28  10833152  Csrp2  cysteine and glycine‐rich protein 2 
461  0.005521  0.0819  0.21  10778675     
462  0.005664  0.0834  3.58  10885029  Frmd6  FERM domain containing 6 
463  0.005669  0.0834  2.6  10813048  Ppap2a  phosphatidic acid phosphatase type 2A 
464  0.005677  0.0834  4.01  10877538     
465  0.005678  0.0834  2.62  10749663  P4hb  prolyl 4‐hydroxylase, beta polypeptide 
466  0.00571  0.0834  2.42  10796701  Gpr158  G protein‐coupled receptor 158 
467  0.005712  0.0834  2.3  10908427  Dnm2  dynamin 2 
468  0.005712  0.0834  4.04  10797949  Bmp6  bone morphogenetic protein 6 
469  0.005733  0.0835  7.74  10839579  Dusp2  dual specificity phosphatase 2 
470  0.005768  0.0839  5.12  10705364  Sertad1  SERTA domain containing 1 
471  0.00581  0.0842  2.57  10887695     
472  0.005815  0.0842  3.51  10923338  Coq10b  coenzyme Q10 homolog B (S. 
cerevisiae) 
473  0.005839  0.0844  2.67  10745062  Eral1  Era (G‐protein)‐like 1 (E. coli) 
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474  0.005874  0.0847  3.76  10742575  Hspa4  heat shock protein 4 
475  0.005911  0.0849  2.43  10752650  MGC95208  similar to 4930453N24Rik protein 
476  0.005913  0.0849  3.84  10784181  Zdhhc20  zinc finger, DHHC‐type containing 20 
477  0.005978  0.0857  3  10938048  Taf5l  TAF5‐like RNA polymerase II, p300/CBP‐
associated factor (PCAF)‐associated 
factor 
478  0.006015  0.0857  3.41  10707121  Gtf2h1  general transcription factor IIH, 
polypeptide 1 
479  0.006042  0.0857  2.83  10839511  Snrnp200  small nuclear ribonucleoprotein 200 
(U5) 
480  0.006045  0.0857  2.11  10894525  Cry1  cryptochrome 1 (photolyase‐like) 
481  0.006048  0.0857  2.68  10858487  M6pr  mannose‐6‐phosphate receptor, cation 
dependent 
482  0.006067  0.0857  2.91  10705485  Fbl  fibrillarin 
483  0.006092  0.0857  3.13  10914923  Cep57  centrosomal protein 57 
484  0.006105  0.0857  0.45  10830267     
485  0.006146  0.0857  3.04  10939498  Rbm41  RNA binding motif protein 41 
486  0.006166  0.0857  3.51  10884200  Efcab10  EF‐hand calcium binding domain 10 
487  0.006167  0.0857  5.59  10708521  Ctsc  cathepsin C 
488  0.006176  0.0857  0.39  10711219  Stx4  syntaxin 4 
489  0.006181  0.0857  2.09  10922415  Imp4  IMP4, U3 small nucleolar 
ribonucleoprotein, homolog (yeast) 
490  0.006187  0.0857  2.76  10846340  Fkbp7  FK506 binding protein 7 
491  0.00619  0.0857  3.33  10932584  Clcn5  chloride channel, voltage‐sensitive 5 
492  0.0062  0.0857  4.92  10799291  Klf6  Kruppel‐like factor 6 
493  0.006202  0.0857  2.17  10884211  Tomm70a  translocase of outer mitochondrial 
membrane 70 homolog A (S. cerevisiae) 
494  0.006212  0.0857  2.91  10843909  Rexo4  REX4, RNA exonuclease 4 homolog (S. 
cerevisiae) 
495  0.006215  0.0857  2.26  10826300  Trmt13  tRNA methyltransferase 13 homolog (S. 
cerevisiae) 
496  0.00623  0.0857  3.4  10871444  Slc6a9  solute carrier family 6 
(neurotransmitter transporter, glycine), 
member 9 
497  0.006234  0.0857  2.81  10896836  Efr3a  EFR3 homolog A (S. cerevisiae) 
498  0.00627  0.086  2.15  10793175  Usp19  ubiquitin specific peptidase 19 
499  0.006276  0.086  0.42  10869614     
500  0.006347  0.0867  2.53  10773610     
501  0.006361  0.0867  2.55  10764773  Rgs16  regulator of G‐protein signaling 16 
502  0.006367  0.0867  3.11  10776968  Tra2b  transformer 2 beta homolog 
(Drosophila) 
503  0.006392  0.0867  2.33  10734148     
504  0.006409  0.0867  8.42  10820748  Utp15  UTP15, U3 small nucleolar 
ribonucleoprotein, homolog (S. 
cerevisiae) 
505  0.00641  0.0867  2.16  10936827  Atp6ap2  ATPase, H+ transporting, lysosomal 
accessory protein 2 
506  0.006416  0.0867  2.34  10708541  Prss23  protease, serine, 23 
507  0.006434  0.0867  2.14  10933015  MGC95208  similar to 4930453N24Rik protein 
508  0.006457  0.0867  3.19  10786743  Ncoa4  nuclear receptor coactivator 4 
509  0.006466  0.0867  3.62  10895144  Dusp6  dual specificity phosphatase 6 
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510  0.00647  0.0867  4.68  10895581  LOC362855  P55 
511  0.006484  0.0867  2.05  10742388  Sqstm1  sequestosome 1 
512  0.006567  0.0875  5.67  10717865     
513  0.006569  0.0875  2.27  10713915     
514  0.006577  0.0875  2.97  10714576  Vldlr  very low density lipoprotein receptor 
515  0.006637  0.0881  4.86  10762115  Naa25  N(alpha)‐acetyltransferase 25, NatB 
auxiliary subunit 
516  0.006679  0.0883  4.25  10813361  Dab2  disabled 2, mitogen‐responsive 
phosphoprotein 
517  0.00669  0.0883  2.82  10936993  Pim2  pim‐2 oncogene 
518  0.006692  0.0883  2.85  10917301  Snf1lk2  SNF1‐like kinase 2 
519  0.006734  0.0885  2.64  10918326  Snx1  sorting nexin 1 
520  0.006737  0.0885  2.74  10889027  Slc35f6  solute carrier family 35, member F6 
521  0.006749  0.0885  2.24  10798499  Hist1h4b  histone cluster 1, H4b 
522  0.006793  0.089  2.24  10813472  Nup155  nucleoporin 155 
523  0.006855  0.0894  2.4  10939310  Gla  galactosidase, alpha 
524  0.006865  0.0894  2.22  10888608  Lbh  limb bud and heart 
525  0.006963  0.0894  2.56  10879502  Cap1  CAP, adenylate cyclase‐associated 
protein 1 (yeast) 
526  0.006982  0.0894  3.13  10800783     
527  0.006986  0.0894  3.29  10719006  Leng8  leukocyte receptor cluster (LRC) 
member 8 
528  0.00703  0.0894  3.72  10765166  Mettl18  methyltransferase like 18 
529  0.007047  0.0894  2.63  10832927     
530  0.007052  0.0894  2.89  10792035  Dusp4  dual specificity phosphatase 4 
531  0.007063  0.0894  2.25  10702485  Pdcd6  programmed cell death 6 
532  0.007063  0.0894  2.42  10850979  Ahcy  adenosylhomocysteinase 
533  0.007069  0.0894  2.58  10781344  Bin3  bridging integrator 3 
534  0.007071  0.0894  2.88  10721925  Grwd1  glutamate‐rich WD repeat containing 1 
535  0.007094  0.0894  2.9  10773800  Rnf215  ring finger protein 215 
536  0.007128  0.0894  2.41  10805100  LOC361346  similar to chromosome 18 open reading 
frame 54 
537  0.00713  0.0894  2.35  10877573  Dbc1  deleted in bladder cancer 1 
538  0.007145  0.0894  2.53  10847693  Api5  apoptosis inhibitor 5 
539  0.007152  0.0894  2.35  10894512  Prdm4  PR domain containing 4 
540  0.00716  0.0894  0.49  10899053     
541  0.00716  0.0894  4.27  10792344     
542  0.007163  0.0894  2.26  10723866  Dgat2  diacylglycerol O‐acyltransferase 2 
543  0.007163  0.0894  2.52  10711657     
544  0.00718  0.0894  2.28  10911576  Fam214a  family with sequence similarity 214, 
member A 
545  0.00719  0.0894  2.42  10754592     
546  0.007196  0.0894  0.19  10742927  Olr1418  olfactory receptor 1418 
547  0.007199  0.0894  3.31  10896065     
548  0.007209  0.0894  3.21  10935962  Plxnb3  plexin B3 
549  0.007209  0.0894  2.26  10866819  Bcat1  branched chain amino acid 
transaminase 1, cytosolic 
550  0.007212  0.0894  2.51  10808929  Lrrc57  leucine rich repeat containing 57 
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551  0.00722  0.0894  2.32  10787817     
552  0.007243  0.0894  4.55  10894498  LOC362855  P55 
553  0.007273  0.0894  3.35  10727806     
554  0.007282  0.0894  2.25  10744134  Eif4a1  eukaryotic translation initiation factor 
4A1 
555  0.00729  0.0894  2.83  10903845  Derl1  derlin 1 
556  0.00731  0.0894  3.95  10852144  Pmepa1  prostate transmembrane protein, 
androgen induced 1 
557  0.007311  0.0894  3.86  10873903     
558  0.007319  0.0894  2.55  10833215  Ddx50  DEAD (Asp‐Glu‐Ala‐Asp) box 
polypeptide 50 
559  0.00736  0.0894  3.36  10806687  Ccdc130  coiled‐coil domain containing 130 
560  0.00736  0.0894  3.35  10702996  Igf2r  insulin‐like growth factor 2 receptor 
561  0.007361  0.0894  3.13  10745558  Rffl  ring finger and FYVE‐like domain 
containing E3 ubiquitin protein ligase 
562  0.007368  0.0894  3  10928254  Orc2  origin recognition complex, subunit 2 
563  0.007381  0.0895  2.37  10796432  Rpp38  ribonuclease P/MRP 38 subunit 
564  0.007409  0.0895  2.42  10891850     
565  0.007415  0.0895  3.97  10859857     
566  0.007445  0.0897  2.02  10915567  Yipf2  Yip1 domain family, member 2 
567  0.007461  0.0897  2.21  10795297  Hist1h4b  histone cluster 1, H4b 
568  0.007463  0.0897  4.3  10802013  Cd74  Cd74 molecule, major 
histocompatibility complex, class II 
invariant chain 
569  0.007482  0.0897  2.53  10869014  Rnf20  ring finger protein 20, E3 ubiquitin 
protein ligase 
570  0.007511  0.0899  2.38  10854494  Nup205  nucleoporin 205 
571  0.00755  0.0902  2.28  10938837     
572  0.007623  0.0909  4.05  10802734  Smad7  SMAD family member 7 
573  0.007648  0.0911  2.52  10758724     
574  0.007665  0.0911  0.32  10703568     
575  0.007697  0.0913  2.09  10862666     
576  0.007715  0.0914  3.46  10812722  Mrps27  mitochondrial ribosomal protein S27 
577  0.007753  0.0917  3.9  10726244  RGD1305014  similar to RIKEN cDNA 2310057M21 
578  0.007771  0.0917  0.47  10783796  Nrl  neural retina leucine zipper 
579  0.00779  0.0918  3.08  10730148  Opalin  oligodendrocytic myelin paranodal and 
inner loop protein 
580  0.007839  0.0919  2.74  10733100  Olr1401  olfactory receptor 1401 
581  0.007845  0.0919  2.66  10713160  Syvn1  synovial apoptosis inhibitor 1, 
synoviolin 
582  0.007849  0.0919  2.32  10807722  Txnl4b  thioredoxin‐like 4B 
583  0.007864  0.0919  2.91  10864621  Jagn1  jagunal homolog 1 (Drosophila) 
584  0.007877  0.0919  2.24  10798490  Hist1h4b  histone cluster 1, H4b 
585  0.007882  0.0919  4.14  10831816  Bak1  BCL2‐antagonist/killer 1 
586  0.007939  0.0919  3.35  10830962     
587  0.007939  0.0919  3.35  10875983     
588  0.007968  0.0919  3.51  10717069  Pde7b  phosphodiesterase 7B 
589  0.007976  0.0919  2.85  10702320  Clvs2  clavesin 2 
590  0.007982  0.0919  3.01  10780908     
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591  0.007991  0.0919  2.29  10931919  Lamp2  lysosomal‐associated membrane 
protein 2 
592  0.007996  0.0919  5.99  10824322  Lmna  lamin A/C 
593  0.007996  0.0919  3.39  10714377     
594  0.008004  0.0919  2.14  10816965  Crtc2  CREB regulated transcription 
coactivator 2 
595  0.008018  0.092  4.67  10750055  Usp16  ubiquitin specific peptidase 16 
596  0.008064  0.0923  5  10835498  Ppapdc3  phosphatidic acid phosphatase type 2 
domain containing 3 
597  0.008116  0.0927  2.85  10776835     
598  0.008156  0.0927  2.17  10775271  Lrrc8c  leucine rich repeat containing 8 family, 
member C 
599  0.008176  0.0927  3.71  10728800  Tmem132a  transmembrane protein 132A 
600  0.008181  0.0927  2.13  10854446  Cald1  caldesmon 1 
601  0.008212  0.0929  4.76  10913866     
602  0.008273  0.0931  2.7  10885045  Psma3  proteasome (prosome, macropain) 
subunit, alpha type 3 
603  0.008276  0.0931  3  10717941  Tcp1  t‐complex 1 
604  0.008276  0.0931  2.95  10726477  Nkx6‐2  NK6 homeobox 2 
605  0.008289  0.0931  3.01  10791522  Hpgd  hydroxyprostaglandin dehydrogenase 
15 (NAD) 
606  0.008295  0.0931  2.11  10846762  Calcrl  calcitonin receptor‐like 
607  0.008332  0.0932  4.15  10834241  Abca2  ATP‐binding cassette, subfamily A 
(ABC1), member 2 
608  0.008333  0.0932  2.68  10751868  Mb21d2  Mab‐21 domain containing 2 
609  0.008351  0.0932  5.42  10837279  Itgav  integrin, alpha V 
610  0.008362  0.0932  2.83  10751769     
611  0.008373  0.0932  2.44  10745509  Myo1d  myosin ID 
612  0.008387  0.0932  3.21  10756229  Insr  insulin receptor 
613  0.00848  0.0939  3.64  10750489  B3galt5  UDP‐Gal:betaGlcNAc beta 1,3‐
galactosyltransferase, polypeptide 5 
614  0.008488  0.0939  3.21  10740959  Kctd5  potassium channel tetramerisation 
domain containing 5 
615  0.008489  0.0939  5.1  10877855     
616  0.008554  0.0941  4.08  10796507  Slc39a12  solute carrier family 39 (zinc 
transporter), member 12 
617  0.008581  0.0941  2.59  10880731  C1qc  complement component 1, q 
subcomponent, C chain 
618  0.008585  0.0941  2.14  10783241  Hnrnpc  heterogeneous nuclear 
ribonucleoprotein C (C1/C2) 
619  0.008585  0.0941  2.05  10937523     
620  0.00859  0.0941  2.36  10713706  Ganab  glucosidase, alpha; neutral AB 
621  0.008593  0.0941  5.82  10911476     
622  0.008624  0.0942  3.16  10758344  Vps37b  vacuolar protein sorting 37 homolog B 
(S. cerevisiae) 
623  0.008638  0.0942  2.63  10936346     
624  0.008654  0.0942  3.56  10840226  Lamp5  lysosomal‐associated membrane 
protein family, member 5 
625  0.008677  0.0943  2.84  10912080  Mrap2  melanocortin 2 receptor accessory 
protein 2 
626  0.008724  0.0946  2.27  10814521  Nceh1  neutral cholesterol ester hydrolase 1 
627  0.00875  0.0947  0.4  10739864     
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628  0.008753  0.0947  8.27  10833031  Sgpl1  sphingosine‐1‐phosphate lyase 1 
629  0.008825  0.0949  2.75  10939570  Zdhhc9  zinc finger, DHHC‐type containing 9 
630  0.008842  0.0949  3.02  10923560  Bzw1  basic leucine zipper and W2 domains 1 
631  0.008863  0.0949  3.33  10745456  Blmh  bleomycin hydrolase 
632  0.008888  0.0949  2.63  10731009     
633  0.008907  0.0949  2.58  10840384  Polr3f  polymerase (RNA) III (DNA directed) 
polypeptide F 
634  0.008916  0.0949  2.45  10881291     
635  0.008918  0.0949  3.86  10775113  Mtf2  metal response element binding 
transcription factor 2 
636  0.008918  0.0949  2.35  10747482  Hcrt  hypocretin 
637  0.008935  0.095  2.37  10747368  Klhl11  kelch‐like family member 11 
638  0.00897  0.095  2.45  10784938  RGD1309922  similar to 2610301G19Rik protein 
639  0.008975  0.095  2.27  10824072     
640  0.008979  0.095  3.19  10834704  Wdr5  WD repeat domain 5 
641  0.008994  0.095  2.53  10866926  Asun  asunder, spermatogenesis regulator 
642  0.009027  0.0952  3.73  10935843     
643  0.00909  0.0957  2.71  10806937  Smarca5  SWI/SNF related, matrix associated, 
actin dependent regulator of chromatin, 
subfamily a, member 5 
644  0.009188  0.0965  2.21  10822436  Armc1  armadillo repeat containing 1 
645  0.009189  0.0965  2.61  10842469  Cebpb  CCAAT/enhancer binding protein 
(C/EBP), beta 
646  0.009215  0.0965  4.17  10857314  Slc6a6  solute carrier family 6 
(neurotransmitter transporter, taurine), 
member 6 
647  0.009216  0.0965  0.43  10892638     
648  0.009247  0.0966  3.12  10817383  Cers2  ceramide synthase 2 
649  0.009294  0.0968  2.31  10740701  Vasn  vasorin 
650  0.009326  0.0968  2.45  10900537  Dazap1  DAZ associated protein 1 
651  0.00933  0.0968  3.29  10725340  Dcun1d3  DCN1, defective in cullin neddylation 1, 
domain containing 3 (S. cerevisiae) 
652  0.009338  0.0968  3.48  10712340  Cd151  CD151 molecule (Raph blood group) 
653  0.009338  0.0968  2.13  10712687  RGD1311946  similar to RIKEN cDNA 1810055G02 
654  0.009362  0.0968  7.48  10842500  Dok5  docking protein 5 
655  0.009364  0.0968  3.34  10908072  Gpr83  G protein‐coupled receptor 83 
656  0.009407  0.0968  3.18  10738209  Cnp  2',3'‐cyclic nucleotide 3' 
phosphodiesterase 
657  0.009408  0.0968  2.16  10856050     
658  0.009408  0.0968  2.58  10864722  Tamm41  TAM41, mitochondrial translocator 
assembly and maintenance protein, 
homolog (S. cerevisiae) 
659  0.009443  0.0971  2.49  10891548     
660  0.009466  0.0971  3.41  10868304  Spink4  serine peptidase inhibitor, Kazal type 4 
661  0.009496  0.0972  0.47  10782599  RGD1306063  similar to HT021 
662  0.009503  0.0972  2.29  10804856  Txnl1  thioredoxin‐like 1 
663  0.009541  0.0973  3.2  10728361  Stip1  stress‐induced phosphoprotein 1 
664  0.009541  0.0973  5.09  10729970  Rbp4  retinol binding protein 4, plasma 
665  0.009573  0.0975  2.35  10832287  Ube2g2  ubiquitin‐conjugating enzyme E2G 2 
276 
 
666  0.009585  0.0975  3.66  10823462  Slc33a1  solute carrier family 33 (acetyl‐CoA 
transporter), member 1 
667  0.009608  0.0975  2.43  10708929  Gdpd5  glycerophosphodiester 
phosphodiesterase domain containing 5 
668  0.009622  0.0975  2.66  10857667  Thumpd3  THUMP domain containing 3 
669  0.009644  0.0975  2.19  10800696  Lims2  LIM and senescent cell antigen like 
domains 2 
670  0.009656  0.0975  2.99  10711987     
671  0.009666  0.0975  5.13  10858152     
672  0.009674  0.0975  0.41  10793052     
673  0.009697  0.0975  9.02  10785019  Slc39a14  solute carrier family 39 (zinc 
transporter), member 14 
674  0.009713  0.0975  2.06  10883609  Smc6  structural maintenance of 
chromosomes 6 
675  0.009713  0.0975  2.16  10875974  Lingo2  leucine rich repeat and Ig domain 
containing 2 
676  0.009746  0.0976  2.11  10742876  Gemin5  gem (nuclear organelle) associated 
protein 5 
677  0.009752  0.0976  4.32  10727228  Fadd  Fas (TNFRSF6)‐associated via death 
domain 
678  0.009807  0.0979  2.74  10851497  Fitm2  fat storage‐inducing transmembrane 
protein 2 
679  0.009811  0.0979  2.64  10706437  Klk6  kallikrein related‐peptidase 6 
680  0.009847  0.0981  0.43  10887336     
681  0.00993  0.0988  3.51  10882221  Tmem88b  transmembrane protein 88B 
682  0.009956  0.0989  3.74  10874802  Ube2j2  ubiquitin‐conjugating enzyme E2, J2 








APPENDIX 7: LISTS OF ARE-CONTAINING MRNAS FROM ARED SEARCH 
Note: repetitions of genes in below tables are due to multiple ARE sequences in the gene.  
Repetitions were not counted for counts of ARE-mRNAs in the text, and non-redundant lists 
were used for counting. 
ARE‐mRNAs from CA1 mRNAs isolated by sucrose PAD method 
PolyA Signal  Gene  ARE  Location 
TRUE  STAT3  AAAAATTTATATT  2313‐2325 
TRUE  Stat3  AAAAATTTATATT  1795‐1807 
TRUE  Stat3  AAAAATTTATATT  1816‐1828 
TRUE  PTBP1  AAATATTTATAAT  1190‐1202 
TRUE  KITLG  AAATTTATTTATA  3909‐3921 
FALSE  Aadat  AATTATTTACAAA  300‐312 
TRUE  Plk3  ACATTTATTTATT  265‐277 
TRUE  Plk3  ACATTTATTTATT  266‐278 
TRUE  Rgs2  ATAAATTTATTTT  659‐671 
TRUE  Rgs2  ATAAATTTATTTT  654‐666 
TRUE  MTHFD2  ATTAATTTATATA  477‐489 
TRUE  MRPS6  ATTCATTTATTTT  8069‐8081 
FALSE  PTGS2  ATTTAATTATTTA  47‐59 
FALSE  Ptgs2  ATTTAATTATTTA  42‐54 
FALSE  Hspa1a  ATTTATTTACTTA  967‐979 
TRUE  HSPA1A  ATTTGTTTATTTA  339‐351 
TRUE  Cdon  CATTATTTATTTT  99‐111 
TRUE  Glce  GATTATTTATATT  349‐361 
FALSE  Cxadr  GTATTTATTTAAA  2336‐2348 
TRUE  KCTD4  TAATATTTAAAAT  388‐400 
TRUE  PPP1R15A  TATAATTTATTAA  17‐29 
TRUE  GLCE  TATTATTTAGAAT  1787‐1799 
TRUE  SERPINB2  TGTTATTTATTAT  275‐287 
TRUE  Serpinb2  TGTTATTTATTAT  244‐256 
TRUE  DUSP2  TTATATTTATACA  595‐607 
TRUE  Dusp2  TTATATTTATATA  517‐529 
TRUE  Dusp2  TTATATTTATATA  549‐561 
TRUE  SOX11  TTTTATTTAAAAA  4497‐4509 
TRUE  CDON  TTTTATTTATAAA  2295‐2307 
TRUE  PLA2G4A  TTTTATTTATATA  415‐427 
TRUE  Mmp9  TTTTATTTATTAT  396‐408 
TRUE  Mmp9  TTTTATTTATTAT  376‐388 
ARE‐mRNAs from CA3 mRNAs isolated by sucrose PAD method 
PolyA Signal  Gene  ARE  Location 
FALSE  Aadat  AATTATTTACAAA  300‐312 
TRUE  Plk3  ACATTTATTTATT  265‐277 
TRUE  Plk3  ACATTTATTTATT  266‐278 
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TRUE  Pvr  ATATATTTATAAA  565‐577 
FALSE  PVR  ATATATTTATAAA  574‐586 
FALSE  Hspa1a  ATTTATTTACTTA  967‐979 
TRUE  HSPA1A  ATTTGTTTATTTA  339‐351 
TRUE  PTER  TTACATTTATAAT  752‐764 
TRUE  DUSP2  TTATATTTATACA  595‐607 
TRUE  Dusp2  TTATATTTATATA  517‐529 
TRUE  Dusp2  TTATATTTATATA  549‐561 
FALSE  Il31ra  TTATATTTATTTT  540‐552 
TRUE  SOX11  TTTTATTTAAAAA  4497‐4509 
ARE‐mRNAs from CA1 mRNAs isolated by sucrose GRADIENT method 
PolyA Signal  Gene  ARE  Location 
TRUE  VLDLR  AAAAATTTATAAA  484‐496 
TRUE  Slc33a1  AAAGATTTATAAA  588‐600 
FALSE  Pnpt1  AAATATTTATTAA  184‐196 
FALSE  PNPT1  AAATATTTATTAT  209‐221 
FALSE  LOC641190  AAATATTTATTAT  176‐188 
TRUE  DDX47  AAATATTTATTTC  3172‐3184 
TRUE  KITLG  AAATTTATTTATA  3909‐3921 
TRUE  BC043118  AAGTATTTATATT  504‐516 
TRUE  HECA  AATTATTTATTTT  2815‐2827 
TRUE  CDH6  ACATATTTATATA  1119‐1131 
TRUE  Lep  ACTTATTTATTTA  439‐451 
TRUE  WSB1  AGATTTATTTAAT  98‐110 
TRUE  Rgs2  ATAAATTTATTTT  659‐671 
TRUE  Rgs2  ATAAATTTATTTT  654‐666 
FALSE  Cdkl1  ATACATTTATTTA  353‐365 
FALSE  ZFP36  ATATATTTAGTAA  628‐640 
FALSE  PVR  ATATATTTATAAA  574‐586 
FALSE  Ldlr  ATATATTTATTGT  188‐200 
FALSE  FGF9  ATATATTTATTTA  634‐646 
TRUE  Calcrl  ATATTTATTTAAA  1192‐1204 
TRUE  Gcnt2  ATATTTATTTAAT  1918‐1930 
TRUE  GCNT2  ATATTTATTTATT  1663‐1675 
TRUE  Vps54  ATCTATTTATTAA  740‐752 
TRUE  Ldlr  ATCTATTTATTTT  1514‐1526 
TRUE  ATP11A  ATTCATTTATTTA  2605‐2617 
FALSE  AZIN1  ATTTATTTAATTA  702‐714 
TRUE  Azin1  ATTTATTTAGATA  186‐198 
TRUE  ZBTB39  ATTTATTTATTTT  1495‐1507 
TRUE  RNF103  ATTTTTTTATTTA  194‐206 
TRUE  WHSC1L1  CTTTATTTATTTT  3551‐3563 
TRUE  CNTN3  GAATTTATTTAAT  752‐764 
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FALSE  Cxadr  GTATTTATTTAAA  2336‐2348 
TRUE  NLN  TAATATTTAAAAT  1864‐1876 
FALSE  LDLR  TAATATTTATTAA  676‐688 
TRUE  Zfp36  TAGTATTTATATA  622‐634 
TRUE  Nln  TATTATTTAGATA  645‐657 
FALSE  INTS2  TTAAATTTATTTT  782‐794 
TRUE  PHTF2  TTACATTTATTTT  172‐184 
TRUE  F2RL2  TTATATTTAAATT  1437‐1449 
TRUE  Slc25a32  TTATATTTACAAA  1174‐1186 
TRUE  PNO1  TTATATTTATAAA  335‐347 
TRUE  DUSP2  TTATATTTATACA  595‐607 
TRUE  MMP16  TTATATTTATACT  2375‐2387 
FALSE  Mmp16  TTATATTTATACT  2361‐2373 
TRUE  Dusp2  TTATATTTATATA  517‐529 
TRUE  RNF138  TTGTATTTATATA  522‐534 
TRUE  NPL  TTTAATTTATAAA  1802‐1814 
TRUE  SOX11  TTTTATTTAAAAA  4497‐4509 
ARE‐mRNAs from CA3 mRNAs isolated by sucrose GRADIENT method 
PolyA Signal  Gene  ARE  Location 
TRUE  Slc33a1  AAAGATTTATAAA  588‐600 
TRUE  Hpgd  AAATATTTAGTAA  417‐429 
TRUE  PTBP1  AAATATTTATAAT  1190‐1202 
FALSE  WDR77  AAATATTTATTCT  1098‐1110 
TRUE  YOD1  AAATATTTATTGA  2128‐2140 
TRUE  DDX47  AAATATTTATTTC  3172‐3184 
FALSE  Trim3  AAATATTTATTTT  567‐579 
TRUE  SLC7A2  AAATTTATTTAAA  3876‐3888 
FALSE  CDC42EP3  AAATTTATTTAAC  393‐405 
TRUE  MTUS1  AAATTTATTTACA  346‐358 
TRUE  Unc5b  AATGATTTATTAT  548‐560 
TRUE  Cry1  AATTATTTAAAAA  66‐78 
TRUE  Cry1  AATTATTTAAAAA  66‐78 
FALSE  Yod1  AATTATTTAATTA  2465‐2477 
TRUE  Dcun1d3  AATTATTTATTGT  1191‐1203 
TRUE  Pnpla2  AATTATTTATTTT  374‐386 
TRUE  CDH6  ACATATTTATATA  1119‐1131 
FALSE  B4GALT5  ACATATTTATATA  1877‐1889 
TRUE  WSB1  AGATTTATTTAAT  98‐110 
FALSE  BTG3  AGTTATTTATATA  346‐358 
FALSE  PSKH1  AGTTATTTATTAT  1944‐1956 
TRUE  DCUN1D3  AGTTATTTATTAT  1205‐1217 
TRUE  Rgs2  ATAAATTTATTTT  659‐671 
FALSE  BMP6  ATACATTTATAAT  1061‐1073 
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TRUE  CTSC  ATATATTTAATAT  5301‐5313 
TRUE  PDK4  ATATATTTAATTA  989‐1001 
TRUE  Spsb1  ATATATTTACATA  1458‐1470 
TRUE  NFXL1  ATATATTTACATT  92‐104 
TRUE  OMD  ATATATTTAGAAT  88‐100 
FALSE  ZFP36  ATATATTTAGTAA  628‐640 
TRUE  Hbegf  ATATATTTAGTTT  650‐662 
FALSE  Hbegf  ATATATTTAGTTT  631‐643 
TRUE  Pvr  ATATATTTATAAA  565‐577 
TRUE  VASN  ATATATTTATAAG  493‐505 
TRUE  D130054N24Rik  ATATATTTATACA  76‐88 
FALSE  DUSP4  ATATATTTATGTT  615‐627 
TRUE  Calcrl  ATATTTATTTAAA  1192‐1204 
TRUE  Rgs16  ATATTTATTTATT  1481‐1493 
TRUE  Vasn  ATGTATTTATAAA  444‐456 
TRUE  Igfbp2  ATGTATTTATATT  98‐110 
TRUE  Syt4  ATTAATTTATAAA  632‐644 
TRUE  ITGAV  ATTAATTTATTTT  962‐974 
FALSE  AGPAT4  ATTCATTTATTTA  103‐115 
TRUE  ATP11A  ATTCATTTATTTA  2605‐2617 
TRUE  MRPS6  ATTCATTTATTTT  8069‐8081 
FALSE  PTGS2  ATTTAATTATTTA  47‐59 
TRUE  ARRDC3  ATTTATTTACAAA  604‐616 
TRUE  Arrdc3  ATTTATTTACAAA  830‐842 
TRUE  NIN  ATTTATTTATGTA  170‐182 
TRUE  Pfkfb3  ATTTATTTATTTA  2432‐2444 
TRUE  SRXN1  ATTTATTTATTTATCTATTTA  1025‐1045 
TRUE  SNX1  ATTTATTTATTTT  2941‐2953 
TRUE  Ube2j2  ATTTATTTATTTT  1649‐1661 
FALSE  Stk40  ATTTATTTTTTTA  527‐539 
TRUE  HSPA1A  ATTTGTTTATTTA  339‐351 
TRUE  Slc14a1  ATTTGTTTATTTA  1087‐1099 
TRUE  NUP155  GATTATTTATTAT  219‐231 
TRUE  GDF15  GTATTTATTTAAA  194‐206 
FALSE  Cxadr  GTATTTATTTAAA  2336‐2348 
TRUE  PPP4R1  TAAAATTTATTAA  855‐867 
TRUE  Trib2  TAACATTTATAAT  1228‐1240 
TRUE  GEMIN5  TAATATTTAATTT  455‐467 
TRUE  Bach1  TAATATTTAATTT  3364‐3376 
TRUE  Zfp36  TAGTATTTATATA  612‐624 
TRUE  Zfp36  TAGTATTTATATA  622‐634 
TRUE  PPP1R15A  TATAATTTATTAA  17‐29 
TRUE  Sirt1  TATTATTTATAGA  111‐123 
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TRUE  Pdk4  TATTATTTATGAA  1942‐1954 
TRUE  Ccdc130  TATTATTTATTTG  101‐113 
TRUE  Hectd2  TATTATTTATTTT  2178‐2190 
FALSE  Il1rap  TCATATTTATAAA  614‐626 
TRUE  Tnfrsf12a  TGATATTTATTTT  480‐492 
TRUE  ASPA  TGATTTATTTATT  497‐509 
TRUE  ATP6AP2  TTACATTTATAAA  94‐106 
TRUE  Psma3  TTAGATTTATTTT  730‐742 
TRUE  F2RL2  TTATATTTAAATT  1437‐1449 
TRUE  SMC6  TTATATTTAGTTT  375‐387 
TRUE  Sacm1l  TTATATTTATAAT  199‐211 
TRUE  DUSP2  TTATATTTATACA  595‐607 
TRUE  PIGM  TTATATTTATATA  5413‐5425 
TRUE  Dusp2  TTATATTTATATA  517‐529 
TRUE  FGF1  TTATATTTATGAT  2361‐2373 
TRUE  Sacm1l  TTATATTTATGAT  199‐211 
TRUE  Dusp1  TTATTTATTTAAC  103‐115 
TRUE  SYT4  TTGTATTTATTAA  464‐476 
TRUE  UBE2G2  TTGTATTTATTAA  2239‐2251 
TRUE  ADAMTS4  TTGTATTTATTTA  297‐309 
FALSE  Utp15  TTTAATTTATTAT  2121‐2133 
FALSE  DIP2C  TTTAATTTATTTT  733‐745 
FALSE  Pigm  TTTAATTTATTTT  1440‐1452 
TRUE  DBR1  TTTCATTTATTAT  766‐778 
FALSE  Cxcr7  TTTTATTTACAAT  617‐629 
TRUE  SLC16A14  TTTTATTTACATA  2358‐2370 
TRUE  Slc12a2  TTTTATTTACATT  1811‐1823 
TRUE  Mat2a  TTTTATTTAGTAA  1352‐1364 
TRUE  IRS2  TTTTATTTAGTTT  1792‐1804 
TRUE  TCP1  TTTTATTTATAAC  4‐1997 
TRUE  P2ry2  TTTTATTTATAAC  839‐851 
FALSE  Gpr158  TTTTATTTATATG  258‐270 
FALSE  Hmgcr  TTTTATTTATTCA  406‐418 
FALSE  RGD1305014  TTTTATTTATTCA  323‐335 
TRUE  FSTL1  TTTTATTTATTCT  998‐1010 
TRUE  RGS3  TTTTATTTATTTA  420‐432 
TRUE  Rgs3  TTTTATTTATTTA  431‐443 
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Advisor: Donald J. DeGracia, Ph.D. 
Major: Physiology 
Degree: Doctor of Philosophy 
The study presented here used “omic” technology to look at the mechanism behind the 
selective delayed death of hippocampus CA1 neurons after transient global brain ischemia.  To 
summarize the results, I have worked up a consistent method of isolating polysomes from whole 
animal model, which is much cleaner than the sucrose density gradient methods.  Both results 
from Hu IP and polysomes experiments strongly agree that control CA1 is in a different state 
compared with control CA3.  My results suggest that the selective vulnerability of CA1 after 
ischemia reperfusion injury may be due to the fact that CA1 is “weaker” from the beginning.  
This finding is significant as it shifts the focus of research from studying the difference of 
ischemia reperfusion injury to the different initial state of CA1 and CA3 cells.  This study has 
also reformed our general idea as revealed by the high resolution of proteomics, which is much 
more superior than that of WB, that contamination makes up big proportion of cell preparation, 
and we should be cautious of the interpretation from those results. 
Results are summarized as below: 
1. The polysomes isolated from whole animal models were demonstrated by traditional WB 
and RNA agarose gel to be concentrated and clean.  However, proteomics suggests that 
ribosomal protein represents only about 25% of the whole protein hits.  The same case 
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was in Hu IP proteomics results. 
2. The main form of ELAV protein family detected in CA1/CA3 in Hu IP and polysomes is 
HuB (Hel_N1).  HuB is present in control, reperfused CA3, reperfused CA1, missing 
only in control CA1. AUF-1, hnRNP K, hnRNP M are also missing only in control CA1.  
This suggests that HuB binding with AUF-1, hnRNP K, hnRNP M forming complexes in 
all experimental groups, only control CA1. 
3. mRNA population is very different between sucrose pad preparation and sucrose gradient 
preparation, although both are enriched with ARE-mRNA and ribosomal proteins.  This 
suggests two different RNA binding complexes have been isolated, which possibly 
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